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Abstract
ROLES FOR PATTERN RECOGNITION RECEPTORS, IMMUNE PROTEINS, AND
NF-κB SIGNALING IN REGULATING BEHAVIORS ASSOICATED WITH AGING
PHENOTYPES
Nicholas William DeKorver, Ph.D.
University of Nebraska Medical Center, 2017
Supervisor: Stephen J. Bonasera, M.D., Ph.D
The aging process is accompanied by functional impairments, including reduced
locomotor function, fragmentation of active states, and alterations in energy balance.
Our lab has demonstrated that immune proteins are increased in specific regions of the
mouse brain that correlate with strain specific deficits. These immune proteins include
toll-like receptors (Tlr), class I major histocompatibility complex proteins (MHC I), and
complement proteins. There is an increasing appreciation for the role of immune proteins
in neurodevelopment; however, their involvement in age-associated deficits is poorly
understood. Here, we present data demonstrating that 1) activation of a specific immune
receptor (Tlr2) leads to changes in cell signaling that may underlie age related functional
deficits, and 2) loss of specific immune proteins (Tlr2 and C3) and mutation of MHC I
H2-Kb lead to impairments in behaviors commonly effected by aging.
First, we present data demonstrating that activation of toll-like receptor 2 by a
synthetic agonists leads to activation of NF-κB signaling in cerebellar granule cells. Our
data, among others, suggests that NF-κB signaling is dysregulated in the aging brain.
Additionally, we suggest that accumulation of amyloid β in the aging brain may act as an
endogenous agonist for Tlr2 activation. This data reveals that a less appreciated
pathway, neuronal immune receptor signaling, may play a role in age related NF-κB
dysregulation.
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Second, analysis of mice lacking specific immune proteins revealed that loss of
complement protein 3 leads to deficits in locomotor function characterized by reduced
gait speed and markers of gait ataxia. Additionally, loss of complement 3 leads to
changes in cerebellar granule cell synapse density and excitability in vitro. Loss of tolllike receptor 2 results in consolidation of active and inactive states in young mice,
suggesting that toll-like receptor 2 may play a role in hypothalamic functions. Mutation of
major histocompatibility complex isoform H2-Kb leads to a progressive obesity
phenotype characterized by reduced activity and deficits in orexin neuron function.
Collectively, this data demonstrates the involvement of immune proteins in regulating
behaviors often disrupted in aging, including locomotor function, active state regulation,
and energy balance.
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Overall Introduction
Aging is characterized by functional deficits across multiple organ systems that lead
to significant impairments in normal function. Deficits in several central nervous system
(CNS) mediated functions including locomotion, metabolism, and cognition are
associated with aging even in the absence of explicit neurodegenerative disease.
Functional deficits in mobility are linked to increased institutionalization and death in
community dwelling adults1. It was found that disturbances in mobility defined by
abnormal gait effect upwards of 35% of adults between 70 and 99 years of age with
roughly half described as neurologic gait disturbances1. Despite the large clinical burden,
a definitive neurologic and/or molecular mechanism underlying age related gait and
mobility disturbances has not been identified.
Similarly,

processes

associated

with

aging

can

influence

an

individual’s

maintenance of energy balance resulting in unintentional weight loss or weight gain.
Roughly 15% of older adults experience unintentional weight loss in the absence of
cancer, gastrointestinal disease, or stroke2. Unintentional weight loss and the inability to
maintain healthy weight are key characteristics of frailty; a geriatric condition associated
with increased health care complications and poorer survival rates3. On the opposite
side of the spectrum, the prevalence of obesity in older demographics of both sexes and
all races is increasing4, 5. Obesity leads to increased risk of heart disease, diabetes,
coronary artery disease, and even certain forms of cancer6-8. The relationship between
obesity and mortality in the elderly population remains controversial, but an independent
association between obesity and all-cause mortality has been shown in adults9. Much of
the debate around mortality risk and obesity results from arguments on how to define
obesity and stratify risk factors in the complex nature of aging physiology. What the data
does clearly demonstrate is that changes in weight, either gains or losses are a strong
predictor of mortality10. A 15 year follow up study of males aged 40-59 at the start of the
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study, demonstrated reduced mortality rates for individuals that maintained a steady
weight compared to those with weight gain or fluctuation11. Additionally, an independent
study demonstrated that even modest weight loss in elderly adults increases mortality
risk12. While peripheral mechanisms, diet, and lifestyle play large roles in energy
balance, changes in CNS function underlying energy balance maintenance likely
contribute heavily to these phenotypes.
Our lab has previously demonstrated that aged mice recapitulate many of the
deficits that occur in human aging, and that these deficits are tied to distinct genetic
backgrounds13. Specifically, we tested cohorts of young (2-3 mo.), middle aged (12-13
mo.), and aged mice (21-24 mo.) from two strains (C57BL/6J and BALBc) generated
from distinct breeding lineages14 to assess age-related functional impairments.
Behavioral assessment was completed using our custom state-of-the-art home cage
monitoring system (HCM). The HCM system functions to automate the quantitative
characterization of mouse behaviors within their home cage environment with high
spatial (within 0.5 cm) and temporal (within 1 ms) resolution for extended periods of time
within no direct human interaction. Using this system we classify bouts of feeding,
drinking, forward locomotion, and non-forward locomotion into active and inactive states
throughout the circadian light and dark cycles. Following classification, we can assess
for genotypic differences in up to 665 distinct measures of feeding, drinking, motor, and
circadian activities. Furthermore, we can determine time budgets for control and mutant
animals to assess the percentage of time spent in active or inactive behaviors during an
average day. The HCM system has been employed in multiple institutions and
behavioral data gathered for C57BL/6J controls are highly similar regardless of location
or investigator, demonstrating the reproducibility of this platform. Specific methods for
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the HCM system and data analysis can be found in the subsequent chapters, and the full
methodology can be found in Goulding et al., 200815.
Our assessment of young (2-3 mo.), middle aged (12-13 mo.), and aged mice (2124 mo.) C57BL/6J and BALBc mice using the HCM demonstrated remarkable strain
specific function deficits compared to young mice of the same strain. Aged C57BL/6J
mice have significant deficits in locomotor function evident by reduced overall daily
locomotion, reduced locomotor bout onsets, increased bout duration, and characteristics
of gait ataxia13. C57BL/6J mice were independently found to exhibit age-dependent
motor dysfunction evident by significantly reduced performance on wire hang task,
reduced latency to fall on rotarod assessment, decreased locomotor activity in open
field, and slower moving speeds16. Interestingly, the oldest group of mice in the previous
study was considered middle aged (8-12 mo.) in our analysis suggesting that with
increasing age impairments become even more pronounced. Balance beam testing of
C57BL/6J mice also demonstrates age-dependent locomotor dysfunctions both with and
without vestibular stimulation evident by increased foot slips and total time to traverse
the beam in aged mice (27-28 mo.)17. It can be concluded from this data that C57BL/6J
mice demonstrate age-associated deficits in locomotion, indicating potential disruption of
CNS pathways responsible for organization and completion of motor functions.
Aged BALBc mice did not demonstrate any deficits associated with locomotor
function. Conversely, aged BALBc mice exhibited significant dysregulation of energy
balance. Normal aging is characterized by maintenance of body weight, and decreased
basal metabolic rate, activity, and food consumption. Both C57BL/6J and BALBc mice
experienced age-associated weight loss when compared to middle aged controls.
However, each strain responds to the weight loss differently. C57BL/6J mice have
reduced activity levels and increased chow consumption, likely in effort to regulate body
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mass. Whereas, BALBc mice show no change in activity and reduced chow
consumption, which may underlie significant weight loss observed with aging. Overall, it
can be concluded from this data that aged BALBc mice fail to compensate for age
related weight loss, signifying potential deficits in pathways that control energy balance.
In efforts to elucidate potential mechanisms underlying the age related functional
deficits observed in C57BL/6J and BALBc mice through unbiased means, our lab
performed microarray analysis of tissues associated with motor and metabolic functions.
Microarray analysis of whole cerebellar and hypothalamic tissues in young, middle aged,
and aged C57BL/6J and BALBc mice demonstrated strain and brain region specific
changes. Within the C57BL/6J cerebellum and BALBc hypothalamus (regions
associated with observed deficits) there was significant upregulation (p < 0.001 for both
regions) in transcripts important for immune/defense functions when characterized by
ontology analysis (Figure 1). Further ontological sub classification demonstrated that
these transcripts belong to specific functional categories including classical and atypical
major histocompatibility complex I proteins (MHC I), pattern recognition receptors
(PRRs), complement, and cell adhesion molecules with significant overlap between
strains and regions (Figure 1). PRRs are classically known for their role in innate
immune defense and recognition of pathogen associated molecular patterns (PAMPs)
and danger associated molecular patterns (DAMPs). PRRs include several subclasses
including toll-like receptors, Nod-like receptors, RIG-like receptors, AIM2-like receptors,
dectin receptors, and C-type lectin receptors among others. Analysis of aged human
cerebellar tissue demonstrated similar upregulation of transcripts analogous to those
increased in the C57BL/6J cerebellum with aging13. Microarray analysis of the C57BL/6J
hypothalamus and BALBc cerebellum demonstrated the site-specific nature of increased
immune/defense transcripts. Ontology analysis of these regions showed increases in
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Figure 1. Age-associated increase in C57BL6 cerebellum and BALB
hypothalamus PRR expression. Top: Differential gene expression in the male BALB
hypothalamus, n=7 young (2-3 mo), n=6 aged (21-24 mo) mice. Bottom: Differential
gene expression in the male C57BL6 cerebellum, n=4 young, n=4 aged mice. In the
hypothalamus young-to-aged comparison, 153 DEGs identified, 113 upregulated in
aged mice. In the cerebellum young-to-aged comparison, 101 DEGs identified, 100
upregulated in aged mice. P values reflect multiple comparison corrections across all
ontologies. RNA purified by standard methods, samples with A260/A280 ratio < 1.8 or
18S peak larger than 28S peak (per BioAnalyzer 2100) discarded secondary to
contamination/degradation. Gene expression measured by Agilent whole mouse
genome 4x44k microarray, candidate genes confirmed by RT-qPCR SyberGreen.
DEGs determined by B statistics. Ontologies per OntoExpress (Draghici et al., 2003).
Panels colored in violet correspond to BALB hypothalamus, panels colored in yellow
correspond to C57BL6 cerebellum, loci in red are common between the two regions.
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transcripts related to signal transduction, development, and neuronal processes. Several
independent studies have also demonstrated increases in immune/defense transcripts
within different brain regions with increasing age18-21. While data demonstrate clear
increases in immune genes within the aging brain, the CNS roles of the proteins
encoded by these transcripts are poorly understood. This may be partly due to the
relative infancy of the field.
The historical perspective that the central nervous system resides in an immune
privileged state, walled off from the peripheral immune system by a tightly regulated
blood brain barrier, has been repeatedly challenged and proven to be false. Acceptance
of this fact has led to vast growth in the knowledge of immune protein functions in the
CNS, but a large portion of this work is focused on neurodevelopment and
neurodegeneration. Our data, along with select others suggests that immune proteins
and pattern recognition receptors are increased in specific regions of the aging brain and
play a role in the development of age-associated functional deficits. Many of the immune
proteins upregulated in the aging brain signal through common pathways, many
involving nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB).
Activation of NF-κB can alter CNS functions though its impact on synapse and cytokine
regulation. Therefore, much of the mechanistic work presented in this dissertation
focuses on NF-κB signaling.
The works presented in this dissertation are the culmination of our attempts, so far,
to elucidate the role of specific immune proteins (complement 3, toll-like receptor 2, and
MHC Class I isoform H2-Kb) in the regulation of behaviors disrupted by the aging
process (metabolism, locomotion, and active/inactive state organization). If behavioral
phenotypes were identified, we performed follow up experiments in attempts to
understand potential mechanisms underlying these changes. Chapter 1 will outline in

7
detail our work to determine how PRR activation can lead to signaling changes in
neurons that may impact functional outcomes. Chapters 2-4 will each focus on a specific
immune protein, the behavioral workup for animals deficient in that protein, and potential
mechanisms for the behavioral findings. Additional immune proteins have been tested,
but as much of this work is in its infancy, only the more mature projects are being
presented as part of this dissertation.
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Chapter 1: Increased Expression and Signaling of Pattern
Recognition Receptors: Potential Mechanisms of age related
functional deficits.
Introduction
Age-Associated Deficits in Mobility
The Administration on Aging (AOA) estimates the number of Americans greater than
65 years of age will increase to 72.1 million by 2030 making up 19% of the U.S.A
population1. Functional impairments that accompany aging have complex etiologies
spanning multiple organ systems. In humans, these declines significantly alter an
individual’s capacity for independent living, leading to increased need for caregivers and
decreased quality of life.

In particular, mobility deficits are linked to increased

institutionalization and death in community dwelling adults2. Slow gait speed (< 1 m/s) in
community-dwelling older adults (age ≥70) increased self-reported difficulties in homebased activities including walking inside home, climbing and descending stairs, as well
as in several gait-independent motor tasks3. Additionally, slower gait speeds in older
adults (age ≥ 65) have been associated with lower survival rates4. Deficits in mobility can
arise from complications within multiple organ systems including the musculoskeletal
system, peripheral nervous system, and central nervous system. However, over half of
reported gait disturbances that plague one third of all adults between the ages of 70 and
99 are deemed neurogenic2. Neurologic gait impairments are extremely difficult to treat, as
limited interventions exist. With inadequate interventions, this clinical burden will continue
to increase as the elderly population grows. Due to the large clinical impact of mobility
disturbances in elderly individuals and the high percentage categorized as having CNS
involvement; we set out to investigate molecular mechanisms of age-related mobility
impairments.
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Our lab previously established a mouse model of age-related locomotor deficits
characterized by decreased overall locomotor activity, reduced gait speed, increased
locomotor bout duration, and markers of gait ataxia5 (General Introduction Figure 1).
Proper locomotor function is dependent on several CNS pathways primarily involving the
cortex, basal ganglia, brainstem, spinal cord, and cerebellum. CNS lesion studies have
aided in understanding the roles of these specific regions. In the context of aging,
disturbances in balance, gait, and coordination of movements indicate deficits in
cerebellar function.
Cerebellar Anatomy, Function, and Age-Associated Changes
The cerebellum resides in the posterior fossa, comprising only 10% of the CNS
volume, but containing over 50% of all neurons. Grossly, the cerebellum consists of a
tightly folded cortical surface with underlying white matter, several deep nuclei, and a
central ventricle. The anatomy of the cerebellum can be broken down by phylogenetic
criteria into the vestibulocerebellum (eye movements and balance), spinocerebellum
(body and limb movement), and cerebrocerebellum (movement planning and sensory
evaluation). On the cellular level, the cytoarchitecture of the cerebellum is organized into
a laminar structure. The outermost molecular layer contains the axons of cerebellar
granule cells, dendrites of Purkinje cells, and two types of inhibitory interneurons, basket
cells and stellate cells. The single cell thick Purkinje cell layer lies between the molecular
layer and the granule cell layer and contains the cell bodies of large, highly arborized
Purkinje cells. Deep to the Purkinje cell layer is a small population of Lugaro cells. The
innermost cerebellar granule cell layer contains densely packed cell bodies of cerebellar
granule cells, unipolar brush cells, and Golgi cells. Finally, imbedded in the white matter
tracks are the deep cerebellar nuclei. Unlike many other regions of the CNS, cerebellar
connectivity is organized on a fixed set of rules around the granule cell, Purkinje cell,
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deep nucleus loop. Incoming mossy and climbing fibers, carrying sensorimotor
information, form excitatory synapses with cerebellar granule cells and Purkinje cells,
respectively. Additionally, both of these projections synapse with neurons in the deep
cerebellar nuclei. Cerebellar granule cells project axons to the molecular layer where
they bifurcate and extend in opposite directions running parallel to one another forming
excitatory synapses with Purkinje cell dendrites. Purkinje cells, the sole output for the
cerebellum, form inhibitory connections with the deep cerebellar nuclei, which project out
to premotor areas.
Historically, the cerebellum has been described for its role in the maintenance of
balance and posture, and the coordination of voluntary movements. However, over the
past several decades the cerebellum has also been shown to play functional roles in
motor learning6, 7, cognition8, emotion9, 10, and behavior9, 10. While the cerebellum is not
necessary for the initiation of movement events, damage to the cerebellum leads to
dysmetria, or erratic movements that vary in size and direction11. Furthermore, lesions to
the cerebellum do not often lead to overt loss of motor function, but instead result in
deficits in specific aspects of motor function including loss of coordination, balance,
tremor, and gait ataxia12. An ataxic gait is characterized by veering movement paths,
irregular foot placement and trajectories, as well as discoordination of joint movements13.
Mechanisms underlying gait disturbances in the elderly are poorly understood.
Overall, the aging process results in minor morphological changes in the majority of
cerebellar regions in humans, predominately characterized by reductions in white matter
and Purkinje cell volumes with no overall changes in cell number. However, within
cerebellar subregions, specifically within the anterior lobe, a selective loss of cerebellar
granule cells and Purkinje cells has been noted with increasing age14. Within rodent
models, there is no measured loss of cerebellar granule cell density with aging15, 16. The
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absence of large anatomical disruption suggests that age related mobility deficits might
occur as a result of alterations at the level of cellular function. Functional changes may
be a result of white matter or cell density changes undetectable with current imaging
modalities or changes at the level of the synapse.
Age-Associated Changes in Synaptic Function
On the neuronal level, deficits in synaptic density, function, and/or regulation can all
negatively impact downstream signaling and result in functional deficits. Aging has been
associated with synaptic changes in multiple regions of the brain, including the
cerebellum. These synaptic changes include increased, but likely less functional
vesicular glutamate 1 (Vglut1) positive puncta in the cerebellar granule cell layer
(Bonasera, et al., 2017). It has also been found that loss of boutons on Purkinje cell
dendritic networks accompany age-associated Purkinje cell involution and cell loss17.
Regulation of neuronal function and synaptic connectivity is coordinated by complex
signaling pathways, and dysregulation within those pathways has profound effects on
downstream function. Several pathways including NF-κB, mTOR, SIRT1, IGF-1, and
P53 have been implicated in the aging process. However, a cross species study using
motif module mapping in promoters of genes upregulated with aging demonstrated that
NF-κB gene regulation is the most widely conserved pathway underlying mammalian
aging18. NF-κB signaling is involved in both synaptic and immune regulation. Analysis of
our aging gene expression data demonstrated that 16% of the cerebellar genes
differentially expressed between young and old C57BL/6 mice with locomotor impairment
are known NF-κB targets; this value rises to 33% by including NF-κB target predictions by
TRANSFAC (ver 7.0 Public 2005)5,

19, 20

. Therefore, we chose to further assess NF-κB

signaling in cerebellar neurons as a potential mechanism for age-related functional
deficits.
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NF-κB Signaling and Functions within the CNS
NF-κB signaling proteins are present in the neuronal soma and synapse, and have
an extended number of roles important for CNS functions21. NF-κB exists as hetero- or
homo-dimers of Rel-family proteins (c-Rel, p52, p50, RelB, and RelA/p65). Each protein
contains a Rel homology domain, a prototypical amino-terminal sequence of roughly 300
amino acids that mediate cytoplasmic retention, dimerization, nuclear translocation, and
DNA binding17, 22, 23. The most characterized, ‘canonical’ combination is a heterodimer of
p65 and p5024.

While the majority of NF-κB signaling proteins are present in neurons, it

was demonstrated that mice genetically lacking p65 fail to express other subunits at the
synapse25-27. This suggests that p65 is the predominant driver of synaptic NF-κB
expression. In a non-activated state p65/p50 is held inactive in the cytoplasm by inhibitory
κB regulatory proteins (IκBs)28. IκBα prevents NF-κB translocation by physically masking
p65 nuclear localization signals. NF-κB pathway activation, by one of over 150 inducers,
causes IκB phosphorylation and degradation, allowing p65/p50 to translocate to the
nucleus and regulate transcription28,

29

. An additional level of NF-κB regulation occurs

through post-translational modifications to p65, p50, and IκB, primarily through
phosphorylation. Phosphorylation of NF-κB family proteins can act to either stabilize
inactive or active forms, thereby regulating both activation and repression of NF-κB
signaling30. The majority of NF-κB regulation studies have been performed in cells other
than neurons; therefore the specific mechanisms guiding the selectivity and duration of
activation in the CNS are not completely understood.
Early studies of NF-κB signaling in neurons provided evidence for high basal
(constitutive) activity based on antibody staining and reporter assays of glutamatergic
neurons in the hippocampus and cortex25. These findings were later extended to other
brain regions including the amygdala, hypothalamus, olfactory bulbs, and cerebellum31, 32.
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Several studies demonstrated that constitutive neuronal NF-κB activity is likely a result of
glutamate signaling and excitatory stimulation27, 33, 34. Inducible NF-κB activity in neurons
has been historically debated. However, inducible NF-κB proteins have been identified at
the synapse, where they traffic back to the nucleus in response to neuronal activity from
glutamate stimulation and regulate activity dependent transcription27, 35. Accordingly, NFκB family proteins c-Rel36-38, RelA/p6527, and p5039 have all been implicated in learning
and memory. Genes with NF-κB transcriptional response elements are selectively
enhanced in response to learning tasks in mouse models, suggesting NF-κB mediated
transcriptional regulation is critical for synaptic changes that underlie plasticity37, 40. Studies
modulating NF-κB activity though exogenous expression or genetic deletion of NF-κB
proteins have revealed marked synaptic changes. Exogenous expression of NF-κB within
hippocampal pyramidal neuron cultures results in an increase in excitatory synapse
density, but no change in inhibitory synapses41. Loss of p65 expression leads to a
reduction in dendritic spines in early hippocampal development. Accordingly, NF-κB
activity is the highest before and during rapid synapse formation and decreases following
synapse formation41. However, mature neurons can increase NF-κB signaling in response
to demand for synaptic plasticity. Mature hippocampal neurons stimulated with bicuculline
or 17β-estradiol show increased dendritic spine and synapse numbers similar to
experience dependent plasticity in mammals42. In the absence of p65 this response is
completely absent, demonstrating the necessity of NF-κB signaling in synapse remodeling
within adult neurons41. Much of the work on NF-κB stems from studies of hippocampal and
cortical neurons. The expression pattern and functions of NF-κB signaling in cerebellar
neurons share some similarities, but also appear to have some distinction.
Cerebellar NF-κB signaling shows temporal differences in activity and induction that
appear to differ from other brain regions. In rats, constitutive NF-κB is expressed in the

16
early developing cerebellum at post-natal day 5 (P5), but constitutive expression is lost by
P7, where it shifts to inducible expression controlled by glutamate43. In mice, cerebellar
granule cell cultures generated from older mice (8-10 days old) show constitutive activity,
whereas cultures generated from younger mice (2-3 days old) show glutamate inducible
NF-κB expression33. Therefore, inducible activation appears to be temporally regulated
during development, as glutamate also fails to activate NF-κB in cerebellar granule cells in
adult mice33. Functionally, NF-κB activation in cerebellar granule cells is important for cell
survival. Overexpression of NF-κB subunit p65 protects cerebellar granule cells from
apoptosis induced by low potassium levels. In parallel, increased expression of IκBα leads
to increased apoptosis even in high potassium conditions44. Other studies have revealed
that long lasting NF-κB activation by exposure to sub-toxic levels of amyloid β protect
cerebellar granule cells from apoptosis upon exposure to higher doses of toxins45, 46. The
role for NF-κB in regulating cell survival mechanisms has been extended to protection
against excitotoxicity and oxidative stress in other neuronal cell types47, 48. While there are
clear protective roles of NF-κB activity, dysregulation of NF-κB activation has been
described in neuroinflammation, Alzheimer’s disease, Parkinson’s disease, and ageassociated hypothalamic decline

49

. This argues that tight regulation of NF-κB signaling is

critical for proper function.
Regulation of NF-κB Signaling
Regulation of NF-κB signaling is extraordinarily complex, due to the vast array of
activating pathways. In the CNS, NF-κB can be activated by inflammatory cytokines (TNFα) in response to tissue injury50,

51

, nerve growth factor (NGF)52, Ca2+

aspartate (NMDA)54, reactive oxygen species (ROS)55, β-amyloid

27, 53

, methyl-D-

56

, and insulin-like

growth factor (IGF-1)57 among others. Additionally, pattern recognition receptors (PRRs)
and immune protein activation can lead to increased NF-κB activation, yet the
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understanding of this mode of activation in neurons is poorly understood. In regards to
activation by immune signaling, the mechanisms of regulation become even more
complicated as many PRRs and immune proteins are transcriptionally regulated by NF-κB
activity creating the potential for the synthesis of further modes of NF-κB activation20. The
primary mechanism for regulating NF-κB activity is through autoregulation by IκB proteins.
Activation of NF-κB leads to the transcription of IκB, which functions to shuttle p65 out of
the nucleus and hold it inactive in the cytoplasm, thereby resolving activation58.

Further

regulation occurs at the level of post-translational modifications to NF-κB family proteins
including phosphorylation, acetylation, glycosylation, ubiquitination, and sumoyation30,
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.

Specific post-translational modifications relevant to our studies will be discussed in the
results and discussion sections.
Dysregulation of NF-κB Signaling in the Aged Cerebellum
Multiple lines of evidence point to NF-κB dysregulation in the aging cerebellum,
including (1) increased immune gene expression, (2) increased granule cell layer
excitatory synaptic density, (3) reduced global excitatory function, (4) the absence of overt
cell loss, and (5) functional impairments. To confirm potential dysregulation of NF-κB
signaling in the aging cerebellum, we performed an unbiased phosphorylated protein array
to assess protein and phosphoprotein levels (1318 site-specific antibodies) from greater
than 30 signaling pathways. Additionally, we generated a protocol for the isolation and
culture of neurons, enriched for primary cerebellar granule cells (pCGCs). This culture
system was then characterized for cell purity, the expression of NF-κB signaling
molecules, PRRs, and immune molecules, as well as for synaptic development. With the
goal of detailing a signaling pathway from PRR activation to NF-κB signaling in cerebellar
neurons, we needed to select a single PRR to serve as the initiation point for our pathway.
Toll-like receptor 2 was chose for the following reasons, (1) Tlr2 expression is increased in
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the aged cerebellum, (2) Tlr2 has a well characterized, commercially available, and
specific synthetic agonist (Pam3CSK4), (3) our lab had access to Tlr2 deficient mice to
serve as controls. Therefore, we stimulated pCGC cultures with Pam3CSK4 and
measured induction of NF-κB activity. Measuring activation of NF-κB signaling can be
achieved at multiple levels using current techniques that investigate independent stages of
activation from DNA binding, transcriptional control, translocation, and signaling protein
phosphorylation. In efforts to provide the most detailed assessment of NF-κB activation in
response to PRR stimulation, we employed multiple methods listed above including
measuring translocation, NF-κB protein phosphorylation, NF-κB reporter assay, and
quantifying downstream transcriptional products. The works presented in this chapter are
the summary of our investigation into mechanisms that may underlie age-related
dysregulation of NF-κB signaling in the cerebellum.

Methods and Materials
Animals
All studies were carried out in accordance with the NIH Guide for the Care and Use
of Laboratory Animals. Breeder triads (2♀ and 1♂) of wild-type C57BL/6J mice were
purchased from Jackson labs (Stock #000664) and mice generated from these breeders
were used for all studies, with exception of phosphoprotein arrays. Breeder triads were
replaced with a new cohort purchased from Jackson after roughly 1 year. For
phosphoprotein arrays adult (12 month) and aged (20 month) C57BL/6J mice were
obtained from Hilltop Labs (C57BL/6Hla®CVF®). Hilltop Labs was a new vendor, so per
University of Nebraska Medical Center policy, the mice were quarantined for 2 months
until adult mice were 14 months of age and aged mice were 22 months of age. At this
time mice were processed for downstream analysis. For all other mice, upon arrival at
UNMC, mice were housed (< 5 per cage) in microisolator cages in rooms with a 12:12
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lighting cycle (lights on 0600 CST), provided with chow (Envigo Teklad #7012) and water
ad libitum. Mice purchased for breeding were allowed to acclimate for at least one week
before being transferred to cages for breeding. To test specificity of Pam3CSK4 à Tlr2
à NF-κB signaling, mice lacking Tlr2 receptor (Tlr2tm1Aki) were used. Mice were housed
and bred using same detailed strategy as above (For full details on these mice, see
Chapter 3 Methods).
Phospho Explorer Antibody Array
Aging frequently impacts cell signaling pathways, which are vital to proper neuronal
function. The components of these signaling pathways, their alterations in specific
groups of neurons, and role in cellular aberrations are of significance, yet remain
unclear. Many proteins in cell signaling are regulated by phosphorylation via kinases that
either inhibit or enhance activity. Therefore, assessing protein phosphorylation status
within a given pathway can offer insight regarding its activation state. Our previous data
suggests dysregulation of NF-κB signaling based on unbiased microarray analysis of the
cerebellar transcriptome. However, as aging affects multiple pathways, we felt it
necessary and more informative to take a similar unbiased approach when assessing
signaling pathway activation. To assess for age related changes in protein
phosphorylation we purchased Phospho Explorer protein microarrays from Full Moon
Biosciences (Sunnyvale CA, Catalog # PEX100). Manufacturer array validation suggests
92% reactivity for mouse proteins across 1318 site-specific and phosphospecific
antibodies from greater than 30 signaling pathways. Each slide contains 2 technical
replicates per Ab, with positive (GAPDH, β-actin) and negative controls. We obtained
samples for 3 biological replicates per cohort of old (22-month) and adult (14-month)
C57BL/6 mice.
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To isolate cerebellar tissues, mice were euthanized with CO2 followed by rapid
decapitation and removal of the brain. The cerebellum and meninges were removed
under a dissection microscope with fine microdissection forceps in ice cold phosphate
buffered saline (PBS) (Hyclone #SH30256). Dissected cerebellar tissue was then flash
frozen in small conical tubes in a dry-ice and ethanol slurry. All samples were stored at 80° C until further processing. To prepare cerebellar lystate for protein arrays, samples
were thawed on ice and 20 mg of cerebellar tissue was removed for lysate preparation.
Remaining tissue was once again flash frozen and stored at -80° C for future use.
Thawed tissues were washed by vortexing in ice cold PBS five times. Protein lysates
were extracted using the buffer provided in the kit with the addition of phosphatase
inhibitors (ThermoFisher #78420) and protease inhibitors (Sigma #P8340) at 1:100
dilution. Briefly, 100 µl of ice-cold extraction buffer was added to tissue along with one
vial of metal beads. To disrupt tissues, samples were taken though 5 cycles consisting of
30 second vortexing followed by 10 minute incubation on ice. Following disruption,
lysates were centrifuged at 10,000 G for 5 minutes at 4° C. The supernatant was
transferred to a new tube and centrifuged again at 18,000 G for 15 minutes at 4° C. The
resulting supernatant was then collected in a clean tube and 100 µl of the lysate was
added to a pre-prepared purification spin column. Columns were centrifuged at 750 G for
2 minutes at 4° C and the remaining lysate was assessed for quality and concentration
(by spectrophotometry at A280). Low quality, cloudy, or unclear lysates can result in low
labeling efficiency and high background. High quality and clarity lysates show two clearly
separated peaks, one between 200-230 nm and a second between 240-270 nm. All
samples used for protein arrays had two distinct peaks and no noticeable opaqueness.
Lysate concentration was determined by bicinchoninic acid (BCA) assay (Pierce Catalog
# 23225) according to manufacturer protocol. After quality control and quantification
lysates were frozen on dry ice and ethanol and stored at -80° C until further use.
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Lysates were allowed to thaw on ice, and 70 µg of lysate was biotinylated using
biotin reagent and N,N-Dimethylformamide provided in the kit. Antibody array slides
were brought to room temperature, dried, and blocked for 45 minutes in provided
blocking buffer. Slides were rinsed extensively with ultrapure water obtained from a MilliQ system. Protein lysate was then coupled to antibody array slides for 2 hours at room
temperature. Slides were washed extensively again. For the detection of proteins, slides
were incubated with Cy-3 streptavadin (Sigma #56402) at 0.5 mg/ml in detection buffer
for 20 minutes at room temperature. Slides were washed extensively again, and quickly
dried using bench top air outlet with an inline flow regulator. All slides were then sent to
Full Moon Biosystems for image collection. Images received from Full Moon Biosystems
were then analyzed using GenePix Pro Microarray Analysis Software (GenePix
4000B,Molecular Devices, Sunnyvale CA), graciously supplied by the University of
Nebraska Medical Center Genomics Core facility to generate fluorescent intensity values
for each spot.
Phospho Explorer Antibody Array Data Analysis
To normalize intensity values across multiple slides, all values were divided by the
median fluorescence value for all spots on the corresponding slide, per manufacturer’s
recommendation. In addition to total and phosphorylated protein levels, we wanted to
assess the ratio of phosphorylated to total protein for each target. Therefore, we divided
the total phosphorylated protein value by the total protein values to generate a ratio for
each phosphorylation site-specific antibody. The resulting normalized values for total,
phosphorylated, and the phosphorylated protein ratios were analyzed using by two-tailed
student t-tests assuming unequal variance with an alpha of 0.05. We used this data to
generate volcano plots of differentially expressed proteins between middle-aged adult
and aged cerebellar samples for total, phosphorylated, and phosphorylation ratios for
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each protein plotted as significance (–log10(p-value)) versus fold change (log2(ratio)).
Proteins with an alpha of <0.05 and a greater than 33% change from adult cerebellar
expression are considered significant in volcano plot analysis. To determine biological
themes

present

in

the

differentially

expressed

protein,

phosphoprotein,

and

phosphoprotein to total protein ratios, we analyzed differentially expressed protein lists
with Panther (version 11.1)60.
Cerebellar Granule Cell Cultures
To prepare cerebellar neuron cultures, post-natal mice (P0/1-P9) were rapidly
decapitated, and the brain was removed and placed into cold calcium-magnesium free
PBS in a petri dish on ice. For the majority of studies, P4-P6 mouse pups were used, as
they yielded the most cells and best viability. For some early validation studies other
ages were used and noted in the results. Brains were then transferred to a new petri
dish with fresh ice cold PBS and the cerebellum was removed under a dissecting
microscope. The white matter in the center of the cerebellum containing the deep
cerebellar nuclei was removed leaving predominately cerebellar folia with a small
amount of white matter connecting them. Meninges were removed in strips by carefully
pulling meningeal tissue laterally along the surface of the brain using fine dissection
forceps. Cerebellar tissue was then transferred to a new petri dish with ice-cold PBS
(Hyclone #SH30256). This process was then repeated for additional brains with a
maximum of 12 per procedure in efforts to minimize time from dissection to culture.
Once all brains were dissected, each was segmented into small relatively uniform (1-2
mm) pieces using micro dissection scissors under a dissecting microscope. Using a 25
mL pipette the tissue pieces were transferred to separate 15 mL conical tubes holding
10 mL of cold PBS. As a wash step dissected tissues were allowed to sink to the bottom
of the conical tubes. PBS was then aspirated from the tubes and 1 mL of a trypsin
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solution (1200 µL of 2.5% Trypsin (Worthington Labs #3707), 33 µL 30% glucose (Fisher
#D16), and 1767 µL of BME stock solution (240 mL Earls Balanced Salt Solution
(EBSS), 2.5 mL Basal Medium Eagle vitamins (Sigma-Aldrich #B6891), 2.5 mL Basal
Medium Eagle amino acid solution (Sigma-Aldrich #B6766), and 1 M NaHCO3 to pH of
7.2-7.4) was added. Tissue was incubated at room temperature in trypsin solution for 3
minutes with occasional manual mixing to evenly distribute tissues in solution. Following
incubation, trypsin solution was removed and 1 mL of DNase solution (150 µL of 1%
DNase (Sigma #DN25), 183 µL 30% D-glucose, and 2817 µL of BME stock solution)
was added to degrade any DNA released for cells damaged during dissection. The
addition of DNase solution aids in downstream trituration, as it reduces tissue clumping.
Using a P1000 pipette set to 750 µL the tissue was triturated until a single cell
suspension was formed (trituration maximum of 15 repetitions). The single cell
suspension was then centrifuged at 700G for 5 minutes at 4 °C. The DNase solution was
then removed and 2 mL of cold PBS with 500 µL of DNase solution was added, followed
by resuspension using a P1000 pipette as previously described. The single cell
suspension in each tube was then filtered through a 40 µm nylon cell strainer (BD Falcon
#352340) into new 15 mL conical tubes to remove any aggregated cells or tissue that
failed to breakdown. After filtering, cells were pelleted by centrifugation at 700G for 5
minutes at 4 °C. The PBS/DNase solution was removed and the pellet re-suspended in 1
mL pre-warmed serum containing plating media (81.5 mL BME stock solution, 5 mL fetal
bovine serum (Gibco #10100-139), 2.5 mL horse serum (Sigma-Aldrich #H1138), 50 µL
pen-strep solution (Gibco #15140-122), 500 µL L-glutamine (Gibco #25030-081), 800 µl
30% glucose D-glucose (Sigma #G8270), and 50 µL of 1% DNAase solution. Cells
density was quantified using a hemocytometer. For immunocytochemistry studies cells
were plated at a density of 200,000 cells per 14 mm onto glass insert petri dishes
(MatTek #P35G-0-14-C) or 24 well plastic bottom dishes (BD Falcon #351147). For
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western blot or RNA analysis cells were plated at 1,500,000 cells per well in 6 well plates
(BD Falcon #353046). All plating surfaces were coated with 100 µM poly-D-lysine
(Sigma #P7886 or #P6407) for 4-6 hours before cell isolation and washed twice with
sterile culture grade water (Hycone #SH30529) before plating. Cells were incubated for
4-6 hours at 37 °C and 5% CO2 to facilitate adherence. Serum containing media was
removed and each coverslip or petri dish was gently rinsed with pre-warm serum free
media (92.4 mL Low-Glucose DMEM (Life #11965-092), 2 mL of N2 supplement (Gibco
#17502-048), 2 mL B27 supplement (Gibco #17504-044), 1.6 µl 20% sucrose (Fisher
#BP22-01), 1 mL L-glutamine, and 100 µl Pen-Strep). Fresh pre-warmed serum-free
media (2 mL) was then added to each well. After two days in culture, 5 µM AraC (Sigma
#C1768) was added to inhibit the growth of dividing cells, primarily glia and endothelial
cells. One half of the media was replaced with fresh serum free media on day 4 and then
every half of the media was changed every three days.
Pam3CSK4 Treatment of Cerebellar Granule Cell Cultures
Cerebellar granule cell cultures were treated with Pam3CSK4 (molecular formula
C81H156N10O13S), a synthetic triacylated lipoprotein that mimics the acylated amino
terminus of bacterial lipoproteins. Pam3CSK4 (Invivogen #tlrl-pms) was diluted in sterile
cell culture grade water (Hyclone #SH30529) at a concentration of 0.5 mg/mL and stored
at -20 °C until further use. Pam3CSK4 has been shown to be a potent activator of NF-κB
signaling through ligation and activation of Tlr1/2 heterodimers in multiple cell types.
Cerebellar granule cell cultures were treated at a concentration of 1 µg per ml of media.
All cultures were treated on day in vitro 6 (DIV6), but the duration of treatment varied
depending on downstream analysis. To assess NF-κB activation pCGCs were treated at
DIV4 and RNA was collected after 2, 8, 24, and 72 hours to quantify NF-κB
transcriptional products. To demonstrate that downstream transcriptional products are
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the result of Tlr2 induced NF-κB activity, pCGC cultures were treated with pyrrolidine
dithiocarbamate (PDTC), a potent inhibitor of NF-κB activation. PDTC is thought to
inhibit NF-κB activity by reversibly blocking phosphorylation and degradation of the IκBα
inhibitory subunit, thereby preventing translocation of NF-κB subunits (p50/p65)61. pCGC
cultures were pre-treated with 300 uM PDTC (Sigma #P8765, reconstituted in sterile
water) for 30 minutes, followed by Pam3CSK4 treatment as detailed above. For Western
blot analysis of NF-κB phosphorylation, pCGC cultures were treated with or without
PDTC pretreatment and protein was collected after 2 hours post treatment. To determine
the level of NF-κB activation by p65-GFP translocation, pCGCs were transfected and
treated for 1 hour and processed for immunocytochemistry. NF-κB activation was also
assessed using a fluorescent p65 reporter assay after 48 hours of Pam3CSK4
treatment.
Cerebellar Granule Cell Culture Transfection
In order to assess NF-κB activation by translocation of p65 or p65 reporter assay,
pCGC cultures were transfected with corresponding plasmids. Transfection of pCGC
cultures were carried out at DIV2 using lipofectamine 2000 (ThermoFisher #11668027)
with 1.0 µg p65-GFP (Addgene #23255) or 1.0 µg p65-GFP-rpt (generous gift from
Dongsheg Cai Laboratory62) and 0.5 µg Tdtomato using manufacturers recommended
protocol. Briefly, in one tube plasmid DNA was combined with DMEM (Life #11965-092)
at the concentrations above to reach 25 µL per well. In a second tube, 2 µL
lipofectamine per well was combined with 23 µL per well of DMEM. The tubes were
mixed, incubated at room temperature for 15 minutes, and 50 µL of the mixture added to
each well. TdTomato transfection served as a counterstain for unbiased identification of
transfected cells.
Immunocytochemistry
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Primary cerebellar neuron cultures were fixed 4% Paraformaldehyde/4% sucrose
solution pre-warmed to 37 °C for 10 minutes at room temperature. Cultures were rinsed
3 times in PBS (Hyclone). To allow antibody access to intracellular protein epitopes, cell
cultures were permeabilized with 0.1% triton X-100 for 10 minutes at room temperature.
Following permeabilization cells were rinsed 3 times for 10 minutes in PBS then blocked
with 5% BSA in PBS for 1 hour at room temperature. After blocking, primary antibodies
were diluted in 1% BSA in PBS and incubated overnight at 4 °C. A primary and
secondary antibody list containing the target, company, catalog number, and dilution for
antibodies used in Chapter 1 is provided in Table 1. After primary incubation cells were
rinsed 3 times in PBS, and incubated with secondary antibodies diluted in 1% BSA in
PBS for 1 hour at room temperature. Cells were then washed 3 times with PBS for 10
minutes

each.

Nuclear

counterstaining

was

completed

with

4’,6-diamidino-2-

phenylindole (DAPI) in PBS for 1 minute. Cells were rinsed twice with PBS and then
cover slipped using Prolong Gold or Diamond Antifade Reagent (Invitrogen P36934 or
P36961). Mounting media was allowed to dry overnight in the dark and then samples
were stored at -20°C until imaging.
Primary Cerebellar Granule Cell RNA Extraction and Quality Assessment
RNA was isolated from cerebellar granule cell cultures using an RNeasy minikit
(Qiagen #74104). Briefly, wells were rinsed once in sterile PBS and 350 µL RLT Lysis
Buffer was added. Wells were repeatedly rinsed with lysis buffer to ensure even cell
disruption. Lysis buffer was then collected into an Eppendorf tube and manually
disrupted using a tuberculin syringe by drawing buffer in and out of the syringe five
times. The remainder of the protocol was performed as described in manufacturer
protocols. RNA samples for developmental expression of PRRs and immune proteins
were not processed with DNase digestion step. However, for samples from treated
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Table 1. List of antibodies used for Chapter 1 experiments
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cerebellar granule cell cultures the DNase digestion step was added. We did not notice
any quantifiable difference in RNA quality obtained from either process. RNA purity was
assessed using a spectrophotometry (NanoDrop II, Thermo, Waltham MA) to measure
A260/230 and A260/280 ratios. RNA degradation was assessed by micro gel
electrophoresis (BioAnalyzer 2100, Agilent Technologies). Only RNA samples meeting
minimum purity and quality were used for downstream analysis. Specifically, any
samples with A260/A280 ratios less than 1.8 were deemed unsuitable for analysis
secondary to RNA contamination. Additionally, any samples with larger 18S instead of
28S peaks, or RNA integrity numbers (RINs) < 7.0 were deemed unsuitable for analysis
secondary to RNA degradation.
Real-Time PCR Analysis
One-Step RT-PCR was performed using Verso SYBR Green 1-Step kits (Thermo
Scientific Catalog #AB4105) according to manufacture protocols with all samples run in
triplicate. All reactions were processed with no enzyme and no template controls. All
primers used were commercially available Qiagen Quantitect primers. A full list,
including catalog numbers, for primers used in the work presented in Chapter 1 are
provided in Table 2. RT-PCR data was analyzed for relative expression using the 2(-ΔΔCT)
method with normalization to Gusb as a housekeeping gene using Microsoft Excel. To
quantify differences between culture days, one-way analysis of variance testing with
Bonferroni post-hoc analysis was performed. For analysis of transcript expression with
Tlr2 stimulation, a one-way ANOVA was performed for the 2-hour and 8 hour treatment
groups. For 24, 48, and 72 hours two-tailed student t-tests were performed. All statistical
comparisons were made using IBM SPSS Statistics 22 or Microsoft Excel 2010.

29

Table 2. List of primers used for Chapter 1 RT-PCR experiments
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Primary Cerebellar Granule Cell Culture Protein Isolation
To analyze the activation state of NF-κB signaling and protein expression lysates
were collected from pCGC cultures in control or treated conditions. Primary neuronal
cultures were washed with twice with ice cold PBS, followed by incubation with RIPA
buffer (1% Triton X-100, 0.1% SDS, 50mM Tris (pH 7.4), 107 mM NaCl, Halt
Phosphatase Inhibitor (ThermoFisher #78420, 1:100), Protease Inhibitor (Sigma
#P8340, 1:100), 5 mM EGTA, and 5 mM EDTA) for 15 minutes on a rotary shaker set to
100-140 rpm. Wells were scraped using a rubber cell scraper and the lysate collected,
sonicated, and centrifuged at 14,000 G for 15 minutes at 4° C. Protein concentration was
then quantified by BCA assay (Pierce Catalog # 23225) according to manufacturer
protocol.
Western Blot Analysis
Lysate was run on 4-12% SDS-Page gels. Protein was transferred to PVDF
membranes, blocked in 5% non-fat milk for total protein antibodies or 5% BSA for
phospho-specific antibodies overnight at 4°C. Blots were then rinsed in TBST and
probed with species appropriate secondary antibodies for 1 hour at room temperature.
For a complete list of antibodies used in this chapter, please refer to Table 1. Some
blots were stripped for multiple rounds of antibody staining using RestoreTM Plus
Western Blot Stripping Buffer (ThermoFisher #46430) for 10 to 15 minutes at room
temperature on a rocker. If blots were to be stripped, they were always probed with
phosphorylation specific antibodies first. All blots were imaged using SuperSignal West
Extended Duration chemiluminescence HRP substrate (ThermoFisher #34075) and
analyzed using AlphaView software (Version 3.4.0.0, ProteinSimple). Data was loaded
into Excel to generate graphics. For comparison of two groups, two-tail student t-tests
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were used. For comparisons of more than two groups, data was analyzed by one-way
ANOVA with Bonferroni post hoc analysis using IBM SPSS Statistics 22.
Confocal Microscopy
All images were collected using a Zeiss LSM 700 scanning confocal microscope
using either 10x (Zeiss EC Pan-Neofluar 10x/0.3 NA, 1.11 µm resolution, #440330-9902000), 20x (Zeiss EC Plan-Neofluar 20x/0.50 NA, 0.67 µm resolution, #420350-9900000), or 40x (Zeiss EC Plan-Apochromat 40x/1.3 NA, 0.26 µm resolution, #4207629800-799) objectives. All data was collected using settings optimized for each
experiment and the settings were maintained across all samples. Confocal imaging was
restricted to a maximum of 4 channels using 405 nm (5 mW), 488 nm (10 mW), 555 nm
(10 mW), and 639 nm (5 mW) diode lasers, with each set to collect on independent
channel for minimal bleed through. For pCGC culture cell type analysis, images were
collected using the 20x objective with 0.5x digital zoom to increase the field of view.
Images for translocation studies were collected at 40x with a 4x digital zoom. To assess
NF-κB reporter assay expression z-stack images were collected at 40x with 0.5x digital
zoom. For PRR and NF-κB signaling protein expression in pCGC cultures, images were
collected using a 40x objective with 2x digital zoom.
pCGC Culture Cell Type Analysis
To determine the relative distribution of cell types to the cultured cell population,
pCGC cultures were fixed and immunostained for markers of neurons (NeuN),
astrocytes (GFAP), and microglia (CD11b) at DIV6. This process was performed on
cultures generated from P3, P5, P7, and P9 C57BL6/J pups to assess if post-natal age
effects cell distribution. Images were collected by confocal microscopy and analyzed
using analyze particles feature in ImageJ software63. A minimum of 8 fields (technical
replicates) per sample were imaged across multiple experimental (biological) replicates
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(P3 n = 3, P5 n = 3, P7 n= 2, P9 n= 3). Images were uploaded as .lsm files and the
global scale was set based on imaging perimeters.

For the DAPI+ and NeuN+ cell

quantification, a macro was used to automate the counting procedure. First, the batch
threshold was set manually where fainter cells were quantifiable while the brighter cells
remained distinct from surrounding cells. Images were then smoothed to ensure
detection of cell borders and converted to binary, where the water shed function was
used to separate closely opposed cells. Cells were quantified using the analyze particles
function controlling for size and circularity. To validate count accuracy, the masks feature
was used and overlaid on the original image. For quantification of the non-nuclear
immunoreactivity of GFAP and CD11b, the positive cells were counted manually using
the cell counter application of ImageJ.
pCGC Culture Apoptosis Analysis
It was clear from cell type quantification that a small percentage of DAPI positive
cells were not NeuN, GFAP, or CD11b positive, suggesting the presence of other cell
types or apoptotic cells that have lost protein expression. Additionally, we felt it
necessary to characterize the level of cell death in pCGC cultures in control conditions.
Therefore, pCGC cultures generated from P5, 7 and 9 mice were fixed for quantification
of cleaved caspase-3 positive cells, as a marker of cell apoptosis. Images were collected
at 20x and quantified using ImageJ analyze particle functions as described previously.
The number of cleaved caspase-3 positive cells and DAPI positive cells were used to
quantify the percentage of apoptotic cells in pCGC cultures at DIV6. For this validation
study we captured a minimum of 8 images per well across multiple wells for each
biological sample (P5 n = 2, P7 n = 2, P9 n = 2). Statistics were not performed due to the
limited number of biological samples assessed.
Quantification of p65-GFP Translocation
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For downstream transcriptional regulation by NF-κB signaling to occur, NF-κB
subunits must translocate from the cytoplasm to the nucleus. As a method of quantifying
NF-κB activation, we assessed translocation of GFP tagged p65 in pCGC cultures
stimulated with a PRR agonist. pCGCs were transfected with p65-GFP and TdTomato
constructs at DIV2 and treated with 1.0 µg / mL of Pam3CSK4 at DIV6. Following 1 hour
of stimulation with Pam3CSK4, cells were fixed, immunostained for IκB, and imaged
using confocal microscopy.

To assess for nuclear translocation of p65-GFP, the

cytoplasmic and nuclear fluorescent intensity of transfected primary cerebellar neurons
was calculated using ImageJ software. The nuclear region of each cell was traced using
the DAPI channel, and the outline of the cell body was traced using counter transfected
TdTomato. The GFP fluorescence of the nuclear region was then measured, followed by
the GFP fluorescence of the cytoplasm after subtracting the nucleus from the cell. The
average nuclear to cytoplasmic ratio and the number of cells with a nuclear to
cytoplasmic ratio greater than 1 were calculated. Similarly, the fluorescent intensity of
IκBα immunostaining in the cytoplasm and nucleus was quantified using ImageJ. We
imaged over 40 cells per condition (60 control, 47 Pam3CSK4) distributed across 3
biological replicates. Data was analyzed by multiway analysis of variance (MANOVA)
using IBM SPSS Statistics 22 controlling for sample, treatment, and sample*treatment
interactions.
Quantification of p65 Reporter
Primary cerebellar granule cell cultures were transfected with p65-GFP reporter and
tdTomato at DIV2. On DIV4 cells were treated for 48 hours with 1.0 µg Pam3CSK4 and
fixed on DIV6. Blinded samples of fixed pCGC cultures were imaged using confocal
microscopy to assess the level of GFP fluorescence in transfected neurons. Cells to be
imaged were identified by Tdtomato expression to avoid selection of only the brightest
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GFP cells. Using ImageJ software, the TdTomato signal was used to create a cell mask
for each transfected neurons and the GFP signaling intensity and integrated density was
measured for each cell. Using this method we analyzed 243 control cells and 190
Pam3CSK4 cells, distributed across 4 biologic replicates (Sample 1 140; Sample 2 108,
Sample 3 104; Sample 4 81). Data was imported into IBM SPSS Statistics 22 and a
multiway analysis of variance (MANOVA) was performed to determine if sample,
treatment, or sample*treatment interactions had an effect on characteristics of GFP
fluorescence (Mean, Median, Max, Integrated Density).

Results
Increased NF-κ B Related Protein Phosphorylation in the Aging C57Bl6/J
Cerebellum
Our previous data demonstrates a significant upregulation of immune protein
transcripts associated with in NF-κB signaling in the cerebellum of aged compared to
young mice. Transcriptional data provides an excellent view into potential dysregulated
cellular processes, but it fails to provide information on the activation state of specific
pathways. As many signaling pathways are regulated by kinases, investigating the
protein phosphorylation state can provide critical knowledge regarding the activation of
specific signaling modalities. In efforts to obtain unbiased data on which signaling
pathways may be dysregulated in the aging cerebellum, we examined differences in
protein expression and phosphorylation status between middle-aged adult (14 mo.) and
aged (22 mo.) male C57BL/6J mice. We assessed levels of phosphorylated proteins
within over 30 signaling pathways, and use ontology analysis to determine over
represented pathways. Differences at individual protein loci were first determined by twosided, unequal variance t-test. Within the aged brain, we detected 31 differentially
expressed total proteins, 19 phosphorylated proteins, and 20 phosphorylated
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protein/total protein ratios (Table 3). Further analysis was performed to generate
volcano plots presenting the data as a function of significance versus fold change. Using
this method we identified 11 total proteins (Figure 1A), 3 phosphorylated proteins
(Figure 2A), and 12 phosphorylated protein/total protein ratios (Figure 3A) with greater
than a 33% change between adult and aged mice. Next, we processed each of the
differentially expressed protein lists through ontology analysis with

Panther (version

11.1) to determine biological themes present within each category60. Ontological
analysis of differentially expressed total proteins demonstrated age-associated
enrichment in several pathways pertaining to reactive oxygen species generation and
response, cell aging, positive regulation of neuron death, response to calcium, cell
responses to damage (gamma and UV radiation), and transmembrane receptor tyrosine
protein tyrosine kinase signaling, among others (Figure 1B). Phosphorylated proteins in
the aged cerebellum correspond to pathways involved in neurotrophin signaling, positive
regulation of superoxide anion generation, negative and positive regulation of apoptotic
signaling, negative regulation of kinase activity, and several pathway associated with cell
stress

responses,

among

others

(Figure

2B).

Ontological

analysis

of

protein/phosphoprotein ratios demonstrated age-associated enrichment for pathways
involved in MAPK signaling, negative regulation of protein kinase signaling, apoptotic
processes, and several CNS specific pathways including neuron differentiation and
neurogenesis (Figure 3B). Of particular interest to our hypothesis, several proteins
differentially expressed in the aged cerebellum interact with spleen tyrosine kinase
(Syk), a kinase upstream of NF-κB activation. These interacting proteins include Src,
Cd5, Zap70, Vav1, Shc1, Pla2g4a, Raf1, and Hsp2764-67. Additionally, c-Pla268, Fos69,
Bim70, Beta-amyloid A471, PKC delta72, and EGFR73 are all increased in the aged brain
and have κB binding sites within the promotor or are linked to NF-κB activation. This
data demonstrates that cerebellar aging is associated with a more global dysregulation
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Table 3. Differentially expressed protein results from phospho protein array
sorted by fold change for total protein, phosphorylated protein, and
phosphoprotein ratios.
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Figure 1. Protein expression data from array and ontology analysis.
Continued on the next page…
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Figure 1. Total protein expression data from array and ontology analysis
continued... Volcano plot generated to demonstrate total protein expression in
middle aged and aged cerebellar tissue versus the statistical significance of the
observed difference. The fold change ratio values are represented on the x-axis
(ratio) with the statistical significance on the y-axis (p-values). Proteins with a 33% or
greater increase in aged mice are represented in the upper left corner. Proteins with a
33% or greater decrease in aged mice are represented in the upper right. The top
center region contains proteins that were significantly different (p < 0.05) between
adult and aged cerebellum, but were less than a 33% change. All proteins below the
center horizontal line failed to reach significance. Differentially expressed proteins
were processed through ontology analysis using PANTHER (11.1) to determine
enriched biological themes.
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Figure
2.
Phosphorylated
expression data from array and
ontology analysis.
Volcano plot
generated
to
demonstrate
phosphoprotein expression in middle
aged and aged cerebellar tissue versus
the statistical significance of the
observed difference. The fold change
ratio values are represented on the xaxis
(ratio)
with
the
statistical
significance on the y-axis (p-values).
Phosphoproteins with a 33% or greater
increase in aged mice are represented
in
the
upper
left
corner.
Phosphoproteins with a 33% or greater
decrease in aged mice are represented
in the upper right. The top center region
contains phosphoproteins that were
significantly different (p < 0.05)
between adult and aged cerebellum,
but were less than a 33% change. All
phosphoproteins below the center
horizontal
line
failed
to
reach
significance. Differentially expressed
phosphoproteins
were
processed
through
ontology
analysis using
PANTHER (11.1) to determine enriched
biological themes.
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Figure 3. Phosphorylated protein to
total protein ratio expression data
from array and ontology analysis.
Volcano plot generated to demonstrate
the ratio (adult/aged) of the total protein
to phosphoprotein ratios based on
specific antibody pairs versus the
statistical significance of the observed
difference. The fold change ratio values
are represented on the x-axis (ratio)
with the statistical significance on the yaxis (p-values). Protein ratios with a
33% or greater increase in aged mice
are represented in the upper left
corner. Protein ratios with a 33% or
greater decrease in aged mice are
represented in the upper right. The top
center region contains protein ratios
that were significantly different (p <
0.05) between adult and aged
cerebellum, but were less than a 33%
change. All protein ratios below the
center horizontal line failed to reach
significance. Differentially expressed
protein ratios were processed through
ontology analysis using PANTHER
(11.1) to determine enriched biological
themes.
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of proteins whose expression and activation regulate NF-κB. These studies further
validate the hypothesis that NF-κB dysregulation may play a role in aging cerebellar
phenotypes. In efforts to detail a potential mechanism for this dysregulation we
generated and characterized an in vitro cerebellar neuron model.
Establishment and Characterization of a Reduced Systems Culture Model
Primary cerebellar neuron cultures have been used as a reduced system to study
processes associated with neuronal function for over 30 years74. As many differences
exist in protocols for isolation and enrichment of cerebellar granule cells for culture, we
deemed it necessary to characterize and validate our culture system. Key tasks in
characterization were to (1) determine optimal post-natal day to harvest cerebellum for
the highest neuronal yield and viability, (2) determine the percentage and type of
neuronal and non-neuronal cells within the culture, (3) assess neuronal morphology and
gene expression to confirm cerebellar granule cell lineage. Cerebellar neuron cultures
generated for these studies are predominately neuronal with a very small population of
astrocytes and microglia when harvested from post-natal mice between the ages of P3
and P9. Quantification of cell types at DIV6 in cultures generated from different aged
mice demonstrated that greater than 75% of cells within pCGC cultures are NeuN
expressing neurons (P3 77.60 ± 2.82%; P5 80.03 ± 1.13%; P7 81.23 ± 3.04%, P9 78.84
± 1.56%), with less than 2% GFAP expressing astrocytes (P3 1.53 ± 1.19%; P5 1.14 ±
0.70%; P7 0.87± 0.17%; P9 0.35 ± 0.11%), and less than 1% CD11b microglia (P3 0.44
± 0.06%; P5 0.53 ±0.12%; P7 0.37 ± 0.11%; P9 0.37 ± 0.06%) (Figure 4A,B). After
quantification it was evident that a percentage of DAPI positive cells were not NeuN,
GFAP, or CD11b positive, suggesting the presence of other cell types or cells that had
lost protein expression. While NeuN is expressed in the majority of neuronal cell types,
there are subpopulations of neurons that lack NeuN expression. These include Purkinje
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cells, inferior olive neurons, γ-motor neurons of the spinal cord, olfactory bulb mitral
cells, and retinal photoreceptors75. Additionally, loss of NeuN protein expression has
been associated with apoptotic pathway activation and cell death76. Data also
demonstrates that NeuN expression can be reduced in neurons due to damage without
loss of cell viability77. To determine if the discrepancy in cell percentages were a result of
cell death, pCGC cultures were immunostained for cleaved caspase-3, a marker of
apoptotic signaling. Quantification of cleaved caspase-3 in DIV cultures generated from
P5, P7, and P9 mice showed that less than 15% of cells in pCGC cultures were positive
for activated caspase-3 (P5 7.52 ± 0.20%; P7 11.31 ± 4.27%; P9 12.5 ± 1.11%) (Figure
4C). This data demonstrates that the discrepancies in cell percentages are partially
explained by the presence of a small population of apoptotic cells within pCGC cultures.
To further validate the neuronal identity of cells in culture and to validate the presence of
a large population of cerebellar granule cells, we transfected pCGC cultures at DIV2
using a DNA vector with GFP under the CMV promoter. This allowed for the
identification of individual neurons. We stained transfected cultures with NeuN and Tau
to identify neurons and their processes. pCGC cultures demonstrated strong Tau
immunoreactivity grossly, and on the level of individually transfected neurons (Figure
5A). It is important to note that transfected neurons morphologically appear to be
granule cells, evident by a small cell body with little cytoplasm, few dendrites, and a long
thin axon. In efforts to confirm the presence of cerebellar granule cells, we isolated RNA
from pCGC cultures at DIV3, DIV6, and DIV9 and assessed the level of GABA(A)
receptor alpha 6 subunit (GABAR alpha 6), a marker of mature cerebellar granule cells78,
79

. RT-PCR analysis demonstrated a significant (p < 0.01) increase in GABAR alpha 6

expression as pCGC cultures matured (DIV3 1.01 ± 0.21; DIV6 14.47 ± 5.04; DIV9
112.25 ± 3.82, data represented as fold change from DIV3) (Figure 5B). pCGC cultures
contain predominantly excitatory synapses immunopositive for vesicular glutamate
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Figure 4. Primary cerebellar granule cell cultures are enriched for NeuN+ cells.
Primary cerebellar neuron cultures were generated from post-natal mice at various
stages (P3, P5, P7, and P9) of cerebellar development to determine if developmental
age affected the resulting cell distribution. (A) Representative image of cell types for
pCGC cultures generated from C57BL/6J mice at day in vitro 6. Images were
captured at 20x with a 0.5x digital zoom (scale bar = 100 mm). (B) Quantification of
immunocytochemistry for markers of neuronal (NeuN+), astrocytic (GFAP+), and
microglia (CD11b+) populations proved that pCGC cultures are enriched for neuronal
cells, independent of the age of mouse between P3 and P9. NeuN+ neurons
composed >75% of the cell population (P3 77.60 ± 2.82%; P5 80.03 ± 1.13%; P7
81.23 ± 3.04%, P9 78.84 ± 1.56%) at all ages, with < 2% GFAP+ astrocytes (P3 1.53
± 1.19%; P5 1.14 ± 0.70%; P7 0.87± 0.17%; P9 0.35 ± 0.11%) and < 1% CD11b+
microglia (P3 0.44 ± 0.06%; P5 0.53 ±0.12%; P7 0.37 ± 0.11%; P9 0.37 ± 0.06%).
For cell type quantification > 10 image were collected for each sample well across
multiple biological replicates for each age (P3 n = 3; P5 n = 4; P7 n = 2; P9 n = 3). (C)
pCGC cultures were immunostained for cleaved caspase-3 to assess levels of
apoptosis. Apoptotic cells were found to represent less than 15% of all cells in pCGC
cultures independent of the age of pup from P5 to P9 (P5 7.52 ± 0.20%; P7 11.31 ±
4.27%; P9 12.5 ± 1.11%). For apoptosis analysis a minimum of 8 images per well
across multiple wells generated from individual biological replicates were collected
(P5 n = 2; P7 n =2; P9 n = 2).
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Figure 5. Primary cerebellar neuron cultures are enriched for cerebellar granule
cells. To validate the enrichment of cerebellar granule cells, primary neuronal cultures
were transfected with pGFP at DIV2 and immunostained for neuronal proteins NeuN
and Tau at DIV6. (A) pCGC cultures contain pGFP transfected neurons that
morphologically resemble cerebellar granule cells in vivo, with a small cell body, few
dendrites, and a long thin axon. Transfected cells are also positive for neuronal
markers NeuN and Tau. Images were obtained at 20x. Scale bar represents 50 mm.
Mature cerebellar granule cells can be identified by the expression of GABA receptor
subunit alpha 6 (GABAR alpha 6). (B) RT-PCR analysis of RNA isolated from DIV3, 6,
and 9 pCGC cultures demonstrates a significant increase in GABAR alpha 6
expression as cultures mature (DIV3 1.01 ± 0.21; DIV6 14.47 ± 5.04; DIV9 112.25 ±
3.82, data represented as fold change from DIV3. * = p < 0.05, **** = p < 0.0001; n = 3
per time point.
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transporter 1 (vGlut1) and with increasing density from DIV3 to DIV6 (Data not shown,
see WT synapse data in Chapter 2 Figure 7 and 8). Additionally, a small number of
inhibitory synapses immunopositive for GAD65 are present, likely resulting from a small
percentage of inhibitory interneurons within pCGC cultures (Data not shown, see WT
synapse data in Chapter 2 Figure 7 and 8). Cerebellar granule cells are still dividing and
migrating from the external granule cell layer to the inner granule cell layer in the postnatal brain. A higher number of granule cells can be isolated from later post-natal stage
brains, but with this increase we also noted increased apoptosis and poorer overall cell
appearance (data not shown). Therefore, using the information gained from the
characterization studies, we chose to use P4-6 C57BL/6 pups for the all downstream
pCGC culture work, as they had the lowest level of apoptosis rates, generated an
acceptable number of cells per pup, and appeared healthy throughout the duration of the
experimental timeline.
Primary Cerebellar Granule Cells in Culture Express Pattern Recognition
Receptors and Immune proteins
The expression of immune proteins and PRRs in neurons has been historically
debated. Recent data demonstrates that neurons express proteins belonging to multiple
classes of immune signaling proteins including complement80-82, major histocompatibility
complex 183-86, toll-like receptors87,

88

, Fc receptors89, and paired immunoglobulin like

receptors89. However, there is limited data on cerebellar granule cell expression of these
proteins. Therefore, we felt it was necessary to assess the expression patterns of
immune proteins with pCGC cultures. RNA was harvested at multiple stages of culture
maturation and RT-PCR was performed to determine developmental patterns of
transcript expression for proteins belonging to the complement (C3, C1q), MHC Class I
(MHC I H2-Q1), toll-like receptor (Tlr2, Tlr4), Leukocyte Immunoglobulin Like Receptor
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(Lilrb3), Triggering Receptor Expressed On Myeloid Cells (Trem2), Fc Receptor (FceGr),
and C-Type Lectin Domain (Clec7a) family proteins. Transcript expression for all
immune proteins tested increased with culture maturation, many with significant 3-5 fold
increases from DIV0 to DIV9 in culture (Figure 6). The increase in expression of PRRs
and immune protein transcripts does not correlate with increases in immune cells, as
Cytarabine (AraC) is added to cultures at DIV2 to prevent expansion of the glial
population. Additionally, DIV6 glial cells make up less than 3% of the culture population.
Therefore, our data confirms the more recent literature demonstrating the expression of
immune protein transcripts in neuronal cells.
Primary Cerebellar Granule Cells in Culture Express NF-κB Signaling Transcripts
and Proteins
Cerebellar granule cell NF-κB signaling is important for early cell survival, but other
functions are poorly understood. Furthermore, there is debate on the level of induced
NF-κB activity with cerebellar granule cells. As our model hypothesizes dysregulated
NF-κB activity in response to PRR stimulation, we deemed it critical to first confirm the
presence of signaling molecules associated with NF-κB activation in our reduced
systems model on both the transcript and protein level. RT-PCR was performed on RNA
isolated from pCGC cultures at DIV0, 3, 6, and 9 and analyzed for the expression of two
functionally nonredundant IκB kinases, IκB Kinase alpha (IKK-α) and IκB Kinase β (IKKβ), which are necessary for phosphorylation of p65, p50, and IκBα. Transcript levels of
NFκB1, the precursor of p50 were also measured. Additionally, we measured spleen
tyrosine kinase (Syk), a kinase downstream of multiple PRRs and potential integration
point in dysregulated signaling through NF-κB. pCGC cultures expressed all of the
transcripts measured, and demonstrated slight increases as cultures matured from DIV0
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Figure 6. Primary cerebellar granule cell cultures express transcripts for
pattern recognition receptors and immune protein. RNA was isolated from
pCGC cultures immediately after isolation or after 3, 6, or 9 days in vitro. RT-PCR
analysis demonstrates increasing expression of transcripts for PRRs and immune
proteins throughout culture maturation. a = significantly different from DIV 0, b =
significantly different from P3, c = significantly different from DIV 6. Data is
representative of 3 biological replicates for DIV 0 and 2 replicates for DIV3, 6 and
9. Significant differences were determined my one-way ANOVA with Bonferroni
post-hoc testing. Error bars represent standard deviation of the mean.
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to DIV 9 (Figure 7A). We noted a significant increase in both kinases responsible for
phosphorylation of NF-κB signaling molecules and trending increases in Syk and NFκB1.
As this was an initial characterization screening, the sample sizes were small. We
would anticipate that with larger sample sizes, these increases would reach significance.
However, these data clearly demonstrate the presence of NF-κB signaling associated
transcripts in pCGC cultures. To confirm protein expression of NF-κB related proteins,
pCGC

cultures

transfected

with

pGFP

to

visualize

individual

neurons

were

immunostained for IKK-α, IKK-β, and Syk. Visual analysis clearly demonstrates the
presence of all three NF-κB related proteins in their expected cytoplasmic distribution at
DIV6 within cerebellar granule cells (Figure 7B). These data collectively confirm that
cerebellar granule cells express immune proteins, PRRs, and signaling proteins
necessary for the activation of NF-κB pathway. However, whether or not NF-κB activity
can be induced by PRR ligation remained unclear. In efforts to answer this question, we
choose to investigate the effect of PRR ligation on NF-κB signaling in pCGC cultures.
To assess if PRR activation leads to increased NF-κB activity in cerebellar granule
cells we need to select and a PRR and agonist to serve as our model system. The Tlr2
receptor was selected for our modeling of PRR induced NF-κB signaling pathway
analysis, because there is commercially available synthetic agonist (Pam3CSK4) that is
selective for Tlr2. Many other PRRs agonists are poorly defined in terms of selectivity.
Additionally, we had obtained Tlr2 knock-out mice (see Chapter 3) that could be used as
to validate pathway specificity.
Activation of Tlr2 in pCGC Cultures Increases NF-κ B Signaling Pathway
Phosphorylation
In the inactive state, NF-κB is sequestered in the cytoplasm by inhibitory IκB family
inhibitors (IκBα). Upon activation of immune receptors, upstream kinases phosphorylate
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Figure 7. Primary cerebellar granule cells express NFκB signaling
molecules IKK-α, IKK-β, and Syk. (A) RT-PCR analysis demonstrates
transcript expression of NFκB pathway associated molecules Syk, IKK-α, IKK-β,
and NFκB1 during culture maturation from day in vitro 0 to 9. (B)
Immunocytochemistry validates protein expression of Syk, IKK-α and IKK-β in
cerebellar granule cells at day in vitro 6. n=3 for DIV 0, n =2 for DIV 3, DIV 6, DIV
9. a = significantly different from DIV 0, b from DIV 3, c from DIV 6. Analysis was
performed by one-way ANOVA with Bonferroni post-hoc tests. Error bars
represent standard error of the mean.
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IKK complexes, which in turn phosphorylate downstream proteins including IκBα, p65,
and p50. Phosphorylation of IκBα leads to polyubiquitination and subsequent
degradation. Phosphorylation of p65 and p50 are indicative of activation and effect DNA
binding, translocation, stability, and direct downstream responses depending on the
specific site of phosphorylation. Each NF-κB subunit has multiple phosphorylation sites
that dictate downstream functions. NF-κB subunit p65 contains 8 serine residues
identified as phosphorylation sites (Ser20590, Ser27691-97, Ser28190,

98

, Ser31199-102,

Ser316103, Ser486104, Ser52999-102, and Ser536105-109, as well as 3 threonine residues
T254110, 111, T435112, 113 , and T505114-116 each targeted by select upstream kinases30. Of
particular interest to our studies, p65 ser536 is phosphorylated by a multitude of kinases
including IKKβ and IKKα and leads to transactivation of p65105,

106, 108, 109

. As both are

present within pCGC cultures, we chose to assess the phosphorylation state of p65
ser536 upon stimulation of Tlr2 with Pam3CSK4. Protein was isolated from pCGC DIV6
cultures after 2 hour treatment with 1.0 µg Pam3CSK4 or vehicle. Tlr2 stimulation
resulted in a greater than 2-fold increase in phosphorylated (ser536) p65 (p-p65)
compared to vehicle treated controls (Figure 8). This increase in phosphorylated p65 is
attenuated with 30 minute pretreatment with PDTC, an NF-κB inhibitor that prevents
IκBα degradation (Figure 8). While phosphorylation of p65 suggests pathway activation,
it is not definitive of activation. Therefore, we chose to measure translocation of p65
protein upon Tlr2 ligation.
Activation of Tlr2 in pCGC Cultures Increases NF-κ B Translocation
Degradation of IκBα and translocation of NF-κB subunits are a requisite for DNA
binding and transcriptional regulation in the canonical signaling pathway. To determine if
Tlr2 activation leads to increased translocation of p65, we transfected DIV2 cerebellar
granule cells with p65-GFP and TdTomato vectors. Validation pilot studies were
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Figure 8. Activation of Tlr2 receptors in pCGC cultures results in increased
phosphorylation of p65 ser536. Phosphorylation of NF-κB signaling proteins
occurs with pathway activation by upstream kinases. 2 hour treatment with 1.0
ug Pam3CSK4 or PDTC + Pam3CSK4 do not significantly alter total p65 protein
levels (Control 1.0 ± 0.04; Pam3CSK4 1.10 ± 0.12; PDTC + Pam3CSK4 1.08 ±
0.34). Pam3CSK4 treatment significantly increases phosphorylated p65
(Ser536) compared to controls (Control 1.00 ± 0.39; Pam3CSK4 2.17 ± 0.33,
one-way ANOVA p < 0.01). This increase is attenuated by pretreatment with
PDTC (PDTC + Pam3CSK4 1.45 ± 0.06, one-way ANOVA, PDTC + Pam3CSK4
vs Control p > 0.05, PDTC + Pam3CSK4 vs Pam3CSK4, p < 0.05).Data is
representative of 3 biological replicates per group. Error bars represent standard
deviation of the mean.
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performed to characterize p65-GFP transfection and to determine an adequate timeline
to assess translocation. Within control pCGC cultures, cerebellar granule cells existed in
both activated (high nuclear fluorescent intensity) and inactivated (high cytoplasmic
fluorescent intensity) states, further confirming the necessity for active NF-κB signaling
in pCGCs (Figure 9A). Live cell confocal microscopy was performed on a small number
of cells to measure translocation in response to Tlr2 activation (Figure 9B). From these
initial pilot experiments we decided measure p65-GFP translocation after 1 hour of
stimulation with Pam3CSK4. For a larger quantitative study, pCGC cultures were treated
with 1.0 µg Pam3CSK4 at DIV6 for 1 hour, fixed, and immunostained for IκBα (Figure
10A). Transfected pCGCs were identified using the TdTomato channel and imaged by
confocal microscopy for downstream calculation of cytoplasmic and nuclear p65-GFP
and IκBα fluorescent intensities. pCGC cultures were created so each well is generated
from an individual mouse. Upon quantification, we noted differing levels of baseline
nuclear and cytoplasmic intensities in cultures generated from different mice. As NF-κB
activity is critical for cerebellar granule cell survival, seeing some cells with activated
NF-κB in culture was not surprising, but it complicated analysis. Therefore, we used a
multivariate analysis of variance (MANOVA) to assess for significant changes due to
Pam3CSK4 treatment as well as a sample by treatment interaction. Tlr2 stimulation
leads a significant (p > 0.05) increase in p65-GFP translocation evident by increased
nuclear to cytoplasmic ratios in all Pam3CSK4 treated samples (Figure 10B).
Quantifying the number of cells with a nuclear to cytoplasmic p65 ratio greater than 1
demonstrated an increase in p65 translocation with Pam3CSK4 treatment and Tlr2
activation (Figure 10C). Quantification of IκBα fluorescent intensity showed a trending,
but non-significant reduction (data not shown). IκBα degradation is necessary for
activation, but is also a product of NF-κB activation functioning as a form of
autoregulation. Therefore, our timeline may not have allowed us to detect significant
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Figure 9. NF-κB localization in pCGC cultures and translocation timeline. (A)
Preliminary experiments demonstrate p65-GFP subcellular localization is
heterogeneous under control conditions evident by the presence of cells with both
high cytoplasmic / low nuclear and low cytoplasmic / high nuclear expression. (B)
Translocation of p65-GFP in response to Tlr2 stimulation appears to occur within
60 minutes treatment, based on preliminary live cell time-lapse imaging trials.
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Figure 10. Trl2 stimulation increases nuclear localization of p65-GFP in pCGC
culture. Translocation of p65 into the nucleus is indicative of activation of NF-κB
signaling. Using a p65-GFP vector, the effect of Tlr2 stimulation of p65 translocation
was assessed by pCGC treatment with Pam3CSK4. (A) Representative images for
control and Pam3CSK4 treated cells transfected with p65-GFP demonstrating an
increased nuclear to cytoplasmic ratio in treated cells. Scale bar = 10 mm. IκBα
florescence was also measured, but showed only trending differences. (B)
Quantification of images demonstrated a significant treatment effect for Pam3CSK4
in increasing the mean nuclear to cytoplasmic ratio of p65-GFP fluorescence
(Control 1.21 ± 0.09; Pam3CSK4 1.58 ± 0.93; p = 0.005 for treatment interaction by
multi-way ANOVA. Data represented for individual samples with greater than 15
cells imaged per sample. (C) Graphic representation of the number of cells that
have a nuclear to cytoplasmic ration greater than or less than 1. Higher
nuclear/cytoplasmic ratios represent p65 translocation and activation. Pam3CSK4
treated cells have higher numbers of activated cells compared to controls. Data
represents 60 control cells and 47 Pam3CSK4 treated cells across 3 biological
replicates.
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degradation, due to generation of new IκBα. Translocation of p65 is indicative of
pathway activation, but it fails to confirm the next step in the sequence of activation,
DNA binding and transcriptional regulation.
Activation of Tlr2 in pCGC Cultures Increases NF-κ B Reporter Activity
Upon translocation to the nucleus, NF-κB proteins function as transcriptional
regulators through DNA binding mediated by Rel homology domains and transcriptional
activation through transcription activating domains (TAD). NF-κB proteins recognize IκB
motifs, a specific DNA sequence characterized as 5’-GGGRNYYYCC-3’ in which R is a
purine, Y a pyrimidine, and N is any nucleotide117. For a gene to be regulated by NF-κB
signaling, the presence of an IκB motif is necessary, but not sufficient to ensure
transcriptional activation. Further levels of regulation by post-translational modifications,
chromatin modifications, and non-Rel family proteins are important in directing specific
transcriptional outcomes. However, as all NF-κB regulated transcripts contain IκB motifs,
identifying when these motifs are bound provides indisputable evidence for NF-κB
activation. Therefore, we obtained a p65-GFP reporter with a GFP open reading frame
controlled by a DNA cassette with 5 tandem repeats of NF-κB transcriptional response
element (TRE), a generous gift from the Dongsheng Cai Laboratory at The Albert
Einstein College of Medicine62. Primary cerebellar granule cell cultures were cotransfected at DIV2 with the p65-GFP reporter and TdTomato for cell visualization and
treated for 48 hours with Pam3CSK4 starting at DIV4. Similar to translocation studies, as
NF-κB is necessary for granule cell survival with a baseline level of activity and a tightly
regulated dynamic range, we anticipated only a small change in activity and some
variability between samples. Therefore, data was analyzed using a MANOVA to
determine interactions for sample, treatment, and sample*treatment that effect
characteristics of GFP fluorescence. Quantification and analysis of reporter intensity
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after 48 hours of Tlr2 stimulation demonstrated a significant treatment effect for mean
GFP intensity (Control 30.5 ± 1.1; Pam3CSK4 34.5 ± 1.2; p = 0.015), median GFP
intensity (Control 28.2 ± 1.1; Pam3CSK4 31.6 ± 1.1; p = 0.03), and GFP integrated
density (Control 2217.7 ± 107.5; Pam3CSK4 2608.7 ± 113.9; p = 0.013) (Figure 11).
Significant sample by treatment interactions were also noted for these measurements
demonstrating variability in the degree to which each sample responded to Pam3CSK4.
However, even with these differences Pam3CSK4 leads to a significant increase in p65GFP reporter expression, further validating that PRR ligation in pCGC cultures can
increase NF-κB activity. While DNA binding of NF-κB is functionally critical for
transcriptional regulation, we wanted to validate increased activity of this pathway
through quantification of downstream transcriptional products.
Activation of Tlr2 in pCGC Cultures Increases Transcriptional Expression of NF-

κ B regulated products
There are an estimated 1.4 x 104 potential κB domains in the human genome where
NF-κB proteins can bind and regulate transcription23. When and where these proteins
actually bind is tightly regulated by a complex network of post-translational modifications,
chromatin modifications, and protein interactions118,

119

. Due to the massive number of

potential targets available to assess NF-κB activation, we had to be selective in our
approach. Thus, we narrowed targets down to those believed to be involved in age
related functional deficits. We chose to quantify transcript levels of a set of genes with
known κB motifs spanning multiple protein classes that are upregulated in the aged
cerebellum5. pCGC cultures were treated on DIV6 with 1.0 µg Pam3CSK4, vehicle
control, or PDTC pre-treatment followed by 1.0 µg Pam3CSK4. RNA was isolated after 2
hours, 8 hours, 24 hours, 48 hours, and 72 hours of treatment from each treatment
group and RT-PCR was performed. Of note, PDTC pretreatment leads to significant cell
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Figure 11. Tlr2 stimulation increases NF-κB activity in pCGC. (A) Representative
image of control and Pam3CSK4 treated pCGC cultures transfected with p65-GFP
reporter demonstrating increased GFP fluorescence with Tlr2 stimulation. (B)
Quantification of p65-GFP reporter intensity. 48 hour Tlr2 stimulation with Pam3CSK4
leads to a significant treatment effect for mean GFP intensity (Control 30.5 ± 1.1;
Pam3CSK4 34.5 ± 1.2; p = 0.015), median GFP intensity (Control 28.2 ± 1.1;
Pam3CSK4 31.6 ± 1.1; p < 0.03), and GFP integrated density (Control 2217.7 ±
107.5; Pam3CSK4 2608.7 ± 113.9; p = 0.013). Additionally, significant
sample*treatment effects were noted for all measurements, demonstrating the
variability between samples. Data represents means for 243 control cells and 190
Pam3CSK4 cells, distributed across 4 biologic replicates (Sample 1 140; Sample 2
108, Sample 3 104; Sample 4 81). Error bars equal standard error of the mean
(SEM). * p < 0.05, ns = not significant for treatment effect by multi-way ANOVA with
treatment, sample, and sample*treatment interactions measured.
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death after 8 hours (data not shown), likely due to strong inhibition of NF-κB activity.
Therefore, we did not assess transcript levels in PDTC + Pam3CSK4 treated cells past
the 8 hour time point. IκBα is a direct product of NF-κB activation, forming an
autoregulatory loop where increased IκBα competes with κB motifs in the nucleus to bind
p65 and shuttle it back to the cytoplasm. As a further validation of NF-κB activation,
transcript levels of IκBα were measured in each condition. Tlr2 stimulation with
Pam3CSK4 leads to a time dependent increase in IκBα transcript. At 2 hours we noted
no significant increase in treated pCGCs (Control 1.05 ± 0.39; Pam3CSK4 0.96 ± 0.39; p
= 1.00). However, at 8 hours Pam3CSK4 treatment resulted in a significant increase in
IκBα transcript compared to controls (Control 1.01 ± 0.15; Pam3CK4 1.97 ± 0.49, p =
0.0053). This increase is attenuated by pretreatment with PDTC (PDTC + Pam3CSK4
0.86 ± 0.18; p = 0.002 compared to Pam3CSK4; p = 1.00 compared to Control).
Increased IκBα is still present after 24 hours of Trl2 stimulation (Control 1.04 ± 0.29;
Pam3CK4 2.02 ± 0.19, p = 0.0013) (Figure 12).
RT-PCR analysis showed that transcripts belonging to immune proteins and PRRs
were also increased upon Tlr2 stimulation, but to varying degrees and after different
durations of activation. Transcript levels of C3 were not increased after 2 hours (Control
1.09 ± 0.52; Pam3CSK4 0.69 ± 0.18; p = 0.406), but were significantly increased after
both 8 (Control 1.04 ± 0.33; Pam3CSK4 2.52 ± 0.20; p = 0.000031) and 24 hours of
treatment (Control 1.04 ± 0.35; Pam3CSK4 4.03 ± 1.22; p = 0.0034). Pretreatment with
PDTC only partially attenuated this increase at 8 hours (PDTC + Pam3CSK4 1.72 ±
0.12; p = 0.0086 compared to control, p = 0.0032 compared to Pam3CSK4) (Figure
13A). Transcript for High affinity Immunoglobulin Gamma Fc receptor (Fcgr1) was
increased after 24 hour Pam3CSK4 exposure (Control 1.03 ± 0.29; Pam3CSK4 2.56 ±
0.26; p = 0.00024) (Figure 13B). Additionally, increases in β2-microglobulin, a protein
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related to MHC class I signaling was not increased at 2, 8, or 24 hours, but after 72
hours of Pam3CSK4 treatment β2-microgloblin transcript was significantly higher than
controls (Control 1.02 ± 0.23; Pam3CSK4 1.60 ± 0.26; p = 0.016) (Figure 13C).
The final group of transcripts we assessed belonged to toll-like receptor family
proteins. Activation of NF-κB yields transcription of Tlr279, 120 and Tlr9121, but Tlr4 does
not appear to be NF-κB regulated. To prove specificity of NF-κB regulated transcription,
and not a general inflammatory response we assessed the levels of Tlr2 and Tlr4
transcript upon Tlr2 stimulation. As Tlr9 is not increased in the aging cerebellum and is
unlikely to be stimulated by extracellular agonists (endogenous or exogenous) due to its
intracellular location, we did not assess Tlr9 levels. Pam3CSK4 treatment of pCGCs
results in a robust increase in Tlr2 transcript at 2 hours (Control 1.01 ± 0.16; Pam3CSK4
3.60 ± 0.60; p = 0.00006). This increase persists after 8 hours (Control 1.02 ± 0.24;
Pam3CSK4 3.01 ± 0.18; p = 0.0008), 24 hours (Control 1.01 ± 0.15; Pam3CSK4 4.35 ±
0.85; p = 0.0002), and 72 hours (Control 1.05 ± 0.38; Pam3CSK4 4.57 ± 0.27; p = 5.6 x
10-6) of agonist exposure. Pretreatment with PDTC attenuates this increase at both the 2
hour (PDTC + Pam3CSK4 0.90 ± 0.47; p = 0.00004 compared to Pam3CSK4; p = 1.00
compared to Control) and 8 hour (PDTC + Pam3CSK4 0.72 ± 0.79; p = 0.0003
compared to Pam3CSK4; p = 1.00 compared to Control) time points (Figure 14A).
Pam3CSK4 treatment does not lead to a significant increase in Tl4 transcript expression
at 2 hours or 8 hours of exposure, demonstrating specific activation of NF-κB
transcriptional regulation (Figure 14B). Furthermore, we felt it was imperative to confirm
this response was not due to a gross activation of glial cells and was specific to
activation of Tlr2 by Pam3CSK4. Therefore, we measured transcripts levels of astrocytic
Gfap and microglial Aif1 and revealing that neither was significantly elevated after 8
hours of Tlr2 agonist exposure (Figure 15).
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Figure 12. Pam3CSK4 treatment of pCGC cultures increases NF-κB activation
and transcription of autoregulatory IκBα. pCGC cultures were treated for 2, 8, or
24 hours with vehicle control, 1.0 ug Pam3CSK4, or a 30 minute pretreatment with
PDTC followed by Pam3CSK4. RNA was isolated and RT-PCR performed to
quantify NF-κB regulated transcriptional products. At 2 hours no significant increase
in IκBα was found between treated and control samples (Control 1.05 ± 0.39;
Pam3CSK4 0.96 ± 0.39; p = 1.00). However, at 8 hours Pam3CSK4 treatment leads
to a significant increase in IκBα transcript compared to controls (Control 1.01 ± 0.15;
Pam3CK4 1.97 ± 0.49, p = 0.0053). This increase is attenuated pretreatment with
PDTC (PDTC + Pam3CSK4 0.86 ± 0.18; p = 0.002 compared to Pam3CSK4; p =
1.00 compared to Control). Increased IκBα is still present after 24 hours of Trl2
stimulation (Control 1.04 ± 0.29; Pam3CK4 2.02 ± 0.19, p = 0.0013). Each time point
with 3 groups was analyzed by one-way ANOVA and Bonferroni post hoc testing of
data normalized to control expression. For time points with 2 groups, a two-tailed
Student t-test was performed. n = 4 for each sample at all time points. Error bars
represented standard deviation, a = p < 0.01 compared to control, b = p < 0.01
compared to Pam3CSK4, c = p < 0.01 compared to PDTC + Pam3CSK4.
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Figure 13. Pam3CSK4 treatment of pCGC cultures increases NF-κB activation
and transcription of multiple classes of immune proteins and PRRs. pCGC
cultures were treated for 2, 8, or 24 hours with vehicle control, 1.0 ug Pam3CSK4, or
a 30 minute pretreatment with PDTC followed by Pam3CSK4. RNA was isolated and
RT-PCR performed to quantify NF-κB regulated transcriptional products. (A)
Expression of C3 is not increased after 2 hours (Control 1.09 ± 0.52; Pam3CSK4 0.69
± 0.18; p = 0.406), but is significantly increased after both 8 (Control 1.04 ± 0.33;
Pam3CSK4 2.52 ± 0.20; p = 0.000031) and 24 hours of treatment (Control 1.04 ±
0.35; Pam3CSK4 4.03 ± 1.22; p = 0.0034). Pretreatment with PDTC only partially
attenuates this increase at 8 hours (PDTC + Pam3CSK4 1.72 ± 0.12; p = 0.0086
compared to control, p = 0.0032 compared to Pam3CSK4). (B) Transcript for High
affinity Immunoglobulin Gamma Fc receptor (Fcgr1) was increased after 24 hour
Pam3CSK4 exposure (Control 1.03 ± 0.29; Pam3CSK4 2.56 ± 0.26; p = 0.00024). (C)
β2-microglobulin, a protein related to MHC class I signaling was not increased at 2, 8,
or 24 hours, but after 72 hours of Pam3CSK4 treatment β2-microgloblin transcript
was significantly higher than controls (Control 1.02 ± 0.23; Pam3CSK4 1.60 ± 0.26; p
= 0.016). Each time point was analyzed by one-way ANOVA and Bonferroni post hoc
testing of data normalized to control expression. For time points with 2 groups, a twotailed Student t-test was performed. n = 4 for each sample at all time points. Error
bars represented standard deviation, a = p < 0.01 compared to control, b = p < 0.01
compared to Pam3CSK4, c = p < 0.01 compared to PDTC + Pam3CSK4.
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Figure 14. Pam3CSK4 treatment of pCGC cultures selectively increases NF-κB
regulated toll-like receptor transcripts. pCGC cultures were treated for 2, 8, or 24
hours with vehicle control, 1.0 ug Pam3CSK4, or a 30 minute pretreatment with
PDTC followed by Pam3CSK4. RNA was isolated and RT-PCR performed to quantify
NF-κB regulated transcriptional products. (A) Pam3CSK4 treatment produces a
robust increase in Tlr2 transcript at 2 hours (Control 1.01 ± 0.16; Pam3CSK4 3.60 ±
0.60; p = 0.00006). This increase persists after 8 hours (Control 1.02 ± 0.24;
Pam3CSK4 3.01 ± 0.18; p = 0.0008), 24 hours (Control 1.01 ± 0.15; Pam3CSK4 4.35
± 0.85; p = 0.0002), and 72 hours (Control 1.05 ± 0.38; Pam3CSK4 4.57 ± 0.27; p =
5.6 x 10-6) of agonist exposure. Pretreatment with PDTC attenuates this increase at
both the 2 hour (PDTC + Pam3CSK4 0.90 ± 0.47; p = 0.00004 compared to
Pam3CSK4; p = 1.00 compared to Control) and 8 hour (PDTC + Pam3CSK4 0.72 ±
0.79; p = 0.0003 compared to Pam3CSK4; p = 1.00 compared to Control) time
points. (B) Pam3CSK4 treatment does not lead to a significant increase in Tl4
transcript expression at 2 hours or 8 hours of exposure, demonstrating specific
activation of NF-κB transcriptional regulation. Each time point was analyzed by oneway ANOVA and Bonferroni post hoc testing of data normalized to control
expression. For time points with 2 groups, a two-tailed Student t-test was performed.
n = 4 for each sample at all time points. Error bars represented standard deviation, a
= p < 0.01 compared to control, b = p < 0.01 compared to Pam3CSK4, c = p < 0.01
compared to PDTC + Pam3CSK4.
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Figure 15. Pam3CSK4 treatment of pCGC cultures does not increase transcript
expression of glial markers. pCGC cultures were treated for 8 hours with vehicle
control, 1.0 ug Pam3CSK4, or a 30 minute pretreatment with PDTC followed by
Pam3CSK4. RNA was isolated and RT-PCR performed to quantify NF-κB regulated
transcriptional products. Pam3CSK4 treatment did not increase levels of Gfap or Aif1
transcript expression in culture, demonstrating the absence of a large glial response.
Each time transcript was analyzed by one-way ANOVA and Bonferroni post hoc testing
of data normalized to control expression. n = 4 for each sample at all time points. Error
bars represented standard deviation. No significant differences were detected.
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To prove specificity, we repeated the above experiment for select transcripts (C3,
β2-microglobulin, Fcgr1, and IκBα) using pCGC cultures generated from mice lacking
Tlr2 receptors (For details on mice, see Chapter 3 methods). Quantification of these
transcripts at 8 and 24 hours revealed no significant differences between control and
Pam3CSK4 treated samples (Figure 16, 8 hour data not shown). These data prove that
increased levels of NF-κB regulated transcripts are a definitive result of Pam3CSK4
activation of Tlr2 and subsequent activation of NF-κB signaling, and not a result of off
target effects.
Potential Activators of Tlr2 Signaling in the Aged Cerebellum
The work presented in this chapter details a potential mechanism for NF-κB
activation in the cerebellum, particularly in cerebellar granule cells. Our data
demonstrates that (1) PRRs, immune proteins, and NF-κB signaling proteins are
expressed in cerebellar granule cells and (2) stimulation of a single specific PRR (Tlr2)
can result in p65 translocation, p65 phosphorylation, DNA binding, and transcriptional
activation resulting in the generation of more immune proteins that is abolished in
neuronal cultures lacking Tlr2. This data clearly displays that PRR to NF-κB signaling is
present in pCGCs and is inducible. One major caveat to activation within this model is
the reliance on a synthetic agonist. While Pam3CSK4 was an excellent tool for activating
this pathway, it does not mimic the human condition. Pam3CSK4 is absent in the aging
brain and its biological counterpart would only be present during infection with specific
bacterial strains. Therefore, if this mechanism does contribute to NF-κB dysregulation in
the aging brain, an endogenous agonist would be necessary to initiate the process.
Reexamination of our protein array data suggests a possible candidate that may
similarly activate Tlr2 signaling within the aging brain.
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Figure 16. Increased PRR and immune protein transcripts in pCGC culture are
specific to Tlr2 activation by Pam3CSK4. Tlr2 knock-out pCGC cultures were
treated for 24 hours with vehicle control or 1.0 ug Pam3CSK4. RNA was isolated and
RT-PCR was performed to quantify NF-κB regulated transcriptional products. In the
absence of Tlr2 receptors, Pam3CSK4 treatment does not increase the transcript
level of C3, β2-microglobulin (β2M), Fcer1, or IκBα after 24 hours of agonist
exposure. This demonstrates that increased PRR and immune protein transcripts in
WT pCGC cultures are a specific result of Tlr2 ligation and not off target effects. Error
bars represent standard deviation. Two-tailed Student’s t-tests between treatment
and control for each transcript demonstrated no significant differences between
treated and control samples. Data is representative of 4 biological replicates per
group. Error bars represent standard deviation from the mean.
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Specifically, we noted that aged cerebellar tissue expresses significantly higher
levels of β-amyloid and tau related proteins compared to adult controls. We noted a
greater than 2-fold increase in the expression of amyloid β A4, also known as amyloid
precursor protein (APP) (Adult 1.00 ± 0.22; Aged 2.13 ± 0.50; p = 0.04). Aged cerebellar
samples were also enriched for total tau (Adult 1.0 ± 0.05; Aged 1.15 ± 0.03; p = 0.028)
and phosphorylated tau (S422: Adult 1.0 ± 0.17; Aged 1.42 ± 0.12; p =0.027) (Table 3).
Other independent studies have demonstrated that Aβ42, a key molecule associated
with Alzheimer’s disease pathogenesis, increases in the aging brain and is a known
activator of PRRs in vivo and in vitro122,

123

. Amyloid β oligomers can activate several

classes of PRRs and immune proteins including toll-like receptors124 and complement125.
However, the research has been focused on glial activation and inflammatory
responses, often in the framework of Alzheimer’s disease. In the context of glial cells,
activation of Tlr2 by amyloid β increases its clearance by promoting phagocytosis124, 126.
Loss of Tlr2 leads to a reduction in phagocytosis and increased accumulation of Aβ42
deposits124. The role for amyloid β induced neuronal PRR activation is much less
understood. Aside from amyloid, PRRs have other endogenous ligands that are present
in the aging brain, often classified as damage associated molecular patterns (DAMPs).
These include endogenous Tlr2 agonists: heat shock proteins (HSPs)127-129 and
HMGB1130, 131. In support of our hypothesis that dysregulation of NF-κB occurs in distinct
brain regions, endogenous PRR ligands appear to be enriched in select brain regions
and cell types within the aging brain.

Conclusion and Discussion
Proposed Mechanism
In this chapter, we described the presence of inducible of NF-κB signaling in
cerebellar granule cells evident by increased translocation, phosphorylation, DNA
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binding, and transcriptional activation in response to stimulation of Tlr2. Our previous
data suggests that NF-κB dysregulation may contribute to age-related cerebellar granule
cell deficits and subsequent locomotor dysfunction. We have also described the
accumulation of β amyloid in the aged C57BL/6 cerebellum, which can act as an
endogenous ligand to PRRs. Based on our data we propose that long term,
compounding activation through multiple inputs leads to dysregulation of NF-κB activity.
Specifically, we propose that (1) increased expression of amyloid β, HSPs, HMGB1, and
other endogenous PRR agonists activate neuronal PRRs, (2) PRR stimulation leads to
increased NF-κB activity, (3) activated NF-κB upregulates transcription of κB regulated
gene products including those for synaptic regulation, PRRs, and immune proteins, (4)
increased expression of immune proteins leads to further NF-κB activation through a
positive feedback loop, (5) continued activation leads to increased expression of PRRs,
immune genes, and synaptic components observed in the aging cerebellum, (6)
increased synaptic proteins lead to cellular dysfunction and downstream functional
deficits (Figure 17). This hypothesis is intentionally broad, as the details of NF-κB
signaling in the aging CNS are limited and there is still much to learn about mechanisms
controlling NF-κB activation. The following paragraphs will discuss some these topics in
relation to our results and general mechanisms for age related cerebellar dysfunction.
Modes of NF-κB Signaling Activation in the Aging Brain
We chose to focus our analysis on a single mode of activation as a proof of principle
that immune receptor stimulation can lead to changes in NF-κB activity in cerebellar
granule cells. The availability of a well-defined commercial agonist, age-associated
increases in expression, and accumulation of potential endogenous agonists made Tlr2
a logical target. However there are several other receptors that are upregulated with
aging that can initiate NF-κB activity and therefore contribute to dysregulation. NF-κB
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Figure 17. Proposed mechanism for NF-κB dysregulation in the aged
cerebellum. (A) NF-κB activity is present at a basal state in young and adult
cerebellar neurons. Basal signaling for cell survival and response to injury leads to
activation of NF-κB signaling through phosphorylation and degradation of inhibitory
IκB. NF-κB proteins translocate to the nucleus and regulate transcription.
Transcriptional products for PRRs, synaptic proteins, etc. are generated for
maintenance of normal cell health. IκB is generated, competes with DNA to bind NFκB proteins, and regulates the level and duration of activation. (B) As aging
progresses, DAMPs and β-amyloid slowly accumulate and initiate aberrant NF-κB
signaling. Increased input through PRRs, leads to increased NF-κB activity (red
arrows), but compensation occurs through increased regulatory activity (IκB) to limit
signaling. Increased PRR transcription leads to higher levels of surface expression.
(C) Further increases in DAMPs and b-amyloid result in higher levels of PRR
activation and NF-κB activity to a point of dysregulation. Products of NF-κB
regulated transcription increase leading to altered expression of synaptic proteins,
immune molecules, PRRs, and markers of cell stress, among others. Changes in
expression results in neuronal dysfunction and age related deficits in the absence of
significant cell death.
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signaling initiators increased in aging including dectins65, 132, 133, complement134, 135, and
Fc receptors136, among others5.
We also speculate that amyloid β acts as a driver of NF-κB activity based on our
observation of increased levels in the aging cerebellum. Amyloid β exposure has been
shown to activate NF-κB activity in cerebellar granule cells, but the effect appears dose
dependent. At low, sub-toxic doses exposure to amyloid β leads to increased NF-κB
activity that protects neurons against subsequent higher dose exposure46. Our Western
blot data shows a significant increase in the deposition of amyloid β, using an antibody
that detects both cleaved forms and APP, which was increased in phosphoarray analysis
(data not shown). One cleavage product, Aβ42 is considered the most pathological form
of amyloid, as it is the most likely oligomerize and form fibrils137-139. It is important to note
that while Aβ42 is often associated with Alzheimer’s disease, studies repeatedly find
amyloid deposition in the brains of elderly subjects in the absence of neurodegeneration
or dementia140-142. The gradual accumulation of amyloid β in the aging cerebellum may
function to inhibit its toxic effects. This is in agreement with our previous findings that
increased PRR expression and synaptic alterations are not associated with cell death.
Furthermore, we observed increased levels of Bcl-2 transcript, a known anti-apoptotic
factor in the aged cerebellum5. In the aging brain, it is unlikely that amyloid β is the sole
driver of NF-κB dysregulation, as aging is associated with increases in several
endogenous activators of immune proteins. A more likely mechanism would involve the
accumulation of PRR activators including Aβ42122, 123, mitochondrial components143, heat
shock proteins (HSPs)127-129, and HMGB1130,

131

, coupled with reduced microglial

clearance144 resulting in a microenvironment increasing cell susceptibility to NF-κB
activation via multiple immune receptors. The resulting NF-κB activation may overwhelm
compensatory mechanisms leading to dysregulation of transcriptional activity. Future
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studies will need to assess the regulatory mechanisms of NF-κB signaling within the
aging brain from initiation to resolution in order validate this hypothesis.
NF-κB Signaling Cascades and Regulation
Our data clearly demonstrates induction of NF-κB activity in response to Tlr2
stimulation, but the mechanism and roles of intermediary kinases responsible for
activation were not determined. We did demonstrate that several kinases upstream from
NF-κB are present in pCGC cultures including IKK-α, IKK-β, and Syk, but we have not
fully detailed the activation of each of these signaling molecules in response to Tlr2
ligation. Previous work from our laboratory suggests age-related increases in
phosphorylation of Syk at several key sites responsible for promoting long-term
activation (unpublished observations). Syk can serve as an integration site for several
upstream immune pathways, which suggests it may be a high value target for future
studies. In concordance with this data, our protein phosphorylation array revealed
increased expression of numerous Syk interacting proteins including including Src, Cd5,
Zap70, Vav1, Shc1, Pla2g4a, Raf1, and Hsp2764-67. Investigating regulation of Syk
activity in response to aging and PRR stimulation may offer novel insight into
mechanisms of age related CNS decline. Additionally, direct inhibition of NF-κB signaling
is acutely toxic to neurons, and constitutive NF-κB activity is important for cell survival.
Therefore, NF-κB cannot serve as a therapeutic target. However, targeting upstream
activators or mechanisms of specific gene regulation may offer potential therapeutic
benefits.
Post-translational modifications, primarily phosphorylation, are critical players in the
regulation of NF-κB activity. Collectively, there are 11 known phosphorylation sites in the
p65 protein, each with roles in NF-κB regulation. The two most studied sites are serine
residues 536 and 276. Our analysis of Tlr2 stimulated cerebellar granule cells
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demonstrated increased phosphorylation of S536 after 2 hours of stimulation. This
increase can be attenuated by pretreatment with PDTC, an inhibitor of NF-κB activity.
S536 is most commonly phosphorylated by several kinases, IKK-α and IKK-β that are
expressed in cerebellar neurons based on our data. The site is located in the C-terminal
transactivating domain and the effect of phosphorylation appears to be context
dependent. The main effect is enhanced transactivation by increasing CBP/p300 binding
and p65 acetylation145. However, S536 phosphorylation has also been shown to
increase p65 turnover107 and reduce nuclear import146. In the context of Tlr signaling,
S536 phosphorylation has been shown to lead to proteosomal degradation of p65 and
therefore attenuation of NF-κB activity107. Selectivity of gene expression has also been
linked to S536 phosphorylation and interactions with IκBα. Nuclear IκBα can prevent
p65 binding to specific promoters of TNF-α, IL-1β, and IL-6, but when phosphorylated at
S536 it does not inhibit binding to the IL-8 promoter. In summary, this data suggests that
S536 phosphorylated p65 may act independently from IκBα in the nucleus to regulate
specific

subsets

of

gene

transcription147.

While

we

did

not

evaluate

S276

phosphorylation, we feel it is worth noting the general understanding of its functional
implications. Protein kinase A activity phosphorylates p65 at S276 leading to increased
NF-κB activity by increasing p65 binding with CBP/p300147. Additionally, p65
phosphorylated at S276 functions in epigenetic repression through interaction with DNA
(cytosine-5)-methyltransferase 1148, selective regulation of gene expression though
cyclin dependent kinase 9 / cyclin T1 complexes149, and regulating other posttranslational modifications (ie. acetylation)145. There are several other sites of
phosphorylation for p65, and numerous other NF-κB family proteins contain
phosphorylation sites including p50, p100, c-Rel, RelB, and p105 that we did not assess.
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Evaluation of each would add value to generating a mechanistic understanding of PRR
mediated NF-κB signaling in cerebellar neurons.
While phosphorylation of NF-κB proteins are the most studied, other modifications
are also critical in guiding activity including acetylation, glycosylation, sumoylation, and
ubiquitination. Acetylation of p65 K310 promotes p65 interactions with CBP/p300
thereby increasing activity145. Ubiquitination of NF-κB protein will often lead to protein
degradation by the proteasome, which can either activate or regulate NF-κB activity.
Ubiquitination of IκBα leads to its degradation freeing p65 to translocate and activate
transcription. However, ubiquitination and degradation of DNA bound NF-κB has been
identified as an important IκBα independent mechanism of regulation150. Glycosylation
can negatively regulate p65 phosphorylation at S536 thereby indirectly regulating
activity111. Similar to ubiquitination, sumoylation functions as a negative regulator of NFκB activation through its actions on both p65151 and IκBα152.
Potential Roles for Non-canonical Signaling
The majority of research, including the work presented in this chapter has focused
on the canonical NF-κB signaling pathway (p50/p65 heterodimer). Data supports the
presence and function of canonical signaling in the CNS25,

27, 32, 153

. However non-

canonical NF-κB activity may also contribute to dysregulation. Non-canonical signaling
involves activation of the p52/RelB complex and is dependent on the inducible
processing of p100 and NF-κB-inducing kinase (NIK)154. Activation of receptor activator
of nuclear factor kappa-B ligand (RANKL), CD40 ligand (CD40L), B cell-activating factor
(BAFF), lymphotoxin beta (LTb), TNF-like weak inducer of apoptosis (TWEAK), or
LIGHT (a member of the TNF ligand superfamily) activates NIK which phosphorylates
and activates IKK-α. Activated IKK-α phosphorylates p100 triggering ubiquitination and
partial degradation of p100 to generate p52 that can function to activate specific target
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genes though dimerizing with RelB154, 155. Our data demonstrated activation of canonical
signaling (p65 translocation and phosphorylation) with stimulation of Tlr2, but it is
possible that additional non-canonical signaling occurs in response to Tlr2 ligation. Much
less is known about non-canonical signaling with the CNS. The transcriptional products
we assessed are only a small snapshot of those regulated by NF-κB activity; therefore it
is possible that non-canonical signaling also plays a role in age-related dysregulation.
Future work to detail non-canonical NF-κB activity in response to immune receptor
ligation in neurons may offer novel insights beneficial for directing future therapies.
Selectivity of NF-κB Gene Regulation
The human genome contains an estimated 1.4 x 104 potential κB binding domains;
yet, activation of NF-κB appears to yield specific transcriptional outcomes. Within our
studies, pCGC cultures were exposed to a constant concentration (1.0 µg/mL) of Tlr2
agonist for a given duration of time, after which we measured NF-κB activity. We
measured translocation at 1 hour, phosphorylation at 2 hours, reporter levels at 48 hours
and transcriptional products at 2, 8, 24, 48, and 72 hours. Interestingly, we noted early
increases in select PRRs and immune protein transcripts, later increases in others, and
no change in others (Lyz, data not shown). This demonstrates a selective transcriptional
response to Tlr2 stimulation. The selectivity of NF-κB responses is dependent on
multiple factors including chromatin structure, phosphorylation, the presence of binding
partners, and duration of activation. The duration of NF-κB activity is controlled by IκBα
dependent export and nuclear degradation of NF-κB signaling proteins156. Our analysis
of transcriptional products demonstrated a significant increase in IκBα as after 8 hours of
Tlr2 stimulation. Additionally we noted a trend towards increased IκBα fluorescent
intensity in the translocation experiments at 1 hour, suggesting regulatory mechanisms
were activated. However, increased levels of NF-κB regulated transcripts persisted
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through all time points, suggesting counter-regulatory mechanisms may have been
attenuated by chronic stimulation. Understanding mechanisms of response to chronic
activation may be a critical when treating conditions characterized by increased NF-κB
activation. Contextually, this supports the idea for chronic activation by amyloid β in the
aging brain, where early activation leads to cell survival mechanisms that are then
overridden by continued input. Amyloid β deposition in the brain is a gradual process of
accumulation, where increasing levels may drive further stimulation of PRRs.
Additionally, the potential for the generation of positive feedback loops through the
production of PRRs and immune proteins would lead to even greater sites for potential
stimulation. A more thorough understanding of the activation cascade and posttranslational status of NF-κB proteins will help inform transcriptional selectivity of NF-κB
activation. Furthermore, with the advent of more cost-effective single cell sequencing
platforms, the full status of transcriptional expression in response to PRR stimulation
could be assessed. This would allow one to determine if there are cell type or
subpopulation specific responses to NF-κB activation. Understanding these mechanisms
on the cellular level would inform future research on the downstream effects on neuronal
structure and function.
Role of NF-κB Dysregulation in the Aging Brain
NF-κB dysfunction is involved in many neurodegenerative conditions including
Alzheimer’s disease, Parkinson’s disease, and aging both systemically and within the
CNS18,

62, 157-159

. Over 500 NF-κB regulated genes have been linked to pathological

conditions, but there is not a single clinically approved NF-κB inhibitor, as global
inhibition leads to many side effects160. Inhibition of NF-κB in cerebellar granule cells
cultures results in apoptosis44, and our unpublished observations). Research on other
cell types, primarily hippocampal neurons, demonstrates that NF-κB activity promotes
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dendritic spine and synapse formation, and is involved in long-term potentiation and
synaptic plasticity26, 41, 161, 162. However, it has also been shown that long-term activation of
NF-κB by TNF-α treatment in cultured hippocampal neurons impairs generation of
synaptic currents by modulation of calcium channels and glutamate receptors163.
Therefore, the effect of NF-κB activation on synapses appears context dependent. Our
future research will be geared toward understanding how NF-κB activation through PRR
stimulation affects neuronal structure and function. Upon inhibition of NF-κB signaling by
PDTC, we noted a decrease in Vglut1 mRNA, but as PDTC treatment leads to cell death
after 24 hours it was not clear if this was a direct effect on synapses or a result of apoptotic
processes (data not shown). Synaptic densities were also measured after stimulation of
Tlr2, but we did not observe differences that reached statistical significance. Our model is
based on chronic dysregulation through multiple inputs, therefore we hypothesis that with
a more chronic or combined NF-κB activation model we would observe synaptic
differences in either density or function.
Overall, our data confirms the presence of inducible NF-κB signaling in cerebellar
granule cells, and begins the process of detailing potential mechanisms of dysregulation
in the aging brain. Additional research is required to identify molecular mechanisms
underlying NF-κB activation and regulation in the aging brain. As direct NF-κB inhibition
is not a viable therapeutic option due to toxicity, determining upstream kinases and
regulatory mechanisms may provide more selective targets to specifically modulate
outcomes of NF-κB activation and therefore functional deficits.
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Chapter 2: Complement Protein C3 Loss leads to Significant
Locomotor Deficits and Cerebellar Synaptic Deficits
Introduction
Complement Pathway Signaling and Regulation
The complement pathway has been well studied for over one hundred years and
primarily known for its function within the innate immune system. The first description of
complement, historically called ‘alexin’ (Greek for ‘to ward off’), came from Buchner and
his colleagues in 1891 when they discovered a heat labile factor in blood that aided in
the killing of bacteria1. Over the next 100 years several major discoveries led to our
current understanding of complement. First, in the early 1900’s Ferrata and Brand
concluded that complement is not a single factor, as they were able to separate
complement into two fractions each necessary for bactericidal function2, 3. Additional
work demonstrated even more complement components, including the discovery of the
heat-stable complement factor C34. Complement was originally thought to be a lipid
complex, but advances in techniques for protein isolation and characterization revealed
that complement factors were in fact proteins. Over the succeeding decades critical
works demonstrated the array of complement proteins including C45, C56, C67, C77, C88,
and C99. It was through the discovery of each of these components that the first details
of the classical complement activation cascade was elucidated with sequential binding of
C1 followed by C4, C2, C3, C5, C6, C7, C8, C9. Since these early discoveries much
progress has been made on the understanding of complement function and different
complement activation pathways.
Within the classical complement activation cascade, IgM or IgG antibody/antigen
complexes bind to C1q, leading to activation of C1r, and consequentially cleavage of
C1s. C1s then cleaves both C4 and C2, leading to the generation of C4b2a (C3
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convertase). C4b2a cleaves C3 into C3a and C3b, which possess distinct biological
functions. C3a, a 10 kD protein fragment functions primarily as an anaphylatoxin to
promote local inflammatory responses via activation of pro-inflammatory signaling
pathways. C3b, in the classical activation pathway binds to the C4b2a complex
generating C5 convertase that in turn cleaves C5 into C5a and C5b. C5b initiates the
formation of the membrane attack complex (MAC) through association with C6, C7, C8,
and C9.10 This complex creates pores in invading cells and leads to the death of the
targeted pathogen.

Over fifty years after the discovery of the classical complement

pathway Pillemer et al. proposed an alternative pathway of activation11.
Now well described, the alternative complement activation pathway occurs in the
absence of antibody/antigen interactions when C3 is spontaneously cleaved into a C3b
like molecule known as C3・(H2O). This spontaneous cleavage of C3 is due to a highly
reactive internal thioester bond. C3・(H2O) can then deposit onto an invading pathogen,
bind to complement factor B, which is then cleaved by factor D to generate C3bBb. The
C3bBb complex is stabilized on the bacterial surface by properdin (Factor P), which is
enriched on the microbial membrane. This stabilized complex functions as a convertase
generating more C3b, and incorporation of an additional C3b into C3bBb generates C5
convertase and the downstream formation of the membrane attack complex. Importantly,
circulating C3b that binds to a surface also functions an oposonin, thereby tagging that
surface whether it be a microbe, cell debris, extracellular protein, etc. for targeted
phagocytosis.
Roughly four decades after the description of the alternative pathway, a third mode
of complement activation was discovered and described as the Lectin pathway12, 13. Like
the alternative pathway of complement activation, the Lectin pathway does not require
an antibody antigen interaction to initiate the cascade. For the Lectin pathway, initiation
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of the complement cascade occurs when mannose-binding lectin (MBL) or ficolin interact
with specific carbohydrate residues less common in the host, leading to MBL-associated
serine protease (MASP) activation. MASP proteins then cleave C2 and C4 to form C3
convertase (MASP-2) or directly cleave C3 (MASP-1)14,

15

. Ficolin proteins can also

interact with MASP proteins to active complexes capable of complement protein
cleavage16.
Complement can also be activated through serine proteases that are not part of the
traditional three cascades. For example, coagulation factors Xa, Xia, and plasmin are
capable of cleaving C3 and C517. Additionally, von Willebrand factor and factor VIII can
activate lectins leading to complement cascade activation18. While complement
activation is critical for proper innate immune responses in the host, it can also be
detrimental if activation goes unchecked. Therefore, there are a host of complement
regulatory proteins to reduce the risk of complement-mediated damage to autologous
tissues.
Complement activation is predominately controlled through regulatory proteins that
exist as membrane bound or plasmatic proteins. Initiation of classical and lectin pathway
activation is regulated by plasmatic C1 inhibitor (C1INH or SERPING1) through
irreversible binding and inactivation C1 subunits C1r and C1s, as well as MASP
proteins19-21. Activation of the alternative pathway is controlled by complement factor H
(CFH) and complement factor I (CFI) where CFI functions as a serine protease to
permanently inactivate C3b and CFH is a cofactor for proper CFI function22.
Furthermore, CFH competes with complement factor B for binding to C3b and
destabilizes C3bBb preventing C5a convertase formation, which also restricts alternative
complement pathway activity20, 21, 23. CFH is also able to regulate complement activation
at the cellular membrane by binding to heparin salts and the C3d portion of C3b
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preventing complement-mediated damage to host cells24-27. Additional membrane bound
regulators of complement activation include decay-accelerating factor (DAF/CD55),
membrane cofactor protein (MCP/CD46), and CR1 (CD35). DAF functions to accelerate
the dissociation of C3 convertase in alternate pathway activation, MCP functions as a
cofactor for CFI and CR1 has multiple roles including serving as a CFI cofactor and
accelerating the dissociation of C3 convertase in all three pathways28-30. Membrane
bound complement regulators are not expressed in all cells and their expression level
varies across tissues, therefore the coordination of both plasmatic and membrane bound
complement regulators is necessary to reduce damage to host cells.
The majority of complement proteins and plasmatic regulators are primarily
synthesized in the liver, with hepatocytes contributing over 90% of serum complement
proteins31. However, there is a wealth of primary data demonstrating synthesis in other
tissues. Interestingly, this includes both tissues/cells that are exposed to peripheral
complement like parenchymal kidney cells and immune cells, as well as areas that are
not normally exposed to complement proteins from peripheral sources like the CNS32-35.
In peripheral systems complement activation results in the destruction of pathogens
through inflammatory and phagocytic responses, and if left unregulated it results in
damage to self-tissues through those same pathways. While the role of complement in
the immune system is well established, much less is known for the role of complement
proteins within the nervous system. This lack of knowledge stems partially from the longstanding, but incorrect belief that the central nervous system is immune privileged.
Interestingly, within the CNS, complement proteins have maintained some aspects of
peripheral roles, but also function in distinct CNS processes like neuronal migration,
neuronal stem cell maturation, synaptic pruning, and cell survival.
Complement Proteins in the Central Nervous System
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Despite the large breadth of knowledge on complement pathway activation and
functions in the periphery, less in known on the roles that complement proteins play
within the CNS. Complement proteins were first identified in the CNS in human samples,
but concern over the specificity of synthesis or entry though leakage in the blood brain
barrier limited the impact of this observation. For complement proteins to have function
roles in the CNS, local synthesis is required as the circulating complement proteins are
excluded from CNS entry by the blood brain barrier. Therefore, complement proteins in
the CNS were not heavily studied until in situ hybridization confirmed the local CNS
synthesis of complement proteins36-38. Through numerous other studies it was
demonstrated that the majority of complement proteins and receptors are expressed in
microglia, astrocytes, and neurons throughout the majority of brain regions33, 39-43. Initial
studies concluded that complement proteins are expressed and synthesized in the CNS,
but the expression was considered to be primarily a result of injury or inflammatory
signaling44,

45

. However, additional studies demonstrated the presence of complement

proteins in the non-pathological state in several glial subtypes and neurons.
Complement Expression in the CNS
The primary producers of complement proteins in the CNS are glial cells including
astrocytes, microglia, and oligodendrocytes. Synthesis of many years of research
concluded that astrocytes are able to produce complement proteins within the classical
and alternative pathways including C1q, C1r, C1s, C2, C3, C4, factor B and factor D38, 41,
46-51

. Astrocytes synthesize terminal complement components C5-C8 and express

complement receptors C1qR, CR2, C3aR, C5aR. As far as complement regulatory
proteins, astrocytes produce both soluble factors including C1INH, factor H, and factor I,
and membrane bound CD59, DAF, MCP, and CR152. Similarly, microglia are able to
synthesize complement proteins of both classical and alternative signaling pathways and
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may be the predominate producer of C1q in the CNS36,

49

.

Oligodendrocytes and

oligodendrocyte precursor cells have been shown to produce numerous complement
proteins including C1q, C1s, C2, C3, C4, C5, C6, C7, C8, and C9, but lack expression of
many complement regulatory proteins53. There is increasing evidence for complement
production in other cell types within the nervous system including pericytes54, endothelial
cells55, and ependymal cells56, but the level of contributions of complement to the CNS
from these cell types is poorly understood. Aside from glial, endothelial, and epithelial
cells, neurons also produce complement proteins. In situ hybridization studies have
demonstrated de novo synthesis of C1q, C2, C3, C4, C5, C6, C7, C8, and C9 in both the
temporal cortex and hippocampus57. Constitutive expression of complement proteins C4
and C1q, as well as inducible expression of C3 has also been observed in cerebellar
granule cells58. Neurons express complement regulatory proteins MCP and CD59 at low
levels, and completely lack DAF and CR1, which may partially explain their susceptibility
to complement mediated cell damage59.
Newly developed techniques for single cell sequencing have greatly increased the
ability to determine complement protein expression in subtypes of neuronal cells with
higher accuracy and efficacy than in situ hybridization. As this technology is just
becoming popularized there is limited data, but initial studies offer promise for providing
a more detailed description of complement expression within discrete neuronal and glial
subtypes. One recent study using the drop-seq single cell-sequencing platform set out to
characterize transcript expression of cells in the arcuate nucleus of the hypothalamus
and median eminence. While the primary output for this study was to identify distinct cell
populations, it also offers great insight to single cell expression of complement proteins.
Astrocytes, microglia, and neurons in this study were shown to expresses variable levels
of RNA for complement proteins and receptors60. A more detailed analysis of data sets
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from future single cell studies will provide novel insights into complement expression in
the CNS.
Complement Functions in the CNS
Complement proteins in the CNS have functional importance in both the healthy and
pathological setting with roles both analogous and distinct to those in the periphery.
Similar to the periphery, complement proteins can function as opsonins and tag cellular
debris for phagocytosis by microglia, the resident CNS phagocytic cell. However, there
are numerous non-immunological roles for complement proteins. Complement proteins
regulate neuronal migration, proliferation, adult neurogenesis, and synaptic regulation.
Loss of the receptor for C3a (C3aR) leads to reduced neurogenesis and decreased
numbers of migrating newly formed neurons in response to ischemic injury61,

62

.

Additionally, stimulation of C3aR through sub-dural delivery of a C3aR agonist results in
a transiently reduced thickness of the cerebellar external granule cell layer (EGCL) and
increased thickness of the cerebellar internal granule cell layer (IGCL). Conversely,
stimulation of C5aR results in the opposite phenotype with increased thickness of the
EGCL and a thinner IGCL, suggesting that C3 and C5 play opposing roles in regulating
cerebellar granule cell proliferation and migration63,

64

. Interestingly, there are no long-

term gross cerebellar abnormalities in mice lacking C3, C5, C3aR, or C5aR64 suggesting
that complement protein expression may serve as a rescue mechanism in the event of
developmental inflammation or the existence of compensatory mechanisms to ensure
proper gross cerebellar development. Complement proteins interactions have also been
shown to regulate the differentiation and migration of neuroprogenitor cell in vitro62.
Aside from roles in differentiation, proliferation, and migration complement proteins
can function in neuroprotection by reducing apoptosis through downstream signaling. C5
deficient mice are more susceptible to glutamate-mediated toxicity, demonstrated by
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increased hippocampal neurodegeneration due to increased AMPA binding capacity in
response to Ca2+ incubation65. C5a has been shown to reduce apoptosis through
ERK1/2 inhibition of caspase-3 and down regulation of glutamate receptor subunit 266-68.
C5a activation has also been shown to lead to rapid activation of protein kinase c and
NF-κB in neuroblastoma cells, further suggesting potential roles in neuroinflammatory
regulation69. Additionally, C3a can protect neurons from N-methyl-D-Aspartate (NMDA)
induced injury; however, a direct mechanism has yet to be determined70.
Finally, complement proteins are important for axon growth and synaptic
development, pruning, and maintenance. C1q regulates axonal growth by direct
interaction with myelin-associated glycoprotein to reduce the activation of growth
inhibitory signaling, thereby enhancing axon growth properties71. Both C1q and C3 have
been shown to deposit and mark or opsonize synapses for targeted pruning by microglia
in the developing brain33, 72. Supporting this role for complement proteins, C1q and C3
knockout mice show significant impairments in synaptic elimination in the lateral
geniculate nucleus of the visual system leading to non-segregated eye-specific territories
and retention of multi-innervated relay neurons33. C1q knockout animals also show
increased presynaptic terminals in layer V pyramidal neurons and increased evoked and
spontaneous epileptiform field potentials, signifying increased excitatory function72. It is
believed that increased synaptic density in complement knockout animals is a result of
reduced engulfment of synapses by microglia. Supporting this hypothesis, loss of C3 or
its receptor leads to a significant impairment in microglial ability to engulf synaptic
proteins in the retinogeniculate system73. While loss of complement clearly leads to
profound changes in synaptic pruning, mice lacking complement proteins still undergo
significant pruning during development suggesting the importance of multiple pathways
in these processes33. In fact, many other immune protein pathways have been shown to
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play critical roles in synaptic regulation, including toll-like receptor signaling (Chapter 1
and 3) and Class I MHC I proteins (Chapter 4). In addition to the role of complement
proteins during development, there is increasing evidence describing complement
proteins functions in aging and neurodegenerative disease74-76.
Increased NF-κB signaling and complement expression are considered hallmarks of
Alzheimer’s disease pathology in both humans and murine models. Recent data has
shown that Beta-amyloid exposure can increased NF-κB signaling in astrocytes leading
to increased C3 production, which can act to disrupt neuronal dendrite morphology and
synaptic function mediated through neuronal C3aR77. Loss of C1q, C3, or antagonism of
C3a in an AD model results in reduced phagocytic microglia and synapse loss further
demonstrating

functions

for

complement

in

regulating

synaptic

disruption

in

neurodegenerative conditions78. Aside from AD pathology, mutations in proteins involved
in the alternative pathway of complement activation have been linked with an increased
risk of age-related macular degeneration79. Additionally, human complement 4 has been
shown to localize to multiple components of neurons including synapses and variation of
the gene encoding for complement 4 has been linked to an increased risk of
schizophrenia80. Complement proteins C1q, and C3 among others have also been
shown to increase in normal aging in both mouse and human samples75, 76. Interestingly,
up regulation of complement proteins appear to occur in distinct brain regions that
correlate with functional declines commonly observed in aging.
Complement Proteins and Functional Deficits Associated with Aging
Aging is associated with cognitive, metabolic, and locomotor disruptions, which lead
to functional impairments that significantly lower quality of life and increase risk of health
complications. Age-related functional deficits are often associated with CNS disruptions
within specific brain regions including the hippocampus and cortex for cognitive decline,
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the hypothalamus for metabolic disturbances, and the cerebellum for locomotor
impairments. Interestingly, complement proteins are increased in a region specific
manner in the aged brain. Complement protein C1q is upregulated in areas often
associated with cognition in mice and humans including the hippocampus and piriform
cortex. Additionally, C1q knockout mice are partially protected against age-related
hippocampus-dependent cognitive decline as assessed by a battery of behavioral
assays thought to measure hippocampal function including the Morris Water Maze
(MWM) and Y-Maze76. Similar to C1q, loss of C3 can protect against age related cell and
synapse loss in the hippocampus and increase synaptic plasticity at 12 months of age81.
The majority of research investigating the role for complement proteins is based in
cognitive research and neurodegenerative disease.
Aside from hippocampal and cortical areas, complement proteins are increased in
other regions of the brain affected by aging and contribute to aging phenotypes. Our lab
has demonstrated that complement proteins are increased in the cerebellum and
hypothalamus

of

mouse

strains

with

locomotor

and

metabolic

phenotypes,

respectively75. Importantly, these changes are not isolated to mouse models as C3 and
C4 transcripts were also found to be elevated in the human cerebellum with increasing
age75. However, the roles of complement in the development of functional deficits are
poorly understood. While complement proteins are commonly associated with glial cell
release and glial function, complement increases in the aged mouse cerebellum and
hypothalamus can only be partially explained by microglia. When glial cells were isolated
from these regions, only increases in C3 in the aged C57BL6/J cerebellum could be
explained by increased transcripts in microglial cells75. This data suggests that other
cells, including neurons have increased complement expression with aging. While the
cognitive effects of complement deletion have been well described, the roles of
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complement within other systems are poorly detailed. Therefore, we set out to determine
genotypic differences between wild-type C57BL6/J control mice and mice deficient in
complement protein C3 (C3 KO) using a custom homecage monitoring system to assess
daily locomotor, eating, and drinking behaviors. Additionally, neuronal cultures were
assessed for differences in synaptic phenotypes to offer cellular mechanisms for any
underlying deficits found during behavioral assessment.

Methods and Materials
Mice and Animal Husbandry
Cohorts of 8 male C57BL/J6 (stock # 000664) and 8 male B6;129S4-C3tm1Crr/J (C3
KO, stock #003641) mice were acquired from Jackson Laboratory. Prior to behavioral
assessment mice were allowed to acclimate to the UNMC vivarium for 1-2 weeks, in
efforts to reduce stress associated with delivery that may alter normal behaviors. For this
acclimation period, mice were singly housed in standard mouse cages on microisolator
racks (Lab Products Inc., Seaford DE). Cages contained a layer of ground corn bedding,
and mice were provided with a neslet and ad libitum access to chow (#7012 Envigo) and
water. Following acclimation mice were moved into the home-cage monitoring system
(HCM) for a total of 21 days. Within the HCM, each mouse was housed in a low profile
cage (Allentown PC10196HT, 48×26×15 cm). Within each cage were a nestlet, niche,
corn bedding, and Alpha-dri Plus® tabs (Shepherd Specialty Papers, Watertown, TN) to
reduce ammonia levels. While in the HCM mice had ad libitum access to milled chow
(#5058 PicoLab) and water. The health of each animal, as well as the level of food and
water available was visually checked daily. Food and water was changed twice weekly,
and the entering and exit weights were used to calculate daily consumption of food and
water. The first 5 days the mice are in the cage are considered acclimation days and are
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therefore not analyzed. The last 16 days are data collection days and analyzed for
genotypic differences in homecage behaviors.
Homecage Monitoring System
The homecage monitoring system was designed to characterize freely behaving
mice with minimal human contact over an extended period of time with high spatial and
temporal resolution. Using this system, activity patterns organized around circadian time
are elucidated. Mouse position in the cage was calculated using three load cells
positioned in a triangle at the base of the cage. Load cell voltage shares a linear
relationship with torque; mouse positions can thus be determined by solving the three
dimensional equations relating torque, force, and moment arm length. Load cell voltages
are sampled at 1 KHz permitting temporal resolution of 1 ms. Feeding was measured by
breaking of a photobeam when mice descend their snout into the feeder. Water intake
was measured through capacitance changes in the lick spout when mice make contact
to drink. For WT and C3 KO mice, feeding, drinking, and movement event data was
collected using Labview 2012 (National Instruments) and a PXI-8109 (National
Instruments) for roughly 24 hours per day for 16 days. Once the data collection was
complete, it was processed using MATLAB 2011b (Mathworks) and a series of
behavioral classification and analysis algorithms. Behavioral data undergoes a brief
user-guided quality control assessment to identify any gross data quality issues (blocked
photobeam, leaking lick spout, excessive position drifts). If identified, these data are
removed from further analysis. Data loss from these errors is typically less than 1%.
Next, automated classification of event data is transformed into measures of feeding,
drinking, and movement. The HCM system can classify over 700 behavioral
characteristics. Using false discovery rate analysis, a list of differentially expressed
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behaviors is generated. For full characterization of this system, please refer to Goulding,
et al. 2008.
Assessment of locomotor function
Mobility is measured using a machine learning algorithm that examines gait speed
and turning angle characteristics of all locomotor events not involving either the feeder or
licker, and uses the distribution of these measures to determine if movements best
conform to forward locomotion, movement in place, or no movement. Data from all
locomotor states can then be further analyzed for duration and circadian timing for each
event. We assessed for gait ataxia in WT and C3 KO mice by using minimum bounding
rectangle (MBR) analysis to quantify the straightness of individual locomotor paths.
Differences in MBRs were quantified by repeated measures ANOVA using genotype as
treatment factor, replicated for each animal over all days of data collection, and
individual mice as covariates.
Metabolic Assays
To test for genotypic differences in body composition or metabolic function, WT and
C3 KO mice were analyzed using Dual energy X-ray absorptiometry (DEXA) and indirect
calorimetry. DEXA studies were performed by standard protocol (modified from mutant
mouse

phenotyping

www.mmpc.org/shared/showFile.aspx?doctypeid=3&docid=104

center
and

Whitelabs

www.whitelabs.org/Lab%20Protocols/live%20animal%20protocols/DEXA%20scanning%
20protocol.htm) using inhalational isoflurane anesthesia, a PIXImus scanner (GE Lunar,
Inside/Outside Inc., WI), and Piximus 2.10 software. The abdomen just below the
diaphragm was chosen as the region of interest, focusing our assessment on central
adiposity. Bonferroni-corrected two-tailed t-tests were used to assess for differences in
DEXA parameters including bone mineral density (BMD), bone mineral content (BMC),
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bone area (BArea), tissue area (TArea), ratio of soft tissue attenuation (RST), total tissue
mass (TTM), percent adiposity, and body weight. Indirect calorimetry was performed
using an open circuit system (Oxymax Equal Flow, Columbus Instruments, OH)
composed of an air pump, CO2 sensor (range 0%-0.8%; 0.002% resolution; drift <
20ppm CO2 per hour), paramagnetic O2 sensor (range 0 – 100%; 0.002% of specified
range resolution; drift < 0.06% of specified range per 24 hours), air dryer, controller, 8
hermetically sealed indirect calorimetry chambers (2.1 x 10.2 x 12.7 cm3, #760M-D8,
Columbus Instruments), chamber photocell bracket (1.27 cm spacing between
photocells), photocell controller (Opto M3, Columbus Instruments), and Oxymax for
Windows 4.49 running on dedicated hardware. Mice were fasted from roughly 5:00 PM
until testing at 11:00 AM. Prior to running indirect calorimetry the system was allowed to
equilibrate prior to calibration. Calibration gasses consisted of 100% N2 and a mixture of
0.5% CO2 / 20% O2 / 79.5% N2 (span gas). Indirect calorimetry data was collected for 20
intervals, each with 2 minute duration epochs. Therefore, 40 minutes of data was
collected for each mouse over a period of roughly 5.5 hours. Basal metabolic rates were
calculated by averaging values from three epochs where the individual mouse
demonstrated the least activity. Activity-associated metabolic rates were calculated by
averaging values from the three epochs where the mouse had the most activity.
ANCOVA analysis was performed to identify significant differences in metabolic
parameters (V̇ O2, DO2, O2-out, V̇ CO2, DCO2, CO2-out, and heat) between genotypes as
a function of adiposity82.
Primary Cerebellar Granule Cell Culture
In efforts to determine if deficits in locomotion observed in C3 KO mice were a result
of anomalies in cerebellar neuron structure or function, cerebellar neuron cultures

101
enriched for granule cells were generated from postnatal day 5 C57BL6/J or B6;129S4C3tm1Crr/J for downstream analysis as detailed in the methods section of Chapter 1.
Transfection
Primary cerebellar granule cell cultures were transfected with a plasmid carrying
GFP under the CMV promoter as described in the methods section of Chapter 1. Briefly,
pCGC cultures at DIV 2 were transfected with 1.0 µg of plasmid DNA per ml of media
using Lipofectamine 2000, according to manufacturer protocols. Using this method we
were able to achieve low-density transfection suitable for analysis of individual cerebellar
granule cell synaptic densities.
Immunocytochemistry
To assess for differences in cell type, apoptosis, or synaptic proteins primary
cerebellar neuron cultures were processed for immunocytochemistry at either day in
vitro 3 or 6, as detailed in Chapter 1 Methods. Briefly, cultures were fixed with prewarmed (37°C) 4% Paraformaldehyde/4% sucrose in PBS for 10 minutes, followed by 3
rinses in PBS. To allow for antibody access to intracellular epitopes fixation was followed
by permeabilization with 0.1% triton X-100 for 10 minutes. Cells were again rinsed 3
times for 10 minutes in PBS, followed by blocking with 5% BSA in PBS for 1 hour at
room temperature. After blocking, primary antibodies were diluted in 0.5 % BSA in PBS
and incubated overnight at 4°C (Table 1). After primary incubation cells were rinsed 3
times in PBS followed by incubation for with species specific secondary antibodies in
0.5% BSA/PBS for 1 hour at room temperature. Cells were again washed 3 times with
PBS for 10 minutes to remove residual secondary antibodies and DAPI counterstained
for 1 minute. Following DAPI counterstaining, cells were rinsed a final time and glass
coverslips were placed on top of cellular monolayers using prolong gold or prolong
diamond mounting media (ThermoFisher, #P36961). Samples were allowed to dry
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Table 1. Antibody list and concentrations used for Chapter 2 experiments.
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overnight at room temperature in the dark, and then stored at -20°C or -80°C until further
processing.
Confocal Imaging of pCGC Cultures
Synaptic densities, cell types, and caspase-3 activation in pCGC cultures were all
analyzed using confocal microscopy under blinded conditions. Images were taken on a
Zeiss LSM 710 configured as previously described in Chapter 1 Methods. For in vitro
synaptic density analysis, z stack images were taken using a 40x objective at 1024 x
1024 resolution (160 µm x 160µm x 4.58 µm; 0.352 µm z-step). For cell type and
cleaved caspase-3 measurements images were collected using a 20x objective with 0.5x
digital zoom at 1024 x 1024 resolution (640 µm x 640 µm) with focus set to the brightest
DAPI plane.
Analysis of Cell Types and Apoptosis
Blinded confocal images were analyzed as described in Chapter 1 Methods with
modification for image intensity and background. Cell type analysis for C3 KO and WT
pCGC cultures was performed using the detect spots feature in IMARIS (Bitplane, South
Windsor CT) controlling for fluorescent signal intensity and quality. Statistics for
activated caspase-3 staining was performed in Microsoft Excel, using a two-tailed
student t-test to compare genotypes. Statistics were not performed on cell type analysis,
as we only used 2 biological replicates for WT controls. However, the data concurs with
that generated for original culture characterization.
Analysis of pCGC Synaptic Density
Gross synaptic densities were quantified in blinded samples using detect spots
function in IMARIS software on blinded confocal images. Settings for puncta size and
quality were optimized for the data set and remained uniform for all samples. Vglut1 and
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GAD65 puncta counts were quantified, along with the number of DAPI positive cells per
field. Data was presented as gross synaptic counts per field, as well as counts
normalized to the number of cells per field. For cell specific synaptic densities per µm of
surface area, pCGC transfected with pGFP were imaged and analyzed. Using the create
surfaces function in IMARIS the structure of the cell was generated. Next, detect spots
was used to identify excitatory and inhibitor synaptic puncta. We then used the split into
surface objects function to identify synaptic puncta in contact with the generated surface.
The number of puncta detected was then normalized to surface area of the individual
cell. All comparisons were performed using two-tailed student t-tests in Microsoft Excel.
Calcium Imaging and Analysis
To assess functional properties of cerebellar granule cells generated from WT and
C3 KO mice, we performed live cell calcium imaging using a calcium indicator dye that is
permeable to cell membranes (Fluo-4AM, ThermoFisher #F14201). pCGC cultures were
loaded with 1 µM Fluo-4AM and pluritonic acid for stabilization and imaged using an
upright flourscent microscope. Cultures were imaged in artificial cerebrospinal fluid (mM:
124 NaCl, 26 NaHCO3, 3 KCl, 2 MgCl2, 2 CaCl2, 1.25 NaH2PO4, 10 glucose, 0.5
ascorbic acid, 1.5 Na-pyruvate, 1 thiourea; pH 7.4, maintained by carbogen [95% O2
and 5% CO2] bubbling at room temperature. pCGC cultures were imaged every 5
seconds, but for 7 minutes with 25 mM KCL added on the 15th cycle to induce
depolarization. Images were then analyzed using Axiovision Software (Version 4.8.2.0).
A total of 60 WT cells and 90 C3 KO cells were analyzed from samples generated from 2
and 3 biological replicates respectively. A third WT sample was lost due to complications
with imaging autofocus parameters. For analysis, baseline fluorescent intensity for each
cell was calculated as the average GFP intensity of the first minute of imaging (a total of
12 cycles with 5 seconds between cycles). The GFP intensity of each cell at each time
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point was then normalized to individual cell baseline to generate a fold change from
baseline. Fold change data was analyzed by two-way repeated measures ANOVA
controlling for genotype, time, and sample. Significant interactions (p < 0.001) included
GFP intensity by time and genotype*time.
Transcardial Perfusion and Tissue Processing
C57BL6/J or B6;129S4-C3tm1Crr/J male mice at 1 and 3 months of age were
deeply anesthetized with 17 µl/g bodyweight of 2.5% Avertin (2,2,2-Tribromoethanol
97%, Sigma #T48402). Transcardial perfusion was performed to preserve tissue
architecture for downstream histological analysis. Once mice were deeply under
anesthesia, they were sprayed with ethanol and the chest cavity was opened using
surgical scissors. The diaphragm was dissected away to expose the apex of the heart. A
25G butterfly needle (BD Biosciences, #367298) connected to a transcardial perfusion
pump (Manostat® Vera) was placed into the left ventricle near the apex of the heart.
Immediately the pump was started and the right atrium was opened with a dissection
scissors. Mice were perfused with PBS for 3 minutes to clear blood, followed by 5
minutes with 4% PFA/PBS (32% Paraformaldehyde Stock, Electron Microscopy
Sciences, #15714). Following perfusion, the brain was collected and post fixed in 4%
PFA/PBS for 24 hours at 4 °C.

To preserve cell architecture and prevent crystal

formation upon freezing, brains were cyroprotected with 30% sucrose at 4 °C until the
tissues sank, roughly 24 hours. Tissues were then embedded in Sakura ® Tissue-Tek ®
O.C.T. (VWR, #4583), and frozen in dry ice and ethanol slurry. Tissue blocks were
stored at -80°C for further processing. For sectioning, OCT tissue blocks were allowed to
equilibrate to the cryostat temperature of -20 °C for 30 minutes. Tissues were sectioned
on a cryostat (Leica Cyrostar NX50) in either the sagittal or coronal plane at 14 µm and
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directly mounted on glass slides (Fisher Scientific, #12-550-15). Tissues mounted on
slides were stored at -80 °C until staining.
Immunohistochemistry
To assess for genotypic differences between wildtype and C3KO mice in vivo, tissue
sections were immunostained with antibodies targeting specific synaptic proteins. For a
full list of antibodies used in the experiments presented in Chapter 2, please refer to
Table 1. Tissue sections were allowed to warm to room temperature for 30 minutes prior
to processing. Slides were washed 3 times in PBS to remove excess OCT, followed by
blocking in 5% bovine serum albumin (BSA) in PBS. To promote antibody access to
intracellular epitopes, the blocking, primary, and secondary antibody buffers contained
0.2 % Triton-X 100. After blocking, slides were incubated overnight at 4 °C in antibody
solution (0.5% BSA in PBS with 0.2 % Triton) containing primary antibodies for
excitatory and inhibitory synaptic proteins. Following overnight incubation, slides were
washed 3 times in PBS. The slides were then covered with antibody solution containing
species-specific secondary antibodies for 2 hours at room temperature in the dark.
Following secondary antibody staining, slides were washed 3 times, counterstained with
DAPI, washed again, and cover slipped with Prolong Diamond anti-fade mounting
media. Slides were allowed to dry overnight in the dark at room temperature and then
stored at -20 °C until imaging.
In Vivo Synaptic Density Confocal Microscopy
Densities of excitatory (Vglut1, Vglut2) and inhibitory (GAD65) synaptic proteins in
wildtype and C3 KO mice were assessed using confocal microscopy. To assess synaptic
density in the molecular layer confocal z-stack images from 3 month old mice were
acquired using 40x objective and 2x zoom on a Zeiss LSM 700 scanning confocal
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microscope. Images were taken at 1024 x 1024 resolution over a 160 µm x 160µm x
12.04 µm window with a z-step of 0.430 µm.

Synaptic formations in the cerebellar

granule cell layer were imaged under the same objective and settings, but with modified
gain and laser intensity.
Analysis of In Vivo Synaptic Density
The primary vesicular protein associated with molecular layer excitatory synapses is
Vglut1 arising from parallel fibers of cerebellar granule cells. Vglut1 puncta in the
molecular layer are very dense and uniform in size. To detect each puncta, we employed
the detect spots feature in IMARIS software controlling for quality of fluorescent signal.
GAD65 positive and Vglut2 positive puncta were assessed using the same feature but
as they are less uniform in size. We also quantified average puncta volume using the
‘Detect spots of varying sizes’ feature with local contrast settings to define sizes. Output
from this analysis included the number of puncta, average puncta mean intensity,
average puncta median intensity, and for Vglut2 and GAD65 the average puncta
volume.
Input to cerebellar granule cells occurs through a specialized glomerular synaptic
structure. Thus, individual synaptic puncta are not well defined. For measuring Vglut1
and Vglut2 in the cerebellar granule cell layer, the ‘Create surfaces’ function was used to
map the structure of the excitatory synaptic glomerulus. GAD65 puncta, which form an
inhibitory ring around each glomeruli were identified using the ‘Detect spots’ feature. The
output for this analysis included the number of glomeruli, average glomerulus surface
area and volume, fluorescent intensity mean and median of glomeruli, and the number,
size and intensity of GAD65 puncta.

Genotypic differences in these metrics were

assessed by two-sided t-tests assuming equal variance as implemented in Microsoft
Excel.
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Results
Loss of C3 leads to locomotor functional deficits characterized by decreased gait
speed, increased locomotor bout duration
Complement protein C3 functions in the CNS to opsonize targets for phagocytosis,
either for immunological clearance or synaptic pruning. C3 is important for pruning within
the cortex and hippocampus, and therefore studies interrogating behavior in C3
knockout mice are often narrowly focused on cognitive functions. A small number of
studies have also included measures of anxiety and gross locomotor function81.
However, the effect of C3 loss on daily behaviors in freely moving mice has not been
assessed. Therefore, we set out to determine if there are any genotypic differences in
behavior between wild type control and mice lacking C3. 1-month old B6;129S4C3tm1Crr/J mice constitutively lacking complement protein C3 (C3 KO) and agematched C57BL/6J controls (WT) were singly housed in a custom state-of-the-art
system for homecage monitoring (HCM) for 21 days. Following quality control and
automated data analysis, 565 behavioral characteristics were measured in WT and C3
KO mice. Using false discovery rate (FDR) analysis, we identified 143 behaviors
differentially expressed between WT and C3 KO mice. Differences were observed in
aggregate measures of intake and movement, time budget analysis, state analysis,
feeding bouts, drinking bouts, and movement bouts. Volcano plots were generated from
differential behaviors lists to generate plots of significance versus fold change from WT.
This analysis yielded 53 with a greater than 2 fold change from controls (Figure 1A). Of
the 53 behaviors, 25 were significantly decreased and 28 significantly increased (Figure
1B). Within this data set are several behavioral differences that correspond to functional
aspects of locomotion, bout probabilities, and feeding and drinking properties.

109

Figure 1. Differentially expressed behaviors in C3 KO mice. (A) Volcano plot
diagram depicting 53 differentially expressed behaviors between WT and C3 KO mice
plotted as significance vs ratio (fold change). Behaviors in the upper left show a
greater than two-fold reduction in C3 KO mice (Red). Behaviors in the upper right
indicated a two-fold or greater increase in C3 KO mice (Green). Behaviors that failed to
reach significance fall below the horizontal dashed line. Behaviors that were
significant, but showed a lower than two-fold difference between genotypes fall into the
upper center segment. (B) Table of differentially expressed behaviors that are
decreased or increased in C3 KO mice. TBA = time budget analysis, BA = bout
analysis, SA = state analysis, BD = bout dominance analysis, PE = photobeam event,
LE = lick event, ME = movement event, PE = photobeam (feeding) event, IP = inactive
phase, LC = light cycle, DC = dark cycle, DCLC = collective dark and light cycle.
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Of particular interest toward determining mechanisms of age related locomotor
deficits, analysis of locomotor function in C3 KO mice demonstrated several marked
impairments. C3 KO mice showed no difference in overall locomotor movement (cm/hr)
across the light and dark cycles either combined or individually (Figure 2A). Additionally,
there was no difference in the number of locomotor bout onsets per hour or in bout
probability (Figure 2B,C). However, C3 KO mice show a significant increase in the
duration of locomotor bouts across the combined light and dark cycles (WT 786.35 ±
263.1, C3 KO 1305.54 ± 370.83 ms, FDR t-test p = 0.0192). This difference holds when
the light cycle and dark cycle are assessed independently as well (Figure 2D).
Increased bout duration is likely a result of a significantly reduced gait speed for forward
locomotion in C3 KO mice (WT 23.73 ± 4.50, C3 KO 15.43 ± 3.04 cm/s, FDR t-test p =
0.0067). This difference holds though both the dark and light cycle individually as well as
combined (Figure 2E). The deficits in locomotor gait speed and increased duration did
not lead to a significant impairment in the distance traveled per locomotor bout (Figure
2F). These data collectively demonstrate that C3 KO mice have deficits in functional
aspects of locomotion, but motivation for movement appears to be spared, as the
number of onsets, probability, and total movement are equal to controls. Therefore, we
chose to further assess functional aspects of locomotion, primarily characteristics of
locomotor paths in WT and C3 KO mice.
Loss of C3 leads to Markers of Gait Ataxia
To determine if there are differences in the way WT and C3 KO mice move, we
measured locomotor path straightness using minimum bounding box areas fit to motor
paths, a reliable means to predict characteristics of gait ataxia. As previously mentioned,
gait ataxia and reduced gait speeds are correlated with poorer health outcomes in the
elderly. Therefore, determining mechanisms of gait disturbances is imperative for future
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Figure 2. C3 CKO mice display slower gait speeds and increased locomotor bout
duration. (A) Over a 24 hour period C3 CKO and WT mice move the same overall
distance throughout both the light and dark cycles. (B) The number of forward
locomotor bouts across the light and dark cycles is unchanged in C3 CKO mice. (C)
There is a trending increase in the probability of locomotor bouts in C3 CKO mice, but
this difference fails to reach significance. (D) C3 CKO mice show a significant
increase in the duration of locomotor bouts across both the light and dark cycles. (E)
Forward locomotor bout speed is significantly reduced in C3 CKO mice, but there is
no difference in the distances traveled per bout (F). * indicate p<0.01, Bonferroni
corrected; error bars are ± 1 standard error of the mean.
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therapies. Analysis of locomotor paths in WT and C3 KO mice revealed a significant
increase in average bounding box area in C3 KO mice (Median Minimum Bounding Box
Area: WT 3.65 cm2, C3 KO 7.91 cm2, p = 1.64

E

-29), which is indicative of less straight

locomotor paths (Figure 3). This finding further validates that C3 KO mice had
significant deficits in the functional aspects of locomotion.
Loss of C3 does not impair metabolism or lead to significant changes in body
composition
Complement proteins are expressed throughout the nervous system, including in
the hypothalamus. As we noted increased complement in the hypothalamus of BALBc
mice with aging, we wanted to determine if loss of C3 leads to any gross changes body
composition

or

metabolism.

To

assess

body

composition,

dual-energy

X-ray

absorptiometry (DEXA) scans were performed on WT and C3 KO mice at 2-3 months of
age. Analysis of these scans demonstrated minimal differences between genotypes.
There was no significant change in bone mineral density (BMD), bone mineral content
(BMC), total bone area, soft tissue ratio (RST), % fat, total tissue mass, or weight
(Figure 4A,B,C,E,F,G,H respectively). The only significant difference was a slight
change in total tissue area (WT 8.45 ± 0.48, C3 KO 90.5 ± 0.60, p = 0.044) (Figure 4D).
Analysis of resting and active metabolism was performed by indirect calorimetry. Loss of
C3 had no effect on any metrics of basal (Figure 5) or active (Figure 6) state
metabolism when normalized for adiposity. These results suggest that loss of C3 leads
to minimal changes in metabolic properties or energy balance phenotypes in the C57Bl6
background. As there were no major differences, we chose to focus the rest of our
analysis on the locomotor deficits observed in C3 KO mice and working towards
identifying mechanisms underlying dysfunction.
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Figure 3. C3 KO mice display characteristics of gait ataxia. (A) Representative
diagram of direct and indirect locomotor paths (solid line) and the bounding box area
necessary to enclose each (shaded rectangle). Larger minimum bounding box areas
are indicative of a less straight or weaving path. (B) Frequency distribution curve of
minimum bounding box rectangle (MBR) areas for WT (blue) and C3 KO (red) mice
demonstrates a significant increase in the median MBR (MBRs; cut off at 10 to better
show small rectangle areas).
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Figure 4. Body composition analysis of C3 KO mice revealed minimal
differences. DEXA scan analysis of WT and C3 KO mice demonstrated no
genotypic differences in bone mineral density, bone mineral content, bone area,
soft tissue ratio, % fat, total tissue mass, or mouse weight. The only difference
appreciated was a small increase in tissue area of C3 KO mice (WT 8.45 ± 0.48,
C3 KO 90.5 ± 0.60, p = 0.044). Data representative of 8 animals per genotype.
Comparisons made by Bonferroni-corrected two-tailed t-tests. * indicates p <
0.05. Error bars represent standard deviation of the mean.
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Figure 5. C3 KO mice show no deficits in basal metabolic function. C3 KO and
WT mice were assessed by indirect calorimetry to determine genotypic differences in
measures of metabolic function. No differences were noted between genotypes for
VO2, O2out, DO2, VCO2, CO2out, or calculated heat during resting periods (basal
state). Data analyzed by multiway ANOVA controlling for genotype and adiposity.

116

Figure 6. C3 KO mice show no deficits in activity associated metabolic
function. C3 KO and WT mice were assessed by indirect calorimetry to
determine genotypic differences in measures of metabolic function. No
differences were noted between genotypes for VO2, O2out, DO2, VCO2,
CO2out, or calculated heat during periods of mouse activity. Data analyzed by
multiway ANOVA controlling for genotype and adiposity.
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Loss of C3 leads to increased Vglut1+ synaptic puncta in cerebellar granule cell
cultures
Complement proteins have been shown to tag synapses for pruning by microglia in
multiple brain regions. Loss of complement expression has been linked to increased
synaptic density in the cortex and hippocampus, but less is known about this process in
the cerebellum33,

72, 81

. The majority of studies have linked complement proteins to

changes in cell proliferation, migration, and survival63,

64

. As we observed significant

functional impairments in C3 KO mice, we chose to measure synaptic density in a
reduced model of cerebellar neurons. To assess for synaptic alterations in cerebellar
granule cells, primary neuron cultures enriched for granule cells were isolated from
postnatal day 5 mice and matured in culture (For full characterization see Chapter 1).
WT and C3 KO granule cell cultures were fixed at multiple stages of synaptic maturation
and immunostained for excitatory and inhibitory synaptic proteins. At the early stages of
synaptic development (day in vitro 3) there was no significant differences in gross
excitatory (WT 367 ± 112; C3 KO 522 ± 98 Vglut1+ puncta per field; p = 0.145) or
inhibitory (WT 27 ± 17; C3 KO 40 ± 1 VGAT puncta per field, p = 0.257) synaptic density
(Figure 7A,B). To ensure that cell density was not a factor, synaptic puncta counts
were normalized to DAPI+ cells per field and there was still no significant difference in
synaptic counts at DIV3 (Figure 7C). When cerebellar neuron cultures were analyzed at
a later stage in synaptic maturation (day in vitro 6), C3 KO cultures showed a significant
increase in excitatory and inhibitory synaptic densities compared to wild-type controls.
This increase in excitatory synapses was consistent across several methods of
quantification and normalization. When assessed as total puncta per field, C3 KO
cerebellar granule cell cultures show a greater than two fold increase in excitatory
synaptic puncta (WT 1090 ± 373; C3 KO 3066 ± 254; p = 0.0016) (Figure 8A,B). There
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was no significant difference in the number of cells per field, but to account for any
difference in synaptic number due to variability in cell density, we normalized synaptic
counts to cells per field as above. C3 KO cerebellar granule cells still showed a
significant increase in excitatory synaptic puncta (WT 23 ± 5; C3 KO 46 ± 7; p = 0.0107)
(Figure 8C).

To assess inhibitory synaptic density, VGAT+ puncta per field were

quantified and C3 KO mice show an increase in inhibitory synaptic puncta (WT 179 ± 89;
C3 KO 392 ± 8; p = 0.0149) (Figure 8AB). This difference falls just below significance
when normalized to cell number per field (WT 3.72 ± 1.2; C3KO 6.01 ± 0.76; p = 0.052)
(Figure 8C).
While gross synaptic densities in culture systems provide a general understanding
of synaptic changes, we wanted to assess how synapses are changed on the single cell
level. To determine how excitatory and inhibitory input onto individual cells differs
between WT and C3 KO mice, cerebellar granule cell cultures were transfected with a
GFP vector to identify individual cerebellar neurons and processes. Cerebellar neuron
cultures were then fixed and stained for excitatory and inhibitory synaptic markers at day
3 and 6 in vitro. Individual cell synaptic input was then analyzed per 100 µm2 of pGFP
cell surface area using create surface, detect spots, and split spots into surface objects
functions in IMARIS, see methods for parameters. Analysis using this method confirmed
our previous finding that C3 KO cultures had a significant increase in Vglut1+ synaptic
puncta compared to WT controls at DIV 6 (WT 2.75 ± 0.49; C3 KO 5.42 ± 0.78; p =
0.0075). When inhibitory VGAT puncta were analyzed, C3 KO cerebellar neurons had
an increased number VGAT+ puncta per 100 µm2 of GFP cell surface area (WT 0.51 ±
0.159; C3 KO 0.81 ± 0.088; p =0.047) (Figure 9A,B).

Cultures analyzed at DIV3,

showed a trending, but non-significant increase in Vglut1+ puncta per 100 µm2 of GFP
surface area (WT 1.02 ± 0.21; C3KO 1.60 ± 0.39; p = 0.085) (Figure 10A,B).
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Additionally, there was no significant difference in total surface area per cell for either
DIV3 (Figure 10C) or DIV6 (Figure 9C). However, quantification of primary dendrite
number demonstrated no significant difference at DIV3 (Figure 10D), but a significant
increase at DIV6 (WT 6.03 ± 0.15; C3 C3 KO 6.83 ± 0.31; p = 0.015) (Figure 9D).
Complement proteins and receptors have been previously described to regulate cell
migration, proliferation, and apoptosis. To assess whether synaptic differences seen in
C3 KO compared to WT cultures were a result of differences in cell percentages,
inflammatory signaling, or changes in apoptosis we performed immunohistochemistry for
cell specific markers including neurons (NeuN), astrocytes (GFAP), and microglia
(CD11b), as well as cleaved caspase 3. Importantly, loss of complement protein C3
does not lead to any significant changes in cell type distribution, cell apoptosis, or
inflammatory signaling in cerebellar neuron cultures that may alter synaptic density
(Figure 11). Levels of other transcripts relating to inflammatory NF-κB signaling were
also assessed by immunohistochemistry with no differences seen in expression of p105,
IKK-α, Syk, or p65 (data not shown). Additionally, pCGC cultures are enriched for
neurons, with low levels of glial cells. Taken together, our data suggests that synaptic
alterations are a result of neuronal complement 3 loss and not a secondary effect from
changes in cell distribution or glial response. Next, we wanted to determine in increased
synaptic density led to any changes in pCGC function that may underlie locomotor
deficits.
Loss of C3 leads to increased responsiveness to KCL induced depolarization
Neuronal activity leads to increased intracellular calcium levels by Ca2+ entry
through L-type voltage-dependent calcium channels and ligand gated channels,
including N-methyl-D-aspartate receptors (NMDARs) and α-amino-3-hydroxyl-5-methyl4-isoxazolepropionate receptors (AMPARs) 83, 84 that respond to glutamate. Additionally,

120

Figure 7. Excitatory and inhibitory synaptic densities are unchanged at
early stages of granule cell culture maturation. Primary cerebellar granule
cell cultures generated from WT and C3 KO mice were assessed for changes in
synapse density at early stages of culture maturation. (A) Representative
images of WT and C3 KO cultures at DIV3 stained with antibodies targeting
excitatory Vglut1 and inhibitory VGAT. Scale bar equals 20 mm.(B)
Quantification of excitatory (WT 367 ± 112; C3 KO 522 ± 98 Vglut1+ puncta per
field; p = 0.145) and inhibitory (WT 27 ± 17; C3 KO 40 ± 1 VGAT puncta per
field, p = 0.257) synaptic puncta per field revealed no significant differences
between genotypes. (C) Normalization of puncta numbers to the number of
cells per field also demonstrated no differences. Data representative of cultures
generated from 3 biological replicates per condition. Comparisons between
genotypes made by two-tailed student t-tests. Error bars represent standard
deviation.
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Figure 8. Increased excitatory and inhibitory synapse density in cerebellar
granule cell cultures generated from C3 KO mice. Primary cerebellar granule cell
cultures generated from WT and C3 KO mice were assessed for changes in synapse
density in mature cultures. (A) Representative images of WT and C3 KO cultures at
DIV6 stained with antibodies targeting excitatory Vglut1 and inhibitory VGAT. A clear
increase in puncta density is observed in both Vglut1 and VGAT staining. Scale bar
equals 20 mm.(B) Quantification of excitatory synaptic puncta reveal a significant
increase in puncta density in C3 KO mice (WT 1090 ± 373; C3 KO 3066 ± 254; p =
0.0016). An increase in inhibitory VGAT puncta density is also noted (WT 179 ± 89;
C3 KO 392 ± 8; p = 0.0149). There were no significant differences in cell densities
between genotypes. However, to ensure that synapse densities were not a result of
small changes in cell density, the data was normalized to cell number. (C) Even with
normalization to cell density, C3 KO cerebellar granule cell cultures have an
increased excitatory synapse density compared to controls (WT 23 ± 5; C3 KO 46 ±
7; p = 0.0107. Differences in inhibitory synapses just failed to reach significance when
normalized to cell number (WT 3.72 ± 1.2; C3 KO 6.01 ± 0.76; p = 0.052).Data
representative of cultures generated from 3 biological replicates per condition.
Comparisons between genotypes made by two-tailed student t-tests. Error bars
represent standard deviation.
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Figure 9. C3 KO cerebellar granule cells have increased excitatory and inhibitory
input on a single cell level. Cell specific synapse densities were quantified by
generating surfaces for individual pGFP transfected cerebellar granule cells. (A)
Representative images of WT and C3 KO pGFP cerebellar granule cells at DIV6
stained for excitatory and inhibitory synaptic puncta. Far left panel is the maximum
projection image from confocal z-stacks (raw), center panel shows the surface and
spot detection, far right panel shows output of surfaces with contacting synaptic puncta
with excitatory (Vglut1) in red and inhibitory (VGAT) in teal. Scale bar represents 20
mm. (B) Quantification of synaptic puncta per 100 mm of pGFP surface area revealed
a significant increase in excitatory (WT 2.75 ± 0.49; C3 KO 5.42 ± 0.78; p = 0.0075)
and inhibitory (WT 0.51 ± 0.159; C3 KO 0.81 ± 0.088; p =0.047) in C3 KO cells. (C)
There were no significant differences in the total surface area of pCGCs between
genotypes. (D) C3 KO pCGCs have an increased average number of primary dendrites
compared to WT controls (WT 6.03 ± 0.15; C3 KO 6.83 ± 0.31; p = 0.015). Data
representative of > 20 cells spread across 3 biological replicates per genotype.
Differences were calculated by two-tailed student t-tests. Error bars represent standard
deviation of the mean.
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Figure 10. Excitatory and inhibitory input onto individual cerebellar granule
cells is similar in WT and C3 KO cultures at DIV3. Cell specific synapse densities
were quantified by generating surfaces for individual pGFP transfected cerebellar
granule cells. (A) Representative images of WT and C3 KO pGFP cerebellar granule
cells at DIV3 stained for excitatory and inhibitory synaptic puncta. Far left panel is the
maximum projection image from confocal z-stacks (raw), center panel shows the
surface and spot detection, far right panel shows output of surfaces with contacting
synaptic puncta with excitatory (Vglut1) in red and inhibitory (VGAT) in teal. Scale bar
represents 20 mm. (B) Quantification of synaptic puncta per 100 mm of pGFP surface
area revealed a trending but not significant increase in excitatory synapse density
(WT 1.02 ± 0.21; C3KO 1.60 ± 0.39; p = 0.085). (C) There were no significant
differences in the total surface area of pCGCs between genotypes. (D) No differences
in the number of primary dendrites were noted between genotypes. Data
representative of > 20 cells spread across 3 biological replicates per genotype.
Differences were calculated by two-tailed student t-tests. Error bars represent
standard deviation of the mean.
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Figure 11. Cerebellar neuron cultures generated from C3 KO mice resemble
those from WT mice. To verify that synaptic changes observed in culture were not a
reflection of changes in cell distribution, pCGC cultures were fixed and
immunostained for cell specific markers of neurons (NeuN), astrocytes (GFAP), and
microglia (CD11B). (A) Quantification of cell types demonstrated no obvious
differences between WT and C3 KO cultures (NeuN: WT 82.6 ± 1.0, C3 KO 79.3 ±
1.8%; GFAP: WT 0.57 ± 0.36%, C3 KO 0.91 ± 0.23%; CD11B: WT 0.37 ± 0.04%, C3
KO 0.26 ± 0.04%). Statistics were not performed, as the number of biological
replicates used to generate wells of technical replicates were small (WT n = 2, C3 KO
n =3).To ensure that apoptosis rates were not a factor in synaptic density differences,
pCGC cultures were immunostained for cleaved caspase-3. (B) Quantification of
activated caspase-3 demonstrated no significant differences between WT and C3 KO
cultures (WT 17.9 ± 2.1%, C3 KO 19.9 ± 8.4%, p = 0.72). Finally, to validate that
synaptic differences were not a result of increased inflammatory signaling, transcript
expression of IL1-b and IkBa was measured. (C,D) Quantification transcripts
indicative of inflammation showed no significant differences between WT and C3 KO
cultures (IκBα: WT 1.12 ± 0.58, C3 KO 1.01 ± 0.32 fold change from control, p = 0.78;
IL1-β: WT 1.02 ± 0.24, C3 KO 0.75 ± 0.8 fold change from control, p = 0.13).
Comparison was made by two-tailed student t-test, n = 3 for each group. Error bars
represent standard deviation.
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Ca2+ is released from the endoplasmic reticulum in response to activity85-90. Downstream
calcium signaling is important for a diverse set of cellular functions including activity
dependent regulation of synapse size, number, and function91-94. Measuring changes in
intracellular calcium levels can serve as a method to assess neuronal response to
activity inducing stimuli. Treatment of neurons with potassium chloride (KCl) results in
robust depolarization by increasing the extracellular potassium concentration, which
causes the opening of voltage-gated calcium channels and rapid Ca2+ influx. Using a cell
permeant calcium indicator dye (Fluo-4, AM) that exhibits fluorescence upon calcium
binding, we assessed neuronal response to KCl induced depolarization in control and C3
KO pCGC cultures. Cerebellar granules cells isolated from C3 KO mice have an
increased responsiveness to KCl depolarization and impaired washout response, taking
longer to return towards baseline fluorescence (Figure 12). A significant genotype*time
interaction for GFP intensity was noted by two-way repeated measures ANOVA. This
data demonstrates potential functional differences between WT and C3 KO cerebellar
granule cells.
Loss of complement protein C3 does not alter cerebellar synaptic density in vivo
Loss of complement proteins in animal models has been shown to result in
increased excitatory synaptic density in select regions of the brain. Furthermore, our in
vitro analysis of cerebellar granule cells revealed significant differences in both
excitatory and inhibitory synaptic densities. We therefore hypothesized that C3 KO mice
may have increased synaptic densities within selected regions of the cerebellum that
underlie locomotor deficits. To quantify synaptic densities in vivo, we processed 1 month
and 3 month old WT and C3 KO mice for immunohistochemistry and subsequent
confocal microscopy of several cerebellar regions. The molecular layer contains the
primary synaptic output from cerebellar granule cells, where projecting parallel fibers
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Figure 12. C3 KO cerebellar granule cells have an increased calcium response to
KCL depolarization in vitro. To determine if C3 KO cerebellar granule cells
demonstrated functional differences compared to WT controls, calcium imaging was
performed to measure cellular response to potassium chloride induced depolarization.
(A) Representative images of WT and C3 KO cerebellar granule cell cultures at
baseline and after KCL induced depolarization. Scale bar represents 20 mm in both
image and inset. (B) Quantification of the fold change in fluorescent intensity from
baseline for WT and C3 KO cerebellar granule cells before and after KCL induced
depolarization. Baselines for individual cells were calculated as the average of the first
60 seconds (12 images spaced at 5 second intervals). Arrows indicate relative
positions of representative images in A. Two-way repeated measures ANOVA
indicated a significant (p < 0.001) interaction between genotype and time. Time was
also significant, but sample and sample by time were not found to be significant. Data
is representative of 60 cells for WT and 90 cells for C3 KO from 2 and 3 biological
replicates, respectively. Error bars represent standard error of the mean.
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synapse with the large dendritic trees of Purkinje cells. As we observed increased
excitatory synaptic density in cultures, we hypothesized we would observe similar
changes in the molecular layer. However, quantification of Vglut1+ excitatory synapses
and GAD65 inhibitory synapses in the molecular layer yielded no significant differences
in synaptic puncta number or mean intensity (Figure 13A,B,C). In addition to Vglut1
positive synapses from cerebellar granule cells, climbing fibers from the inferior olive
form Vglut2 excitatory synapses in the molecular layer. Quantification of Vglut2 positive
synapses also yielded no differences in density or intensity (Figure 14A,B). As we
observed no differences in the molecular layer, we decided to assess the granule cell
layer. Excitatory mossy fibers from the pons form excitatory synapses with cerebellar
granule cells in a specialized synaptic structure surrounded by a ring of inhibitory
synapses. Quantification of glomeruli number, intensity, and volume of Vglut1 positive
glomeruli and the GAD65 inhibitory surrounding synapses demonstrated no differences
in vivo (Figure 15). Quantification of Vglut2 positive glomeruli number, intensity, and
volume also showed no differences (Figure 16). These findings were unexpected,
especially given the large differences observed in culture. However, as we observed
differences in synaptic function, it is possible there are differences in synaptic activity but
a normal synaptic density. The implications of these findings will be discussed in further
detail below.

Conclusion and Discussion
Here, we present data generated from an unbiased behavioral assessment of C3
KO mice, where we identified a novel locomotor phenotype characterized by reduced
gait speed, increased locomotor bout duration, and evidence of gait ataxia. Additionally,
we identified increased excitatory and inhibitory synaptic density and increased KCL
excitability in cerebellar granule cell cultures generated from C3 KO mice. Intriguingly,
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Figure 13. C3 KO mice show no difference in excitatory or inhibitory synapse
density in the molecular layer of the cerebellum compared to control mice. 3month old WT and C3 KO mice were processed and imaged for excitatory (Vglut1)
and inhibitory (GAD65) synapses. (A) Representative images of WT and C3 KO
molecular layer synapse densities. Scale bar represents 50 mm. (B) Quantification
of the number of excitatory and inhibitory synaptic puncta in the molecular layer
demonstrated no genotypic differences. (C) No differences in the average puncta
fluorescent intensity were observed between groups. Data is representative of 4
WT and 3 C3 KO mice. Error bars represent standard deviation. Statistical analysis
was performed using two-tailed student t-tests.
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Figure 14. C3 KO mice show no difference in excitatory synapse density in the
molecular layer of the cerebellum compared to control mice. 3-month old WT
and C3 KO mice were processed and imaged for excitatory (Vglut2) synapses
arising from climbing fibers. (A) Representative images of WT and C3 KO molecular
layer synapse densities. Scale bar represents 50 mm. (B) Quantification of the
number of excitatory synaptic puncta in the molecular layer demonstrated no
genotypic differences. (C) No differences in the average puncta fluorescent intensity
were observed between groups. Data is representative of 4 WT and 3 C3 KO mice.
Error bars represent standard deviation. Statistical analysis was performed using
two-tailed student t-tests.
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Figure 15. C3 KO show no changes in excitatory or inhibitory synapses in the
cerebellar granule cell layer. Cerebellar granule cells receive excitatory input from
mossy fiber s in a specialized synaptic glomerular structure surrounded by a ring of
inhibitory synapses. (A) Representative images of WT and C3 KO cerebellar granule
cell layer stained for Vglut1 and GAD65. Scale bar represents 50mm. (B)
Quantification of several properties of excitatory and inhibitory synapses
demonstrated no significant differences between genotypes. The number of Vglut1
glomeruli was lower in C3 KO mice, but this difference failed to reach significance
when adjusted for multiple comparisons. Data represents 4 WT and 3 C3 KO mice.
Error bars represent standard deviation. Statistical analysis was performed using
two-tailed student t-tests adjusted for multiple comparisons.
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Figure 16. C3 KO show no changes in excitatory synapses in the cerebellar
granule cell layer. Cerebellar granule cells receive excitatory input from mossy
fibers in a specialized synaptic glomerular structure surrounded by a ring of
inhibitory synapses. (A) Representative images of WT and C3 KO cerebellar
granule cell layer stained for Vglut2. Scale bar represents 50mm. (B) Quantification
of several properties of excitatory synapses demonstrated no significant
differences between genotypes. Data represents 4 WT and 3 C3 KO mice. Error
bars represent standard deviation. Statistical analysis was performed using twotailed student t-tests adjusted for multiple comparisons.

132
we did not identify any in vivo differences in synaptic density or puncta intensity in either
the molecular layer or cerebellar granule cell layer of C3 KO mice.
This work stems from our initial observation of increased pattern recognition
receptors and immune proteins in the cerebellum of aging mice with locomotor deficits.
Identification of age-associated brain region specific changes in gene expression and
synapse density, coupled with functional deficits relating to that particular brain region
spurred the idea that immune proteins may have functional roles in regulating neuronal
properties underlying aging deficits. Complement protein expression was amongst those
upregulated in the aging cerebellum. As complement proteins had previously been
identified to function in synaptic regulation and pruning, we chose to assess mice lacking
a specific complement protein (C3) for alterations in behaviors compared to wild type
controls.

Much of the current knowledge for C3 in the CNS stems from research

focused on neurodevelopment and pathological conditions. A small number of studies
have investigated the role of complement proteins in aging from a behavioral
perspective, but the focus was directed towards detecting deficits in cognitive functions.
Data from these studies revealed that C1q protein is drastically increased in the aged
brain, deposits in close proximity to synapses, and is correlated with declines in
hippocampal dependent cognitive functions76. C1q deficiency may protect against agerelated hippocampal decline of function, but interestingly no differences were observed
between 3-month-old mice lacking C1q and WT controls76. Similarly, complement 3
deficiency has been shown to protect mice from age related deficits in hippocampal
function. In Shi, et al., 2015 the authors robustly demonstrate that C3 deficiency protects
against age related decreases in synaptic density in multiple regions of the
hippocampus, decreases in hippocampal long-term potentiation, and neuron loss in CA3
of the hippocampus81. Additionally, they demonstrate that C3 KO mice have improved
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spatial and contextual memory at 16 months of age compared to WT controls and
demonstrate an anxiolytic phenotype. In both studies the authors note no gross
observable deficits in motor function in complement deficient mice. In Shi, et al., 2015
motor function was assessed by SHIRPA (SmithKline Beecham, Harwell, Imperial
College and Royal London Hospital phenotype assessment) and rotarod with no
significant impairments noted between WT controls and C3 KO mice. While this may
appear to contradict the findings of our study, the sensitivity and measured aspects of
function between the methods used varies greatly between studies.
The SHIRPA procedure was designed to provide a rapid assessment of mouse
phenotyping in a high-throughput manner, mimicking many aspects of human
neurological examination95, 96. The primary SHIRPA screen offers a general overview of
physical and neurological health, as well as gross motor and sensory functions97.
However, the sensitivity of the SHIRPA screen has previously been questioned,
especially in the context of mobility function. Primary SHIRPA examination of transgenic
synphilin 1 mice showed no deficits compared to wildtype mice, despite marked deficits
in rotarod and footprint testing97,

98

. Similarly, deficits in exploratory behavior were

missed in 129/SvJ and C57BL/6J mice developmentally deficient in vitamin D97, 99. One
of the major pitfalls to this form of assessment is the reliance on observational
measurements in real time. Rotarod testing is a well characterized assessment for
identifying locomotor deficits. Interestingly, C3 KO mice demonstrated no significant
impairments on rotarod testing at either 4 or 16 months of age81. While this may appear
contradictory to our findings of locomotor deficits in C3 KO mice, it is important to note
the scale of deficits measured in each task. Our data indicates slowed gait speed and
markers of gait ataxia that may not impair function in a forced locomotor task, but effect
daily ambulatory activity.

C3 KO mice in our analysis were subject to continuous
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analysis, 24 hours per day for 16 days. Mice in the homecage system are freely moving
within a habituated home space offering assessment of true daily functions in the
absence of forced testing. Additionally, rotarod measures a very different aspect of
motor

function

compared

to

homecage

monitoring.

Rotatrod

testing

requires

balance/vestibular function to perform the task, while there is no dependence on balance
in homecage monitoring. Quantification of daily ambulatory function, especially gait
speed is a critical measure of overall health as reduced gait speeds in the elderly are
associated with poor healthcare outcomes100. Interestingly, the lack of deficits on rotarod
assessment may suggests that C3 KO mice do not demonstrate impaired motor
learning, but the exact methods of rotarod testing would need to be assessed to make
that conclusion.
In efforts to elucidate a mechanism for altered locomotor function in C3 KO mice, we
assessed synaptic density in cultures enriched for cerebellar granule cells. Our data
demonstrated increased excitatory and inhibitory synapse density in C3 KO pCGC
cultures after 6 days in vitro, but not at an earlier time point. Additionally, C3 KO cultures
showed an increased response to KCL depolarization compared to controls. The
mechanisms underlying increased synaptic density in these cultures are currently
unknown. Previous research has shown increased synaptic density in C3 KO mice in
other neuronal types, results from reduced microglial pruning stemming from the loss of
complement 3 tagged synapses33. While this is certainly a possibility, pCGC cultures in
our studies are enriched for neurons with a low percentage of glial cells, both astrocytic
(< 1.0%) and microglial (< 1.0%). Therefore, while it is possible that even in a system
with reduced glial numbers synaptic aberrations appear from reduced pruning, it may
also be indicative of neuronal driven processes of synaptic regulation. Recently,
astroglial C3 release was shown to negatively affect neuronal dendritic complexity and
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synaptic properties through binding to C3aR on the neuronal surface in culture
conditions with low microglial numbers77. Further analysis suggests that C3aR mediated
dendritic and synaptic changes result from intraneuronal calcium signaling77. The mice
used in our study constitutively lack complement 3 expression from all cell types,
therefore synaptic changes observed in pCGC cultures may be a result of lost C3
secretion from the small percentage of astrocytes in culture. Treatment of cortical
cultures with recombinant C3 was shown to reduce dendritic arborization and synapse
density in vitro77. As we also noted an increase in the number of primary dendrites in C3
KO pCGCs, it is likely that C3 plays a role in regulating dendritic growth in addition to
synapses in cerebellar granule cells as well. Our data demonstrating increased
responsiveness to KCL induced depolarization also proposes that loss of C3 leads to
changes in synaptic function. However, additional electrophysiology experimental
validation is necessary to definitively prove changes in synaptic function in cerebellar
granule cells of C3 KO mice. We feel it is important to note functions of other
complement family proteins in cerebellar synaptic regulation, as they it may offer
additional insight into neuron specific roles of complement proteins. There is a wellestablished set of complement like proteins that function in synaptic regulation through
neuronal interactions. Cerebellin 1 (Cbln1) is a member of the cerebellin subfamily of the
C1q family of proteins. Cbln1 is highly expressed in cerebellar granule cells and
functions as a transneuronal regulator of synapse development101. Specifically, Cbln1
functions in the formation and stabilization of the cerebellar granule cell Purkinje cell
synapse, as well as in controlling synaptic plasticity though regulation of post-synaptic
endocytosis of AMPA receptors102. Whether similar mechanisms exist from complement
3 has yet to be determined. Future studies to identify cell specific roles of complement
proteins will be greatly improved by current works to create cell specific complement
deficient mouse lines.
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Our in vivo analysis of C3 KO mice yielded the unexpected finding that synaptic
densities in WT and C3 KO mice did not differ in either the molecular layer or the
cerebellar granule cell layer. Based on our in vitro data we expected to observe
increased synapse density in the molecular layer, the sole target region of cerebellar
granule cell parallel fibers. It is possible that changes in vitro are due to the reduced
culture conditions where glial cells are extremely low in number and within an in vivo
system compensatory mechanisms are present. Cerebellar granule cells in culture
synapse with other cerebellar granule cells and with a small population of inhibitory
interneurons. A more physiological system and area of future study would be to use cocultures of cerebellar granule cells and Purkinje cells. As C3 KO granule cells showed
increased calcium response to KCL induced depolarization, it is possible that cerebellar
granule cells synapses in vivo have altered functions that underlie deficits observed in
homecage behavioral phenotyping. Decreased tonic inhibition of cerebellar granule cells
was identified as a cause of gait ataxia in a mouse model of Angelman syndrome103.
Increased synaptic activity or number could result in increased activation of Purkinje
cells. Proper Purkinje cell function is important for locomotor behavior. Purkinje cells are
rhythmically modulated during locomotor function with high activity during transitions
between ipsilateral stance and swing phases, and low activity at mid-stance104,

105

.

Altering Purkinje cell input could interfere with rhythmic signaling leading to impaired gait
dynamics and ataxia.
It is also important to note that as complement proteins are expressed throughout
the brain, alterations in other regions of the brain controlling locomotor function may also
be involved. However, as C3 KO mice did not show overt loss of locomotor function, we
do not expect significant involvement of primary motor circuits. Additionally, analysis of
the primary motor cortex in 1 month old C3 KO mice did not reveal any differences in
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synaptic density from WT controls (data not shown). Deficits observed appear to be
more characteristic of cerebellar functional changes. A more detailed assessment of
other behaviors controlled by cerebellar function (motor learning, balance, posture, eye
movement) may reveal further deficits.
Our previous research demonstrated increased expression of complement proteins
in the aged cerebellum in mice with increased excitatory synaptic density and locomotor
deficits. Interestingly, loss of complement 3, one of transcripts increased in the aging
brain also leads to locomotor deficits and synaptic alterations in vitro. As complement
plays a role in regulating synapse density, it is possible that complement expression is
increased as a compensatory mechanism for synaptic changes in the aging brain. Our
data clearly demonstrates that loss of complement protein leads to impaired
characteristics of locomotor function, but not an overt loss of locomotion, which is similar
to many aging phenotypes. Identifying mechanisms underlying gait disturbances in the
elderly is critical for the development of novel therapeutic strategies. Further analysis of
cerebellar functions in C3 KO mice may offer insight into age related locomotor deficits
and potential therapies.

138

References
[1] H. B: Zur Nomenklatur der schutzenden Eiweisskorper
Centr Bakteriol Parasitenk 1891, 10:699-701.
[2] A F: Berlin Klin Woch 1907, 44:366.
[3] E. B: Berlin Klin Woch 1907, 46:1075.
[4] 1914;21:604. CA: Z Immunitätsforsh 1914, 21:604.
[5] Mueller-Eberhard HJ, Biro CE: Isolation and Description of the Fourth Component of
Human Complement. J Exp Med 1963, 118:447-66.
[6] Nilsson UR, Mueller-Eberhard HJ: Isolation of Beta If-Globulin from Human Serum
and Its Characterization as the Fifth Component of Complement. J Exp Med 1965,
122:277-98.
[7] Nilsson U: Separation and partial purification of the sixth, seventh and eighth
components of human haemolytic complement. Acta Pathol Microbiol Scand 1967,
70:469-80.
[8] Manni JA, Muller-Eberhard HJ: The eighth component of human complement (C8):
isolation, characterization, and hemolytic efficiency. J Exp Med 1969, 130:1145-60.
[9] Hadding U, Muller-Eberhard HJ: The ninth component of human complement:
isolation, description and mode of action. Immunology 1969, 16:719-35.
[10] Nesargikar PN, Spiller B, Chavez R: The complement system: history, pathways,
cascade and inhibitors. Eur J Microbiol Immunol (Bp) 2012, 2:103-11.
[11] Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC: The properdin
system and immunity. I. Demonstration and isolation of a new serum protein, properdin,
and its role in immune phenomena. Science 1954, 120:279-85.
[12] Kawasaki T, Etoh R, Yamashina I: Isolation and characterization of a mannanbinding protein from rabbit liver. Biochem Biophys Res Commun 1978, 81:1018-24.
[13] Kozutsumi Y, Kawasaki T, Yamashina I: Isolation and characterization of a mannanbinding protein from rabbit serum. Biochem Biophys Res Commun 1980, 95:658-64.
[14] Hajela K, Kojima M, Ambrus G, Wong KH, Moffatt BE, Ferluga J, Hajela S, Gal P,
Sim RB: The biological functions of MBL-associated serine proteases (MASPs).
Immunobiology 2002, 205:467-75.
[15] Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T: Proteolytic activities of two
types of mannose-binding lectin-associated serine protease. J Immunol 2000, 165:263742.
[16] Matsushita M, Endo Y, Hamasaki N, Fujita T: Activation of the lectin complement
pathway by ficolins. Int Immunopharmacol 2001, 1:359-63.
[17] Amara U, Rittirsch D, Flierl M, Bruckner U, Klos A, Gebhard F, Lambris JD, HuberLang M: Interaction between the coagulation and complement system. Adv Exp Med Biol
2008, 632:71-9.

139
[18] Santizo F, Zenteno E, Pina-Canseco S, Hernandez-Cruz P, Cruz MM, Mayoral LP,
Perez-Campos E, Martinez-Cruz R: Lectin activity of the coagulation factor VIII/von
Willebrand complex. Tohoku J Exp Med 2009, 217:209-15.
[19] Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B: C1 inhibitor: molecular
and clinical aspects. Springer Semin Immunopathol 2005, 27:286-98.
[20] Pickering MC, Cook HT: Translational mini-review series on complement factor H:
renal diseases associated with complement factor H: novel insights from humans and
animals. Clin Exp Immunol 2008, 151:210-30.
[21] Zipfel PF, Skerka C: Complement factor H and related proteins: an expanding family
of complement-regulatory proteins? Immunol Today 1994, 15:121-6.
[22] Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM: Complement factor I
in health and disease. Mol Immunol 2011, 48:1611-20.
[23] Conrad DH, Carlo JR, Ruddy S: Interaction of beta1H globulin with cell-bound C3b:
quantitative analysis of binding and influence of alternative pathway components on
binding. J Exp Med 1978, 147:1792-805.
[24] Kazatchkine MD, Fearon DT, Austen KF: Human alternative complement pathway:
membrane-associated sialic acid regulates the competition between B and beta1 H for
cell-bound C3b. J Immunol 1979, 122:75-81.
[25] Manuelian T, Hellwage J, Meri S, Caprioli J, Noris M, Heinen S, Jozsi M, Neumann
HP, Remuzzi G, Zipfel PF: Mutations in factor H reduce binding affinity to C3b and
heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin
Invest 2003, 111:1181-90.
[26] Noris M, Remuzzi G: Overview of complement activation and regulation. Semin
Nephrol 2013, 33:479-92.
[27] Zipfel PF, Heinen S, Jozsi M, Skerka C: Complement and diseases: defective
alternative pathway control results in kidney and eye diseases. Mol Immunol 2006,
43:97-106.
[28] Kim DD, Song WC: Membrane complement regulatory proteins. Clin Immunol 2006,
118:127-36.
[29] Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP: Control of the
complement system. Adv Immunol 1996, 61:201-83.
[30] Liszewski MK, Leung M, Cui W, Subramanian VB, Parkinson J, Barlow PN,
Manchester M, Atkinson JP: Dissecting sites important for complement regulatory
activity in membrane cofactor protein (MCP; CD46). J Biol Chem 2000, 275:37692-701.
[31] Alper CA, Rosen FS: Genetics of the complement system. Adv Hum Genet 1976,
7:141-88.
[32] Lalli PN, Strainic MG, Yang M, Lin F, Medof ME, Heeger PS: Locally produced C5a
binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigeninduced apoptosis. Blood 2008, 112:1759-66.
[33] Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, Micheva
KD, Mehalow AK, Huberman AD, Stafford B, Sher A, Litke AM, Lambris JD, Smith SJ,

140
John SW, Barres BA: The classical complement cascade mediates CNS synapse
elimination. Cell 2007, 131:1164-78.
[34] Vieyra MB, Heeger PS: Novel aspects of complement in kidney injury. Kidney Int
2010, 77:495-9.
[35] Zhou W, Marsh JE, Sacks SH: Intrarenal synthesis of complement. Kidney Int 2001,
59:1227-35.
[36] Lampert-Etchells M PG, Finch CE, Johnson SA: Regional localization of cells
containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer's
disease. Neurodegeneration 1993, 2:111-21.
[37] Rozovsky I, Morgan TE, Willoughby DA, Dugichi-Djordjevich MM, Pasinetti GM,
Johnson SA, Finch CE: Selective expression of clusterin (SGP-2) and complement C1qB
and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 1994, 62:74158.
[38] Veerhuis R, Janssen I, Hoozemans JJ, De Groot CJ, Hack CE, Eikelenboom P:
Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathol 1998,
96:287-96.
[39] D'Ambrosio AL, Pinsky DJ, Connolly ES: The role of the complement cascade in
ischemia/reperfusion injury: implications for neuroprotection. Mol Med 2001, 7:367-82.
[40] Davoust N, Jones J, Stahel PF, Ames RS, Barnum SR: Receptor for the C3a
anaphylatoxin is expressed by neurons and glial cells. Glia 1999, 26:201-11.
[41] Gasque P, Fontaine M, Morgan BP: Complement expression in human brain.
Biosynthesis of terminal pathway components and regulators in human glial cells and
cell lines. J Immunol 1995, 154:4726-33.
[42] Morgan BP, Gasque P: Extrahepatic complement biosynthesis: where, when and
why? Clin Exp Immunol 1997, 107:1-7.
[43] Nataf S, Stahel PF, Davoust N, Barnum SR: Complement anaphylatoxin receptors
on neurons: new tricks for old receptors? Trends Neurosci 1999, 22:397-402.
[44] Veerhuis R, Nielsen HM, Tenner AJ: Complement in the brain. Mol Immunol 2011,
48:1592-603.
[45] Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA: Genomic
analysis of reactive astrogliosis. J Neurosci 2012, 32:6391-410.
[46] Barnum SR: Complement biosynthesis in the central nervous system. Crit Rev Oral
Biol Med 1995, 6:132-46.
[47] Gasque P, Ischenko A, Legoedec J, Mauger C, Schouft MT, Fontaine M: Expression
of the complement classical pathway by human glioma in culture. A model for
complement expression by nerve cells. J Biol Chem 1993, 268:25068-74.
[48] Levi-Strauss M, Mallat M: Primary cultures of murine astrocytes produce C3 and
factor B, two components of the alternative pathway of complement activation. J
Immunol 1987, 139:2361-6.
[49] Veerhuis R, Janssen I, De Groot CJ, Van Muiswinkel FL, Hack CE, Eikelenboom P:
Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate

141
human glial and neuronal cell cultures to secrete early complement proteins, but not C1inhibitor. Exp Neurol 1999, 160:289-99.
[50] Walker DG, Kim SU, McGeer PL: Complement and cytokine gene expression in
cultured microglial derived from postmortem human brains. J Neurosci Res 1995,
40:478-93.
[51] Walker DG, McGeer PL: Complement gene expression in human brain: comparison
between normal and Alzheimer disease cases. Brain Res Mol Brain Res 1992, 14:10916.
[52] Woodruff TM, Ager RR, Tenner AJ, Noakes PG, Taylor SM: The role of the
complement system and the activation fragment C5a in the central nervous system.
Neuromolecular Med 2010, 12:179-92.
[53] Hosokawa M, Klegeris A, Maguire J, McGeer PL: Expression of complement
messenger RNAs and proteins by human oligodendroglial cells. Glia 2003, 42:417-23.
[54] Verbeek MM, Otte-Holler I, Ruiter DJ, de Waal RM: Human brain pericytes as a
model system to study the pathogenesis of cerebrovascular amyloidosis in Alzheimer's
disease. Cell Mol Biol (Noisy-le-grand) 1999, 45:37-46.
[55] Vastag M, Skopal J, Kramer J, Kolev K, Voko Z, Csonka E, Machovich R, Nagy Z:
Endothelial cells cultured from human brain microvessels produce complement proteins
factor H, factor B, C1 inhibitor, and C4. Immunobiology 1998, 199:5-13.
[56] Canova C, Neal JW, Gasque P: Expression of innate immune complement
regulators on brain epithelial cells during human bacterial meningitis. J
Neuroinflammation 2006, 3:22.
[57] Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of mRNAs for
complement proteins of the classical pathway in Alzheimer brain. Brain Res 1997,
769:391-5.
[58] Thomas A, Gasque P, Vaudry D, Gonzalez B, Fontaine M: Expression of a complete
and functional complement system by human neuronal cells in vitro. Int Immunol 2000,
12:1015-23.
[59] Singhrao SK, Neal JW, Rushmere NK, Morgan BP, Gasque P: Spontaneous
classical pathway activation and deficiency of membrane regulators render human
neurons susceptible to complement lysis. Am J Pathol 2000, 157:905-18.
[60] Campbell JN, Macosko EZ, Fenselau H, Pers TH, Lyubetskaya A, Tenen D,
Goldman M, Verstegen AM, Resch JM, McCarroll SA, Rosen ED, Lowell BB, Tsai LT: A
molecular census of arcuate hypothalamus and median eminence cell types. Nat
Neurosci 2017, 20:484-96.
[61] Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, Nilsson AK,
Zwirner J, Wetsel RA, Gerard C, Pekny M, Pekna M: Complement: a novel factor in
basal and ischemia-induced neurogenesis. EMBO J 2006, 25:1364-74.
[62] Shinjyo N, Stahlberg A, Dragunow M, Pekny M, Pekna M: Complement-derived
anaphylatoxin C3a regulates in vitro differentiation and migration of neural progenitor
cells. Stem Cells 2009, 27:2824-32.

142
[63] Benard M, Gonzalez BJ, Schouft MT, Falluel-Morel A, Vaudry D, Chan P, Vaudry H,
Fontaine M: Characterization of C3a and C5a receptors in rat cerebellar granule neurons
during maturation. Neuroprotective effect of C5a against apoptotic cell death. J Biol
Chem 2004, 279:43487-96.
[64] Benard M, Raoult E, Vaudry D, Leprince J, Falluel-Morel A, Gonzalez BJ, Galas L,
Vaudry H, Fontaine M: Role of complement anaphylatoxin receptors (C3aR, C5aR) in
the development of the rat cerebellum. Mol Immunol 2008, 45:3767-74.
[65] Tocco G, Musleh W, Sakhi S, Schreiber SS, Baudry M, Pasinetti GM: Complement
and glutamate neurotoxicity. Genotypic influences of C5 in a mouse model of
hippocampal neurodegeneration. Mol Chem Neuropathol 1997, 31:289-300.
[66] Mukherjee P, Pasinetti GM: Complement anaphylatoxin C5a neuroprotects through
mitogen-activated protein kinase-dependent inhibition of caspase 3. J Neurochem 2001,
77:43-9.
[67] Mukherjee P, Thomas S, Pasinetti GM: Complement anaphylatoxin C5a
neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo. J
Neuroinflammation 2008, 5:5.
[68] Osaka H, Mukherjee P, Aisen PS, Pasinetti GM: Complement-derived anaphylatoxin
C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem 1999, 73:303-11.
[69] O'Barr SA, Caguioa J, Gruol D, Perkins G, Ember JA, Hugli T, Cooper NR: Neuronal
expression of a functional receptor for the C5a complement activation fragment. J
Immunol 2001, 166:4154-62.
[70] van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, Fontaine M:
Complement anaphylatoxin C3a is selectively protective against NMDA-induced
neuronal cell death. Neuroreport 2001, 12:289-93.
[71] Peterson SL, Nguyen HX, Mendez OA, Anderson AJ: Complement protein C1q
modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo. J
Neurosci 2015, 35:4332-49.
[72] Chu Y, Jin X, Parada I, Pesic A, Stevens B, Barres B, Prince DA: Enhanced
synaptic connectivity and epilepsy in C1q knockout mice. Proc Natl Acad Sci U S A
2010, 107:7975-80.
[73] Schafer DP, Lehrman EK, Kautzman AG, Koyama R, Mardinly AR, Yamasaki R,
Ransohoff RM, Greenberg ME, Barres BA, Stevens B: Microglia sculpt postnatal neural
circuits in an activity and complement-dependent manner. Neuron 2012, 74:691-705.
[74] Stephan AH, Barres BA, Stevens B: The complement system: an unexpected role in
synaptic pruning during development and disease. Annu Rev Neurosci 2012, 35:369-89.
[75] Bonasera SJ, Arikkath J, Boska MD, Chaudoin TR, DeKorver NW, Goulding EH,
Hoke TA, Mojtahedzedah V, Reyelts CD, Sajja B, Schenk AK, Tecott LH, Volden TA:
Age-related changes in cerebellar and hypothalamic function accompany non-microglial
immune gene expression, altered synapse organization, and excitatory amino acid
neurotransmission deficits. Aging (Albany NY) 2016, 8:2153-81.
[76] Stephan AH, Madison DV, Mateos JM, Fraser DA, Lovelett EA, Coutellier L, Kim L,
Tsai HH, Huang EJ, Rowitch DH, Berns DS, Tenner AJ, Shamloo M, Barres BA: A

143
dramatic increase of C1q protein in the CNS during normal aging. J Neurosci 2013,
33:13460-74.
[77] Lian H, Yang L, Cole A, Sun L, Chiang AC, Fowler SW, Shim DJ, Rodriguez-Rivera
J, Taglialatela G, Jankowsky JL, Lu HC, Zheng H: NFkappaB-activated astroglial release
of complement C3 compromises neuronal morphology and function associated with
Alzheimer's disease. Neuron 2015, 85:101-15.
[78] Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry
KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B: Complement
and microglia mediate early synapse loss in Alzheimer mouse models. Science 2016,
352:712-6.
[79] Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa
S, Cipriani V, Ripke S, Igo RP, Jr., Buitendijk GH, Sim X, Weeks DE, Guymer RH,
Merriam JE, Francis PJ, Hannum G, Agarwal A, Armbrecht AM, Audo I, Aung T, Barile
GR, Benchaboune M, Bird AC, Bishop PN, Branham KE, Brooks M, Brucker AJ, Cade
WH, Cain MS, Campochiaro PA, Chan CC, Cheng CY, Chew EY, Chin KA, Chowers I,
Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B, Edwards AO,
Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ, Gieger
C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes
G, Ioannidis JP, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, C NK, Khan JC,
Kim IK, Kiyohara Y, Klein BE, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P,
Lotery AJ, Meitinger T, Mitchell P, Mohand-Said S, Moore AT, Morgan DJ, Morrison MA,
Myers CE, Naj AC, Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C,
Park KH, Pauer GJ, Peachey NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp
R, Rudolph G, Ryu E, Sahel JA, Schaumberg DA, Scholl HP, Schwartz SG, Scott WK,
Shahid H, Sigurdsson H, Silvestri G, Sivakumaran TA, Smith RT, Sobrin L, Souied EH,
Stambolian DE, Stefansson H, Sturgill-Short GM, Takahashi A, Tosakulwong N, Truitt
BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L, Vingerling JR, Vithana EN,
Webster AR, Wichmann HE, Winkler TW, Wong TY, Wright AF, Zelenika D, Zhang M,
Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R, Baird
PN, Gorin MB, Wang JJ, Klaver CC, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates
JR, Swaroop A, Weber BH, Kubo M, Deangelis MM, Leveillard T, Thorsteinsdottir U,
Haines JL, Farrer LA, Heid IM, Abecasis GR, Consortium AMDG: Seven new loci
associated with age-related macular degeneration. Nat Genet 2013, 45:433-9, 9e1-2.
[80] Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, Tooley K,
Presumey J, Baum M, Van Doren V, Genovese G, Rose SA, Handsaker RE,
Schizophrenia Working Group of the Psychiatric Genomics C, Daly MJ, Carroll MC,
Stevens B, McCarroll SA: Schizophrenia risk from complex variation of complement
component 4. Nature 2016, 530:177-83.
[81] Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX,
Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA: Complement C3-Deficient Mice
Fail to Display Age-Related Hippocampal Decline. J Neurosci 2015, 35:13029-42.
[82] Tschop MH, Speakman JR, Arch JR, Auwerx J, Bruning JC, Chan L, Eckel RH,
Farese RV, Jr., Galgani JE, Hambly C, Herman MA, Horvath TL, Kahn BB, Kozma SC,
Maratos-Flier E, Muller TD, Munzberg H, Pfluger PT, Plum L, Reitman ML, Rahmouni K,
Shulman GI, Thomas G, Kahn CR, Ravussin E: A guide to analysis of mouse energy
metabolism. Nat Methods 2011, 9:57-63.

144
[83] Jonas P, Burnashev N: Molecular mechanisms controlling calcium entry through
AMPA-type glutamate receptor channels. Neuron 1995, 15:987-90.
[84] Cohen S, Greenberg ME: Communication between the synapse and the nucleus in
neuronal development, plasticity, and disease. Annu Rev Cell Dev Biol 2008, 24:183209.
[85] Hagenston AM, Bading H: Calcium signaling in synapse-to-nucleus communication.
Cold Spring Harb Perspect Biol 2011, 3:a004564.
[86] Hagenston AM, Fitzpatrick JS, Yeckel MF: MGluR-mediated calcium waves that
invade the soma regulate firing in layer V medial prefrontal cortical pyramidal neurons.
Cereb Cortex 2008, 18:407-23.
[87] Hardingham GE, Bading H: Nuclear calcium: a key regulator of gene expression.
Biometals 1998, 11:345-58.
[88] Power JM, Sah P: Nuclear calcium signaling evoked by cholinergic stimulation in
hippocampal CA1 pyramidal neurons. J Neurosci 2002, 22:3454-62.
[89] Stutzmann GE, LaFerla FM, Parker I: Ca2+ signaling in mouse cortical neurons
studied by two-photon imaging and photoreleased inositol triphosphate. J Neurosci
2003, 23:758-65.
[90] Watanabe S, Hong M, Lasser-Ross N, Ross WN: Modulation of calcium wave
propagation in the dendrites and to the soma of rat hippocampal pyramidal neurons. J
Physiol 2006, 575:455-68.
[91] Flavell SW, Cowan CW, Kim TK, Greer PL, Lin Y, Paradis S, Griffith EC, Hu LS,
Chen C, Greenberg ME: Activity-dependent regulation of MEF2 transcription factors
suppresses excitatory synapse number. Science 2006, 311:1008-12.
[92] Mauceri D, Freitag HE, Oliveira AM, Bengtson CP, Bading H: Nuclear calciumVEGFD signaling controls maintenance of dendrite arborization necessary for memory
formation. Neuron 2011, 71:117-30.
[93] Saneyoshi T, Fortin DA, Soderling TR: Regulation of spine and synapse formation
by activity-dependent intracellular signaling pathways. Curr Opin Neurobiol 2010,
20:108-15.
[94] Shalizi A, Gaudilliere B, Yuan Z, Stegmuller J, Shirogane T, Ge Q, Tan Y, Schulman
B, Harper JW, Bonni A: A calcium-regulated MEF2 sumoylation switch controls
postsynaptic differentiation. Science 2006, 311:1012-7.
[95] Rogers DC, Fisher EM, Brown SD, Peters J, Hunter AJ, Martin JE: Behavioral and
functional analysis of mouse phenotype: SHIRPA, a proposed protocol for
comprehensive phenotype assessment. Mamm Genome 1997, 8:711-3.
[96] Rogers DC, Jones DN, Nelson PR, Jones CM, Quilter CA, Robinson TL, Hagan JJ:
Use of SHIRPA and discriminant analysis to characterise marked differences in the
behavioural phenotype of six inbred mouse strains. Behav Brain Res 1999, 105:207-17.
[97] Brooks SP, Dunnett SB: Tests to assess motor phenotype in mice: a user's guide.
Nat Rev Neurosci 2009, 10:519-29.
[98] Gold SJ, Hoang CV, Potts BW, Porras G, Pioli E, Kim KW, Nadjar A, Qin C,
LaHoste GJ, Li Q, Bioulac BH, Waugh JL, Gurevich E, Neve RL, Bezard E: RGS9-2

145
negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental
Parkinson's disease. J Neurosci 2007, 27:14338-48.
[99] Harms LR, Eyles DW, McGrath JJ, Mackay-Sim A, Burne TH: Developmental
vitamin D deficiency alters adult behaviour in 129/SvJ and C57BL/6J mice. Behav Brain
Res 2008, 187:343-50.
[100] Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, Brach J,
Chandler J, Cawthon P, Connor EB, Nevitt M, Visser M, Kritchevsky S, Badinelli S,
Harris T, Newman AB, Cauley J, Ferrucci L, Guralnik J: Gait speed and survival in older
adults. JAMA 2011, 305:50-8.
[101] Yuzaki M: Cbln and C1q family proteins: new transneuronal cytokines. Cell Mol Life
Sci 2008, 65:1698-705.
[102] Hirai H, Pang Z, Bao D, Miyazaki T, Li L, Miura E, Parris J, Rong Y, Watanabe M,
Yuzaki M, Morgan JI: Cbln1 is essential for synaptic integrity and plasticity in the
cerebellum. Nat Neurosci 2005, 8:1534-41.
[103] Egawa K, Kitagawa K, Inoue K, Takayama M, Takayama C, Saitoh S, Kishino T,
Kitagawa M, Fukuda A: Decreased tonic inhibition in cerebellar granule cells causes
motor dysfunction in a mouse model of Angelman syndrome. Sci Transl Med 2012,
4:163ra57.
[104] Armstrong DM, Edgley SA: Discharges of interpositus and Purkinje cells of the cat
cerebellum during locomotion under different conditions. J Physiol 1988, 400:425-45.
[105] Edgley SA, Lidierth M: Step-related discharges of Purkinje cells in the paravermal
cortex of the cerebellar anterior lobe in the cat. J Physiol 1988, 401:399-415.

146

Chapter 3: Loss of Toll-like Receptor 2 results in significant
consolidation of active states
Introduction
Age-Associated Deficits in Sleep and Introduction to Sickness Behaviors
Aging is accompanied by deficits in the ability to regulate transitions between active
and inactive states according to circadian rhythm. Altered circadian rhythm in the elderly
has been linked to increased napping frequency and duration1, higher fragmentation of
rest and activity cycles2,

earlier onset sleep3, and early awakening from sleep4.

Additionally, sleep fragmentation characterized by multiple awakenings and arousals
that disrupt normal sleep architecture is associated with advancing age. Sleep
fragmentation is accompanied by significant clinical outcomes, including cognitive
impairment5, 6, falls7, decreased patient quality of life8, and social isolation9. In adults
older than 65, insomnia and sleep disordered breathing (usually from obstructive sleep
apnea) account for 60% and 40% of sleep fragmentation complaints, respectively10.
Animal models of aging have also demonstrated fragmentation of activity with advancing
age. One study of wheel running activity in adult (6-9 mo.) and aged (19-22 mo.) old
C57BL/6J mice revealed increased fragmentation with no change in maximum running
activity in aged mice. Fragmentation was characterized by shorter bouts of activity with
longer rest periods in between bouts11. CNS aging2, 12, 13 and CNS neurodegeneration1416

both contribute significantly to insomnia and active state fragmentation. Given the high

prevalence and impact that sleep fragmentation has on older adults’ lives, it is not
surprising that sleep disturbances are associated with greater future health care
expenditures17, 18
Sleep is a highly complex physiological process organized over multiple sites within
the CNS. Within the CNS, functional changes in hypothalamic regions, including the
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suprachiasmatic nucleus and lateral hypothalamus have been proposed to underlie
sleep fragmentation19,

20

. The lateral hypothalamus (LH) is a critical region for the

generation and regulation of sleep behaviors. The LH contains a discrete neuronal
population that expresses orexin, a 33/28 peptide hormone (orexin A/B, respectively)
first described for its involvement in narcolepsy, an acquired sleep disorder21. Mice
genetically engineered to ablate prepro-orexin22, orexin receptor-222, or orexin23 all
exhibit severe sleep fragmentation. Electrophysiological studies demonstrate that resting
membrane voltages in orexinergic neurons are intrinsically depolarized24, making them
exquisitely sensitive to excitatory synaptic input25-27. Orexinergic neurons share
reciprocal inhibitory projections with LH neurons expressing melanin-concentrating
hormone (MCH). Data obtained from optogenetic approaches strongly support the
concept that under basal conditions (e.g., without sleep pressure28) joint activity of
orexinergic and MCH neurons constitute a biological “switch” that toggles between wake
(active) and sleep (inactive) states29, 30. Therefore, to better understand sleep regulation
and potential causes of CNS mediated age associated sleep fragmentation; it is critical
to identify molecules that regulate orexingergic neuron function.
Changes in sleep patterns are often associated with infections, and suggest that
immune signaling may play a role in sleep regulation. Sickness behaviors are a set of
coordinated behavioral changes (including increased sleepiness, anorexia, and lethargy)
that focus metabolic resources toward fighting infections. Sickness behaviors have been
directly linked to the suppression of orexinergic signaling31, thereby suggesting that
immune proteins may play a role in the regulation of orexinergic neuron function. In fact,
one particular group of immune proteins, hypothalamic toll-like receptors, has been
strongly linked to sickness behaviors32,

33

. Specifically, toll-like receptor 2 (Tlr2), has

been shown to play a prominent role in organizing sickness behavior34, 35.
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Toll-like Receptor 2 Signaling and Expression
Tlr2 is an intrinsic membrane protein containing multiple extracellular tandem
leucine-rich-repeat motifs that fold into a characteristic horseshoe shape36. Tlr2 forms
heterodimers with similarly shaped partners such as toll-like receptor 1 (Tlr1), or toll-like
receptor 6 (Tlr6); alternatively, Tlr2 forms homodimers with itself37,

38

. These dimers,

when organized into larger structures containing Cd14 and Cd36, recognize extracellular
diacylated and triacylated lipopeptide ligands39. Of all toll-like receptors, Tlr2 has been
shown to recognize the largest array of pathogen associated molecular patterns from
distinct bacteria, yeast, and viruses.

Bacterial peptidoglycans, lipoproteins, atypical

lipopolysaccharide, and glycosylphosphotidylinositol lipids can all serve as agonists.
Additionally, yeast zymosan, human cytomegalovirus (hCMV) envelope proteins, and
hCMV miRNA UL112-3p activate Tlr240-43. Aside from exogenous sources, numerous
endogenous ligands activate Tlr2 receptors. These include biglycans44, endoplasmin45,
High Mobility Group Box Protein 1 (HMGB1)46, Heat Shock Protein 60 (HSP60)47, Heat
Shock Protein 7048,
crystals54,

55

49

, human cardiac myosin50, hyaluronan51-53, monosodium urate

, alpha synuclein56, oxidative stress related carboxyalkylpyrroles57, and

necrotic cell products58. Activation of Tlr2 dimers results in complex intracellular
signaling cascades59, but can be summarized by (1) Tlr2 ligand binding recruiting the
adaptor protein MyD88, (2) MyD88 activation of pathways that phosphorylate IkB,
causing (3) nuclear translocation of NF-κB60. The effects of NF-κB activation are context
dependent, where the duration and location of activation are important in determining the
end outcome. Within neurons, NF-κB signaling plays a role in axon growth61, dendritic
arborization62, synapse formation63-65, plasticity63, 64, and behavior65.
Tlr2 is widely expressed throughout the CNS on multiple cell types including
microglia, astrocytes, neurons, and oligodendrocytes66,

67

. Within the hypothalamus,
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orexinergic neurons strongly express both Tlr2 transcript and protein68. Additionally,
hypothalamic expression of the putative Tlr2 endogenous agonist Hsp70 occurs under a
variety of stressor conditions69,

70

. Changes in Tlr2 signaling may have an impact on

regulation of orexinergic signaling and regulation of active states. Supporting this theory,
NF-κB, the downstream signaling pathway of Tlr2 has been tied to regulation sleep
behaviors. Injection of a cell permeable NF-κB inhibitor attenuates IL-1beta-induced
sleep and febrile responses71. This data suggests that Tlr2 signaling through NF-κB may
function in regulating sleep behaviors by multiple mechanisms. This may include NF-κB
mediated changes in neuron structure and function or through NF-κB mediated cytokine
signaling. In efforts to determine the role of Tlr2 in the regulation of activity patterns and
circadian rhythm, we tested control C57BL/6J (WT) and Tlr2tm1Aki (Tlr2-/-) male mice in
our HCM system at two time points, 4-4.5 months and 8-8.5 months. Using this system
we were able to assess the circadian nature of daily activity and inactivity and determine
if there are any genotypic differences between mice lacking function Tlr2 signaling and
WT controls.

Methods and Materials
Mice and Animal Husbandry
Tlr2tm1Aki homozygous mutant mice (engineered with a constitutive mutation deleting
a transmembrane domain and protein cytoplasmic tail)72 were obtained from a
colleague’s colony and triad-mated to create cohorts of mutant mice. We confirmed
presence of this genetic lesion by PCR of DNA obtained from tail biopsy of putative Tlr2/-

mice. WT male and female (C57BL/6) mice were obtained from Jackson labs and triad-

mated to create a WT colony. Since Tlr1, Tlr6, and Tlr10 do not form homodimers, Tlr2-/mice cannot transduce intracellular signals evoked by exogenous or endogenous Tlr2
ligands73, 74, and do not have a dominant negative phenotype evoked from aberrant Tlr1,
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Tlr6, or Tlr10 signaling. Prior to behavioral testing, mice were housed in the UNMC
vivarium at a density of ≤5 per cage in a microisolator system (Lab Products Inc.,
Seaford DE), provided with chow (Envigo Teklad #7012) and water ad libitum, given
environmental enrichment (Crinkle Paper Pouches, WF Fisher), and maintained on a
12:12 circadian lighting cycle (lights on 0600 CST). Vivarium temperatures ranged
between 20-23 °C. Mice were separated by sex at weaning. All studies were performed
in full concordance with both institutional and federal regulations regarding animal care
and use. The protocol was approved by the UNMC Institutional Animal Care and Use
Committee (IACUC).
Body mass composition determination
We performed a longitudinal assessment using dual emission x-ray absorptiometry
(DEXA) for in vivo estimates of mouse adiposity. We evaluated one cohort of male WT
(n = 8) and male Tlr2-/- (n = 8) mice at 4-4.5 months and 8-8.5 months of age. One
mouse was lost by attrition from the 8-8.5 month old WT cohort. Before data collection,
all instrumentation was calibrated to a phantom approximating mouse body composition
characteristics. Briefly, mice were lightly anesthetized with isoflurane, and imaged
(Piximus I, GE Lunar). Measures of body mass composition, including bone mass
density (BMD), bone mineral content (BMC), bone area (BArea), tissue area (TArea),
ratio of soft tissue attenuation (RST), total tissue mass (TTM), and percent adiposity (%
fat) were calculated from images using vendor provided software (Piximus 2.10).
Differences in cohort DEXA and body weight values were determined by unpaired twosided Student’s t-tests, with Bonferroni correction of the critical p to control the false
positive rate.
Metabolic rate determination
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We performed a longitudinal assessment of mouse metabolic parameters using
indirect calorimetry with the mouse cohorts detailed above. Briefly, mice were fasted
overnight prior to metabolic assay. Animals were placed individually in a calorimetry
chamber (8 total; Oxymax, Columbus Instruments), and tested between 12:00 and 17:00
for one day. Measures of metabolic rate, including maximum oxygen uptake (VO2),
global oxygen delivery (DO2), oxygen output (O2out), maximum CO2 production, (VCO2),
global CO2 removal (DCO2), CO2 output (CO2out), and heat generated were calculated
using vendor provided software (Oxymax for Windows 4.49). These metabolic
parameters were adjusted for mouse adiposity per ANCOVA75. Full details regarding our
system components and operation are provided in Bonasera et al. 201776.
Home cage behavioral monitoring
Using the mouse cohorts described above, we performed a longitudinal assessment
of home cage behaviors including feeding, drinking, movement, and circadian rhythm.
Briefly, mice were placed in a custom-designed home cage monitoring arena (32 total)
with ad libitum access to milled chow (#5058, PicoLab) and water. This system provides
high spatial (within 0.5 cm) and temporal (within 1 ms) precision of all mouse behaviors.
Mice are habituated to the home cage environment for 5 days before the start of data
collection, which then proceeds for at least 15 days (to ensure collection of at least 14
days of data for each mouse). The system collects data at all times (except brief
intervals every 3-4 days for replacement of mouse food and water supplies). After the
mouse is introduced to the home cage, it is not handled until the end of the experiment.
Since mouse handling is a well-appreciated stressor known to alter many behaviors77,
we thus capture mouse home cage behaviors without imposing significant external
stressors. Behavioral data obtained from this system describing C57BL/6 mice are highly
similar regardless of system location or investigator (Tecott, Goulding, personal
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communication). Data passing automated quality control procedures are then classified
to determine mouse active/inactive states, mouse intake (of food and water) bouts, and
mouse movement (locomotion and movement-in-place) bouts. Following classification,
we determine up to 665 distinct measures of mouse feeding, drinking, movement, and
circadian activity. We employ false discovery rate (FDR) statistics to minimize familywise error rates; behaviors found significant in this manner are subjected to further
analysis. Full details regarding our system hardware and software characteristics have
been published76, 78, 79.
We examined circadian periodicities using Lomb-Scargle analysis80, 81; this method
detects multiple periodicities within a time series and has been validated in the setting of
incompletely sampled data streams. Feeding, drinking, and movement data were binned
into 6-minute epochs, and significant periodicities (up to 60 hr duration) were calculated
using an implementation described by Van Dongen et al., 199982 and coded in MATLAB
2011b (MathWorks, Natick MA). We examined patterns of active state onset and
duration using the comparison clustering algorithm described by Goulding et al. (2008)
and coded in MATLAB 2011b. Briefly, active state onset and duration data from the WT
and Tlr2-/- groups are combined. Between 2-50 clusters were fit to this dataset using
bivariate normal distributions. We then test the null hypothesis that WT and Tlr2-/- mice
are equally represented in a given cluster by calculating a c2 statistic comparing the
observed to predicted number of data points that WT and Tlr2-/- contribute to this cluster.
The overall difference between WT and Tlr2-/- mice active state patterns is thus
represented by the sum of c2 values over all clusters.
The major limitations of our home cage behavioral monitoring approach include brief
epochs of data loss secondary to blocked photobeams (e.g., chow pile, or resting mouse
close enough to encroach on the beam radius), licker malfunction (in particular, drips),
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mouse weight gain/loss during the experiment, and excessive rearing along the cage
wall (both altering reported movement distances). All of these issues are identified
during our data quality control phase, and removed from the dataset at that time. Since
these issues occur infrequently and at random times, there are no statistical problems
introduced by removing this small percentage of collected data during the quality control
phase.
Open field assay
Mice were placed with their head facing into the same corner of an open field arena
(49 cm long × 49 cm wide × 15 cm high, white walls and floor, custom fabricated by
California Model and Design, San Francisco, CA). Locomotor activity was recorded at 30
frames/s to .mp4 format from a camera mounted directly above the arena; video files
were analyzed using EthoVision XT8 (Noldus, Leesburg VA) to measure locomotor
distance, center dwell time, center crossings, and thigmotaxis. We defined our
thigmotaxis zone as extending 7 cm from the arena walls; the remainder of the arena
was defined as the center zone. Mice were tested in 20 minute trials between 11:00 and
15:00 under room lighting. The arena was washed with dilute Clidox-S solution, rinsed
with 70% ethanol, and dried between mouse trials. We compared total open field
distance between WT and Tlr2-/- cohorts using unpaired, two-sided Student’s t-tests.
Center crossings and center dwell times (normalized to locomotor distance) were
compared using unpaired, two-sided Student’s t-tests. We performed Bonferroni
adjustment of critical p value to account for 3 comparisons.
Elevated zero maze
Mice were placed in the center of the zero maze closed path (34 cm inner diameter,
46 cm outer diameter, on four-braced legs 58 cm off the ground; 12 cm high walls for
closed path, white Plexiglas, California Model and Design, San Francisco). Behavior was
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recorded at 30 frames/s to .mp4 format from a camera mounted directly above the
arena. Video files were analyzed using EthoVision XT8 (Noldus) to determine locomotor
distance within the arena, and assessed for zone crossings and zone dwell time by
manual observation. Zone crossings were scored only when all four of the animal’s paws
crossed the border between open and closed regions of the maze. Mice were tested in 6
minute trials between 11:00 and 15:00 under room lighting. Arena was washed with
dilute Clidox-S solution, rinsed with 70% ethanol, and dried between mouse trials. We
compared total zero maze locomotor distance between WT and Tlr2-/- cohorts using
unpaired, two-sided Student’s t-tests. We compared zone crossings and zone dwell
times (normalized to locomotor distance) using unpaired, two-sided Student’s t-tests. We
performed Bonferroni adjustment of critical p value to account for 3 comparisons.

Results
FDR identifies 73 differentially expressed behaviors between 4-4.5 mo old WT and
Tlr2-/- mice, but none in the same mice at 8-8.5 months old
Most of the genotypic differences between the WT and Tlr2-/- 4-4.5 mo old cohorts
involve behaviors occurring during the circadian light cycle (46 of the 73 total). Tlr2-/mice showed significantly less light cycle movement, feeding, and drinking, and
budgeted significantly less time to perform these behaviors compared to WT controls.
Bout metrics for light cycle intake/movement onsets, intake/movement durations, per
bout

intake/movement,

bout

intake/movement

intensities,

and

bout

intake

rates/movement speeds all show large genotypic differences as a consequence of the
overall paucity of Tlr2-/- light cycle behaviors. Inactive and active state properties
(discussed in next section) were generally characterized by Tlr2-/- mice having fewer
daily active/inactive states, lower active/inactive state transition rates, but longer
active/inactive state durations. These findings are all consistent with the concept that
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Tlr2-/- mice have consolidated active and inactive states. Further analysis of behavioral
data demonstrated 57 behaviors with a greater than two-fold change between Tlr2-/- and
WT mice at 4-4.5 months of age that reached statistical significance (Figure 1A). In this
figure, 38 of the 57 behaviors identified as having genotypic differences were observed
during the light cycle. Interestingly, at 8-8.5 months of age, these same mouse cohorts
demonstrated far fewer genotypic differences in behavior. No differences were
appreciated by FDR analysis; however significant differences in 6 behaviors were noted
by volcano plot analysis (Figure 1B).
4-4.5 mo old Tlr2-/- mutant mice demonstrate greater active and inactive state
stability
As mentioned above, most of the behaviors differing between young WT and Tlr2-/cohorts reflect significant changes in how these two genotypes regulate active states.
We therefore decided to examine mouse active and inactive state properties in greater
detail. Over the combined dark and light cycles, Tlr2-/- mice had fewer active states per
day (Figure 2A, Table 1), fewer active states per hour (Figure 2B), and a shorter active
phase (Figure 2C) compared to WT mice. Active state durations trended to be longer in
Tlr2-/- mice, but this finding did not achieve statistical significance. Similarly, over the
combined dark and light cycles Tlr2-/- mice had fewer inactive states per day (Figure
2D), fewer inactive states per hour (Figure 2E), a longer inactive phase (Figure 2F), and
longer duration inactive states (Figure 2G) compared to WT mice. These findings are
consistent with Tlr2-/- mice experiencing fewer transitions between active and inactive
states throughout the circadian day, and thus having increased state stability. Simply
stated, when Tlr2-/- are active they tend to remain active, and when inactive remain
inactive.
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Figure 1. Volcano plot of differentially expressed behaviors between wildtype
and Tlr2-/- cohorts. A. 4-4.5 month old cohort. Generally, Tlr2-/- mice
demonstrated fewer behaviors overall during the circadian light cycle, and had
altered active/inactive state properties. Dashed vertical lines depict boundaries for
two-fold decreases (left) and increases (right) in behavior (WT compared to Tlr2-/-);
dashed horizontal line depicts behavioral significance p<0.05. Behaviors between
the left and right dashed vertical lines show no significant differences between WT
and Tlr2-/- mice. Descriptions of identified behaviors are provided in columns A-C of
Supplemental Table 1. Abbreviations forming behavior names are as follows: AFL > activity-feeding-licking overall averages; TBA -> time budget analysis; SA ->
active/inactive state analysis; BA -> intake/movement bout analysis; BD -> bout
dominance analysis; DCLC -> behaviors aggregated across both dark and light
cycles; DC -> behaviors aggregated over dark cycle; LC -> behaviors aggregated
over light cycle; PE -> photobeam event (feeding); LE -> lickometer event (drinking),
ME -> movement event; AP -> mouse active phase; IP -> mouse inactive phase.
Identified behaviors (per column A) are: (1) BA_ME_DCLC_Go_LC_ActProb, (2)
TBA_
DCLC_MeanPerAct_LC,
(3)
TBA_DCLC_MeanPerStop_LC,
(4)
BA_ME_DCLC_Other_ LC_BoutTotDur_ms, (5) SA_IP_NumActStates_EatDrink,
(6)
BA_ME_DCLC_Other_LC_
BoutTotMove_cm,
(7)
SA_NumActStates_SmallEatLargeDrink,
(8)
SA_IP_NumActStates_
SmallEatLargeDrink,
(9)
BA_ME_DCLC_Stop_LC_BoutTotMove_cm,
(10)
BA_PE_DCLC_
Small_LC_BoutRate_onperms,
(11)
BA_PE_DCLC_Small_LC_BoutNumber, (12) TBA_ DCLC_MeanPerFeed_LC, (13)
BA_PE_DCLC_Large_LC_MeanToralBoutDur_ms,
(14)
BA_
PE_DCLC_Large_LC_BoutRate_onperms,
(15)
BA_PE_DCLC_Large_LC_BoutNumber,
(16)
AFL_avg_LC_Move_m,
(17)
BA_LE_DCLC_Large_LC_BoutRate_onperms,
(18)
BA_LE_
DCLC_Large_LC_BoutNumber, (19) SA_PerActStates_SmallEatLargeDrink, (20)
BA_PE_DCLC_Large_LC_MeanTotalBoutIntake_mg,…continued on next page
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…Figure 1 continued. (21) SA_AP_PerActiveStates_ SmallEatSmallDrink, (22)
BA_PE_DCLC_Small_LC_MeanTotalBoutIntake_mg, (23) AFL_ avg_LC_Chow_gkg,
(24)
SA_AP_NumActiveStates_SmallEatSmallDrink,
(25)
BA_LE_
DCLC_Large_LC_BoutRate_onperactms, (26) AFL_avg_LC_Liquid_g (27) SA_AP_
NumActStates_NoEatNoDrink, (28) SA_AP_NumActStates_SmallEatLargeDrink, (29)
BA_PE_DCLC_Small_LC_MeanTotalBoutDur_ms, (30) BA_ME_DCLC_Other_LC_
BoutRate_onperms, (31) BA_ME_DCLC_Other_LC_BoutMeanNumber, (32) SA_
NumActStates_SmallEatSmallDrink, (33) BA_LE_DCLC_Small_LC_BoutProbability,
(34)
SA_AP_PerActStates_NoEatNoDrink,
(35)
TBA_DCLC_MeanPerStopAtOther_LC,
(36)
SA_IP_NumActStates_LargeEatLargeDrink,
(37)
SA_AP_PerActStates_SmallEatLargeDrink,
(38)
BA_PE_DCLC_Large_BoutRate_onperms, (39) BA_PE_DCLC_Large_BoutNumber,
(40)
BA_ME_DCLC_Stop_LC_BoutRate_onperms,
(41)
BA_ME_DCLC_Go_LC_BoutRate_
onperms,
(42)
SA_PerActStates_SmallEatSmallDrink,
(43)
BA_ME_DCLC_Stop_LC_
BoutMeanNumber,
(44)
BA_ME_DCLC_Go_LC_BoutMeanNumber,
(45)
BA_ME_DCLC_
Go_LC_BoutTotMove_cm,
(46)
BA_LE_DCLC_Small_LC_BoutRate_onperactms,
(47)
SA_
IP_NumActStates_SmallEatSmallDrink, (48) SA_DCLC_LC_MeanInactMove_cm, (49)
BA_ LE_DCLC_Large_BoutSlopeIntensity_mgs, (50) BA_LE_DCLC_Large_DC_
BoutSlopeIntensity_mgs, (51) SA_DCLC_LC_MeanInactDur_ms, (52) TBA_DCLC_
MeanPerActShortStopAtHomeBase_LC, (53) SA_DCLC_MeanInactMove_cm, (54)
BA_PE_
DCLC_DC_BoutMeanDur_ms,
(55)
BA_PE_DCLC_Small_DC_BoutMeanSize_evtdur,
(56)
BA_PE_DCLC_Small_DC_BoutMeanSize_mg,
(57)
BA_PE_DCLC_Small_BoutMeanDur_ms. B. 8-8.5 month old cohort. Behaviors
significantly differing between WT and Tlr2-/- mice depicted per A. Supplemental
Table 1 provides descriptions for each of these behaviors. Identified behaviors are (1)
BD_Chow_BtSizeRsq,
(2)
BD_Chow_BtSizePerRSq,
(3)
SA_
NumActStates_SmallEatLargeDrink, (4) SA_AP_NumActStates_SmallEatLargeDrink,
(5) BA_ PE_DCLC_Small_TotalDur_ms, (6) BA_PE_ DCLC_Small_PerCumIntake.
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Figure 2. 4-4.5 mo old Tlr2-/- mice have fewer, more consolidated active and
inactive states throughout the day. (A) Boxplot of number of daily active states.
Red line depicts group median, the box spans the first through third quartiles, the
whiskers extend to the most extreme data points not identified as outliers. Lack of
overlap between notches of adjacent box pairs suggests that the true medians
differ at 95% confidence. For all boxplots, blue depicts values from WT mice, green
depicts values from Tlr2-/- mice. (B) Daily active state rate (per hour). (C) Daily
active state phase duration. Axis on left depicts number of seconds × 104; axis on
right depicts duration in hour-minute format. (D) Daily number of inactive states. (E)
Daily inactive state rate (per hour). (F) Daily inactive state phase duration. Axes as
given in (C). (G) Median duration for a single inactive state. Axes as given in (C).
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This altered active/inactive state transition frequency is particularly evident during
the circadian light cycle (Table 2). Compared to WT, Tlr2-/- mice expressed fewer active
states (Figure 3A), had a lower active state rate (Figure 3B), and a shorter active state
duration (Figure 3C) during the circadian light cycle. Similarly, Tlr2-/- mice had fewer
inactive states (Figure 3D), a lower inactive state rate (Figure 3E), and a longer inactive
state duration (Figure 3F) during the circadian light cycle. These values suggest that WT
mice spend 13% of the light cycle in an active state, while Tlr2-/- mice spend 4% of the
light cycle in an active state. Not surprisingly, decreased light cycle activity duration in
Tlr2-/- mice was accompanied by decreased feeding, drinking, and movement compared
to WT controls (Figure 3G,H,I,J respectively). Tlr2-/- mice clearly experience fewer
transitions between active/inactive states during the circadian light cycle compared to
WT.
This Tlr2-/- light cycle phenotype is well illustrated in Figure 4, which shows a dual
plot actogram for a representative 4-4.5 month old WT and Tlr2-/- mouse over 16 days.
Note that the Tlr2-/- mouse demonstrated decreased light cycle activity, and greater
active state consolidation over this time period compared to WT (longer solid lies above
bout markers). These findings extend to all the mice within the WT and Tlr2-/- cohorts
(Figure 5A). For all mice within a cohort across all experiment days, Figure 5A depicts
active state onset on the x axis and active state duration on the y axis. This data clearly
demonstrates that Tlr2-/- mice express fewer active states during the light cycle
compared to WT controls. This plot also demonstrates that short duration active states
occurring throughout the circadian dark cycle are statistically underrepresented in Tlr2-/mice.
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Figure 3. 4-4.5 mo old Tlr2-/- mice demonstrate dramatic behavioral
consolidation during the circadian light cycle. (A) Boxplot of the number of
circadian light cycle active states. Red line depicts group median, the box spans the
first through third quartiles, the whiskers extend to the most extreme data points not
identified as outliers. Lack of overlap between notches of adjacent box pairs suggests
that the true medians differ at 95% confidence. For all boxplots, blue depicts values
from WT mice, green depicts values from Tlr2-/- mice. (B) Circadian light cycle active
state rate. (C) Circadian light cycle active state duration. (D) Circadian light cycle
number of inactive states. (E) Circadian light cycle inactive state rate. (F) Circadian
light cycle inactive state duration. (G) Circadian light cycle chow consumption. (H)
Circadian light cycle water consumption. I. Circadian light cycle movement. J. Total
daily light cycle movement.
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Figure 4. Dual plot actogram demonstrating dark cycle active state
consolidation and light cycle inactive state consolidation of a representative
Tlr2-/- mouse in comparison to a representative WT mouse. X axis depicts
military time (lights off at 12:00 and 36:00, lights on at 24:00 and 48:00) in hours.
Y axis depicts experimental day. Note that the data shown in the last half of one
daily trace is the first half of data shown in the following day (except for the last
day of collection). Drinking, feeding, and movement events are depicted by blue,
orange, and green hash lines, respectively. The empty rectangles at the top of
tracings for each day represent duration of calculated active states. Dashed
vertical lines show lighting transitions, grey background depicts dark cycle.
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8-8.5 mo old Tlr2-/- mice demonstrate fewer differences in active and inactive
states.
There were no genotypic differences between 8-8.5 mo old WT and Tlr2-/- mice in
overall active/inactive state properties including (1) number of daily active states, (2)
active state onset rates, (3) active phase durations, (4) number of daily inactive states,
(5) inactive state onset rates, (6) inactive phase duration, or (7) inactive state duration.
Similarly, there were no genotypic differences between 8-8.5 mo old WT and Tlr2-/- mice
in light cycle active/inactive state properties including (1) number of light cycle active
states, (2) light cycle active state onset rates, (3) light cycle active state duration, (4)
number of light cycle inactive states, (5) light cycle inactive state onset rates, (6) light
cycle inactive state duration, or (7) light cycle feeding, drinking, and movement. All of
these metrics showed significant phenotypic differences between 4-4.5 mo old WT and
Tlr2-/- mice.
However, 8-8.5 mo old Tlr2-/- mice continue to demonstrate a statistically significant
underrepresentation in short duration active states occurring during the dark cycle
(Figure 5B), with this finding further extending to short duration active states within the
light cycle. However, this phenotype is less pronounced in the older mouse cohort
apparent by comparison of similar time epochs in Figures 5A and 5B.
Tlr2-/- mice show less variability in circadian patterns of movement, feeding, and
drinking compared to WT.
We performed Lomb-Scargle analysis of movement, feeding, and drinking time
series (from 4-4.5 month and 8-8.5 month old WT and Tlr2-/- mice) to assess periodicity
of these behaviors. In both 4-4.5 month old mice and 8-8.5 mo old mice, normalized
power of the 24-hour spectral component is significantly greater in Tlr2-/- mice compared
to WTs for movement, feeding, and drinking (Figure 6). The decrease in amplitudes of
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Figure 5. Tlr2-/- mice have fewer short duration active states throughout the
circadian day. (A) 4-4.5 mo old mice. Each point represents an active state from a
WT (top left) or Tlr2-/- (bottom left) mouse within the cohort over the total
experimental duration. x axis depicts active state onset time, y axis depicts active
state duration (in log). Dashed lines depict onset (left) and offset (right) of the dark
cycle, which is further highlighted in light grey. Active states highlighted in green
depict regions where states with these specific onset/duration properties are
statistically overrepresented in wildtype mice and underrepresented in Tlr2-/- mice.
Note that for 4-4.5 mo old mice, these states include shorter duration active states
throughout the circadian day, as well as all duration active states for the last half of
the light cycle. (B) 8-8.5 mo old mice. Each point represents an active state from a
WT (top right) or Tlr2-/- (bottom right) mouse. Plot annotations otherwise per (A).
Active states highlighted in violet depict regions where states with these specific
onset/duration properties are statistically overrepresented in wildtype mice and
statistically underrepresented in Tlr2-/- mice. For 8-8.5 mo old mice, these states
include shorter duration active states throughout the circadian day.
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Figure 6. Tlr2-/- mice have stronger 24-hour periodicities compared to WT
mice. (A) Lomb-Scargle periodogram for movement, 4-4.5 mo old mice. WT
periodogram in blue, Tlr2-/- periodogram in green. (B) Observed movement for WT
(blue) and Tlr2-/- (green) cohorts, 4-4.5 mo old mice. Thin line with points depicts
the mean values for each cohort. (C) Lomb-Scargle periodogram for feeding. 4-4.5
mo old mice. WT in blue, Tlr2-/- in green. (D) Observed feeding for WT (blue) and
Tlr2-/- (green) cohorts. 4-4.5 mo old mice. (E)Lomb-Scargle periodogram for
drinking. 4-4.5 mo old mice. WT in blue, Tlr2-/- in green. (F) Observed drinking for
WT (blue) and Tlr2-/- (green) cohorts. 4-4.5 mo old mice. (G) Lomb-Scargle
periodogram for movement, 8-8.5 mo old mice. WT periodogram in cyan, Tlr2-/periodogram in dark green. (H) Observed movement for WT (cyan) and Tlr2-/- (dark
green) cohorts. 8-8.5 mo old mice. Thin line with points depicts the mean values
for each cohort. (I) Lomb-Scargle periodogram for feeding. 8-8.5 mo old mice. WT
in cyan, Tlr2-/- in dark green. (J) Observed feeding for WT (cyan) and Tlr2-/- (dark
green) cohorts. 8-8.5 mo old mice. (K) Lomb-Scargle periodogram for drinking. 88.5 mo old mice. WT in cyan, Tlr2-/- in dark green. (L) Observed drinking for WT
(cyan) and Tlr2-/- (dark green) cohorts. 8-8.5 mo old mice. For A,C,E,G,I,K error
bars are ± 1 standard deviation. No significant periodicities of longer than 24 hours
obtained for any behaviors.
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these 24-hour spectral components (as well as 12-hour and 8-hour ultrudian spectral
components) between 4-4.5 month old and 8-8.5 month old mice suggests that the older
mice have greater variability in minute-to-minute and day-to-day movement, feeding, and
drinking events compared with younger mice, and is consistent with our prior
observations showing age-related decreases in the amplitude of these same spectral
components in older C57BL/6 and BALB mice (unpublished data). Lomb-Scargle
analysis suggests that Tlr2-/- mice have less variability in movement, feeding, and
drinking behaviors compared to WT mice, regardless of age. This data is supported for
consolidated behavioral states in Tlr2-/- mice, indicating less fluctuation in neuronal
pathways driving state regulation.
Tlr2-/- mice have lower body weights than WT cohorts, but otherwise show no
genotypic differences in metabolic parameters.
WT mice were significantly heavier (WT 25.2 ± 0.8 g; Tlr2-/- 23.1 ± 1.1 g; p<0.0008
at 4-4.5 months; WT 29.0 ± 0.9 g; Tlr2-/- 26.7 ± 1.7 g; p<0.004 at 8-8.5 months), and had
a greater total tissue mass (TTM: WT 21.3 ± 0.8 g; Tlr2-/- 19.8 ± 1.0 g; p<0.006 at 4-4.5
months; WT 25.4 ± 0.85 g; Tlr2-/- 23.3 ± 1.5 g; p<0.005 at 8-8.5 months) than Tlr2-/- mice
at both ages assessed. No significant differences in BMD, BMC, BArea, TArea, RST, or
% adiposity were noted at either 4-4.5 or 8-8.5 months. We noted no significant
differences in the metabolic parameters of VO2, O2out, DO2, VCO2, CO2out, DCO2, and
heat either at rest (basal status) or with moderate activity.
No difference between WT and Tlr2-/- cohorts in both 4-4.5 and 8-8.5 mo old mouse
cohorts for select behavioral measures
Regarding home cage phenotypes, we noted no significant differences in overall
food and water consumption, or overall daily movement. There were no differences in
the 24 hour behavioral time budgets for inactivity, feeding, drinking, locomotor, or
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nonlocomotor movements. Similarly, there were no differences in active state time
budgets examining percentage of time devoted to feeding, drinking, locomotion, and
nonlocomotor movements. Additionally, there were no differences in the probabilities of
specific behaviors occurring after the start of new active states or preceding the finish of
ongoing active states. We also found no significant differences in the dark cycle (4-4.5
month old) or dark and light cycle (8-8.5 month old) patterns of feeding, drinking, or
movement bouts, including no differences in hourly bout onset rates, bout probabilities,
bout speed/intensities, bout durations, or per-bout intake/movement.
Finally, we assessed anxiety-related behaviors by elevated zero maze and open
field assays, and found that Tlr2-/- mice demonstrated increased anxiety related
behaviors (increased thigmotaxis and decreased entries into open field center; Figure 7)
compared to WT mice in the open field assay. Additionally, we note that 4-4.5 month old
Tlr2-/- mice demonstrate significantly reduced locomotion in both the open filed and
elevated zero maze assays (data not shown). No genotypic differences were
appreciated in zone transitions, time spent on open arm, or time spent on closed arm.
These data suggest that loss of Tlr2 function in C57BL/6 mice is associated with
decreased exploratory behavior and increased anxiety-related behaviors.

Conclusions and Discussion
We provide the first description of Tlr2-/- mouse behavior in a home cage
environment assessed over an extended period of time. Most notably, we find that loss
of Tlr2 function in 4-4.5 month old mice leads to a marked consolidation of both mouse
active and inactive states, as determined by active/inactive state durations, onset
frequencies, and a marked paucity of all behaviors occurring during the circadian light
cycle. As a result of these changes, we also note that Tlr2-/- mice demonstrate stronger
day-to-day periodicity of movement, feeding, and drinking behaviors as revealed by
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Figure 7. 4-4.5 mo old Tlr2-/- mice show decreased locomotion and increased
thigmotaxis in an open field assay of exploratory behavior. Leftmost plot
depicts open field total distance. White bars depict WT (n=8), grey bars depict Tlr2-/(n=8). Error bars are ± 1 standard deviation. ** p<0.01. Rightmost plot depicts open
field center dwell time (left pair of bars, with corresponding left vertical axis) and
number of center crossings (right pair of bars, with corresponding right vertical axis).
Annotations per above. * p<0.05.
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Lomb-Scargle analysis. Of note, nearly all of these genotypic differences were no longer
observed upon repeat examination of these same mouse cohorts at 8-8.5 months of
age, although there was still evidence of active/inactive state consolidation in older Tlr2-/mice.
Behavioral phenotypes arising from Tlr2 loss remain unclear due to the limited
scope of available data. Multiple studies suggest that Tlr2 functional loss is accompanied
by altered energy balance and metabolism. For example, baseline hyperphagia
accompanied by obesity and increased adiposity (on both regular and high fat diets),
poor glucose tolerance, and increased respiratory ratio (RER) has been described in 4and 7-month old Tlr2tm1Aki constitutive knockout mice bred to a C57BL/6 background83.
This same study also noted increased light cycle (and unchanged dark cycle) activity in
12 month old Tlr2 knockout compared to wildtype controls. By contrast, mice with Tlr2
lesions derived from a different founder strain (Tlr2tm1Kir) demonstrated hyperphagia,
enhanced glucose tolerance, decreased insulin resistance and decreased RER on a
high fat diet compared to controls84. Similar resistance to the metabolic syndrome
phenotype was noted in 3+ month old Tlr2tm1Aki mice bred to a C57BL6/Hsd background
and receiving a high fat diet85. Three month old mice with constitutive knockout of both
Tlr2 and Tlr4 (bred to a C3H/HeJ background) maintained on a high fat diet for 8 weeks
were noted to have lower body weights, enhanced glucose tolerance, and increased
dark cycle locomotor activity compared to control mice kept on the same high fat diet86.
Our study finds no evidence of hyperphagia, obesity, or increased adiposity in Tlr2-/mice fed a regular diet compared to C57BL/6 controls; in fact, Tlr2-/- mice were
significantly lighter at 4-4.5 and 8-8.5 month time points. These results differ from data
presented by Shechter et al. (2013, their Figure 1B). We also did not observe any
differences in metabolism between WT and Tlr2-/- mice. There are no obvious factors to
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explain these discrepancies, which may be secondary to differences in mouse breeding
strategy, housing (singly housed after HCM in our study), diet, or handling across
different rodent colonies. Differences in how the two studies dispensed food (powdered
vs pelleted chow) may also account for discrepancies in food intake.
Tlr2 functional loss has also been linked to sleep performance. EEG evaluation of
sleep architecture revealed increased consolidation of both awake and sleeping states in
Tlr2/Tlr4 double mutant mice, demonstrating significantly less NREM sleep during the
dark cycle while simultaneously showing greater REM sleep during the light cycle
compared to wildtype cohorts (Sartorius et al., 2012). Our observed phenotypes of dark
cycle active state consolidation and light cycle inactive state consolidation are consistent
with the sleep phenotypes reported by Sartorius and colleagues. Finally, there is
evidence that Tlr2tm1Aki mice have decreased anxiety-related behaviors (increased open
field locomotion with decreased thigmotaxis, increased open arm dwell time on an
elevated plus maze, decreased marble burying), impaired social behaviors (less
recognition in a three-chamber social novelty assay, fewer contacts in a reciprocal social
interaction test), increased aggression (more attacks in a cotton bud biting test),
impaired sensorimotor gating (decreased prepulse inhibition of an otherwise normal
acoustic startle response), and impaired cognition (diminished freezing to aversive
context, diminished novelty seeking, poor performance in a Barnes maze task)
compared to wildtype cohorts87,

88

. We noted increased anxiety-related behaviors as

assessed by open field and elevated zero maze; similar factors as discussed above may
explain these discrepancies.
Tlr2 signaling occurs when either Tlr1/Tlr2 heterodimers (in concert with Cd14)
detect triacylated lipopeptides89, or when Tlr2/Tlr6 heterodimers (in concert with
Cd36/Cd14) detect diacylated lipopeptides90. Tlr2 signaling in these contexts are early
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events promoting inflammation91 and sickness behavior35. Tlr2 regulation of active and
inactive state lengths likely occurs either upon the orexinergic/MCH neuronal
populations, or onto the interneuron network immediately upstream of these centers92, 93.
Orexinergic neurons strongly express both Tlr2 transcripts and protein, and are thus
potential loci where integration of animal health status and animal alertness/activity may
occur68. Tlr2 expressed by orexinergic neurons is thus particularly well placed to
integrate animal health status and animal activity, since orexinergic neurons receive
excitatory inputs from multiple CNS regions signaling potential life-threatening conditions
(e.g. posterior hypothalamic nucleus94 (thermoregulation); ventrolateral preoptic
nucleus94, 95 (overall arousal state); bed nucleus of stria terminalis95 (anxiogenic states);
amygdalar CRF projections96 (stress responses); nucleus accumbens97,

98

(reward);

locus coeruleus and dorsal raphe nuclei99, 100 (arousal states)).
Further, sickness behaviors have been directly linked to suppression of orexinergic
signaling31. Organization of CNS systems converging onto MCH neurons is not wellunderstood at this time; however, MCH neuronal activity can by modulated by
neurotransmitters characteristic of the above systems, including glutamate, GABA,
norepinephrine, and serotonin101. Our data suggests that following Tlr2 activation,
activity fragmentation will increase, active state durations will decrease, and affected
individuals may thus limit time spent in social contact with conspecifics. This response is
an important aspect of current sickness behavior frameworks102, providing a mechanistic
connection for how individuals experiencing illness show strong tendencies to decrease
movement and feeding behaviors.
In summary, we describe a previously unappreciated role of the pattern recognition
receptor Tlr2 in regulating active state consolidation throughout the circadian day. As
mentioned in the introduction, understanding mechanisms controlling active/inactive
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state transitions are highly relevant to understanding sleep/wake cycle regulation. Our
data suggest that interventions to block Tlr2 signaling may be novel and promising
avenues for treatment of insomnia and related sleep disturbances. Further research to
identify (1) how different pattern recognition receptors influence the orexinergic/MCH
neuronal “switch”, (2) how signaling from these molecules ultimately affects neuronal
architecture and (3) how pattern recognition receptors influence neuronal function are
critical to close current knowledge deficits.
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Chapter 4: Mutation of MHC I H2-Kb Leads to adult onset
progressive obesity due to reduced orexin neuron activity and
increased sedentary behavior
Introduction
Age Related Deficits in Energy Balance and Metabolism
Aging has a dichotomist effect on weight and metabolic status, where some
individuals trend towards obesity, yet others towards frailty. Grossly, age-related
changes in body composition have been described in both genders and consist of the
loss of lean body mass and an increase in fat deposition1-3. However, it is clearly evident
that not all elderly individuals gain weight, and only a portion of those that do, gain a
significant enough amount of weight to be deemed obese. Another fraction of the elderly
population loses weight, and a small percentage of those individuals can even reach a
state of frailty. Frailty is a geriatric condition characterized by unintentional weight loss,
reduced capacity for physical activity, low muscle strength, and slower gait speeds4.
Importantly, an individual on either end of this spectrum, either obese or frail, have
considerably increased risk for downstream health complications.
Globally, over 1.4 billion adults are overweight (BMI > 25) and more than half a
billion are considered obese (BMI > 30).

By 2030 these numbers could rise

considerably to 2.16 billion overweight (38% of population) and 1.12 billion obese (25%
of population) individuals if the current rate of change continues5, 6. Obesity leads to
increased risk of comorbid conditions including heart disease, stroke, type II diabetes,
and certain forms of cancer culminating in over 2.8 million obesity related deaths per
year7. The prevalence of frailty varies greatly depending on whether it is defined as a
phenotype or as an accumulation of deficits8. The prevalence of frailty is 14% when
defined as a phenotype, where 3 of the 5 following criteria are met: 1) weight loss, 2)
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fatigue and exhaustion, 3) weakness, 4) low physical activity and slowness, and 5)
mobility impairment. This prevalence increases to 24% when frailty is viewed as a
collection of symptoms, diseases, conditions, and disability and based on risk
accumulation theory9-12. A summary analysis of survival rates for frail older adults
compared to non-frail older adults average roughly 50% for frail patients when using the
phenotypic description and 15% when using the accumulation of deficits model8.
Additionally, using pooled prevalence data, the estimated increased mortality risk of
frailty was concluded to be between 3-5%8. A 2017 study by Kiu, et al., used latent class
analysis of data collected from the I-Lan Longitudinal Aging Study (ILAS) and subdivided
patients with frailty into three groups, those with mobility impairments (slowness and
weakness), those without mobility impairments (weight loss and exhaustion), and those
with low physical activity13. Analysis of healthcare complications in each group
demonstrated that those with mobility impairments have the worst outcomes
characterized by poorer body composition, worse bone health, reduced cognitive ability,
lower survival rates, and worse overall health outcomes compared to robust controls.
Individuals with non-mobility based frailty still showed significant health concerns with
higher risk of metabolic serum abnormalities and poorer bone health.
There is much debate within the literature on how to clinically define frailty and
obesity, but definitions and classifications will only be truly relevant for patients if factors
contributing to the development and pathophysiology of these diseases are understood
to a point where therapeutic options become available. Therefore, it is critical to identify
risk factors that underlie the development of obesity and frailty, and more generally
regulate metabolic and energy balance changes in aging. The etiology of obesity is
multifactorial, but twin studies suggest between 40-70% of obesity cases arise due to an
underlying genetic cause14. Currently, only 15% of obesity phenotypes have been linked
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to specific genes, including MC4R and leptin mutations15-17. Therefore, a large
percentage of obesity phenotypes likely have genetic contributions that are yet to be
described. The etiology of frailty is just as complicated, as it requires deficits in multiple
functional areas for diagnosis and each of these deficits can arise from a multitude of
pathologies. One well-described precursor to frailty development is behavioral
adaptation to declining physiologic reserves4. The etiology of these changes is
multifactorial, encompassing environmental and age-related physiologic changes. While
there is much focus on peripheral mechanisms of obesity and frailty development such
as diet and exercise, CNS contributions, particularly hypothalamic function, likely play a
significant role in the development of these conditions but are poorly understood.
Functions of the Hypothalamus in Energy Balance
Specific hypothalamic nuclei function to link nutrient sensing to energy balance
regulation through control of feeding, drinking, and arousal behaviors.

In general,

energy balance can be considered the equilibrium of caloric intake and expenditure. The
hypothalamus can be split into three gross anatomical regions, the anterior
hypothalamus, posterior hypothalamus, and tuberal hypothalamus. Each of these
regions is made up of several small nuclei that fall either medially or laterally, and
contain distinct populations of cells with specific functions in the regulation of energy
balance through orexinergic or anorexingenic signaling.

Three critical hypothalamic

areas for the studies presented here are the arcuate nucleus, paraventricular nucleus,
and lateral hypothalamus.
The arcuate nucleus (ARC) is a collection of neurons located in the mediobasal
hypothalamus adjacent to the third ventricle and superior to the median eminence.
Through specific cell types and receptor expression the arcuate nucleus integrates
peripheral signaling on nutrient status to the CNS. Activation of proopiomelanocortin

183
(POMC) neurons by leptin, glucose, insulin, or other signaling molecules that indicate a
nutrient high state, leads to the release of α-melanocyte stimulating hormone (α-MSH) at
POMC axon terminals. α-MSH acts on melanocortin receptors to

activate an

anorexinergic path, thereby suppressing food intake. Contrarily, neuropeptide Y/agouti
related peptide (NPY/AgRP) cells within the ARC provide orexigenic signaling through
the action of NPY on NPY receptors (NPYR). Each of these paths also possess
reciprocal inhibition to one another where cocaine- and amphetamine-regulated
transcript (CART) functions as an antagonist to NPY receptors, and AgRP as an
antagonist to melanocortin receptors. Activation of NPY/AgRP neurons by grehlin leads
to release of AgRP from axon terminals, providing antagonistic activity to α-MSH at
melanocortin receptors and strongly inhibits POMC perikarya within the arcuate nucleus
through NPY and GABA18-27. Axons from the ARC project primarily rostral from the
arcuate to innervate the dorsomedial hypothalamic nucleus (DMH), paraventricular
nucleus (PVN), and the lateral hypothalamus in succession during postnatal
development28.
The paraventricular nucleus of the hypothalamus lies laterally to the superior portion
of the third ventricle and receives input from multiple brain regions, including, but not
limited to, the arcuate nucleus, lateral hypothalamus, preoptic area, pons, and medulla29,
30

. Neurons within the PVN are commonly classified into two groups, magnocellular

(large) and parvocellular (small). Parvocellular autonomic neurons project to the nucleus
tractus solitarius, interomediolateral column of the spinal cord, and dorsal motor nucleus
of vagus, which are all key regions for the regulation of sympathetic functions31-34.
Through downstream projections and synapses from these PVN targets, it is connected
to multiple organ systems with critical autonomic functions. PVN connects to the liver,
pancreas, white and brown adipose tissues to regulate hepatic glucose flux, adipose
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deposition, thermogenesis, peripheral glucose uptake, and pancreatic secretion35-39. In
addition to autonomic projections, the PVN functions as a critical regulator of
neuroendocrine function. Parvocellular neuroendocrine cells release signaling peptides
that regulate the production of pituitary hormones through projections to the median
eminence and access to the pituitary portal system31. Magnocellular neuroendocrine
neurons project to the posterior pituitary, where they release vasopressin and oxytocin to
the systemic circulation. Both GABAergic and glutamatergic interneurons also exist
within the PVN and function to integrate input and organize output in response to energy
status31, 40, 41. POMC neuronal protections from the ARC synapse on both magnocellular
and parvocellular neurons expressing receptors of α-MSH, where release leads to
satiety as previously described42. Furthermore, NPY/AgRP neurons from the ARC
synapse with parvocellular neurons in the PVN, where NPY activity leads to increased
feeding43,

44

. The formation of PVN inputs from the ARC is developmentally regulated

process that occurs in the postnatal period in mice, and is critically tied to leptin
signaling. Data suggests a postnatal leptin surge that occurs in mice is important for the
development of ARC projections, as well as dendritogenesis, neurogenesis, and
synaptogenesis45-48. Leptin deficiency leads to impaired development of ARC projections
to the PVN. This can be rescued by exogenous leptin therapy, but only during the
postnatal period as adult treatment with leptin has no effect in restoring this pathway28.
Impaired development of POMC and NPY/AgRP connections to the PVN leads to
impairments and energy balance and may be involved in the development of obesity
phenotypes.
The lateral hypothalamus (LH) is also a critical region for the maintenance of energy
balance. The LH is less well defined and partitioned into discrete cell populations or
nuclei compared to other regions of the hypothalamus. Within the lateral hypothalamus
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there are scattered populations of neurons that express both excitatory and inhibitory
neurotransmitters, as well as several neuropeptides. In situ hybridization and
immunohistochemistry studies have identified populations of neurons positive for
excitatory vesicular glutamate-2, inhibitory GABA neurons, orexin/hypocretin (Orx),
melanin concentrating (MCH), neurotensin (Nts), and galanin (GAL)49-54. Each of these
cell populations have important roles in the regulation of energy balance, but in the
context of this project we will focus on the orexinergic neuron system of the lateral
hypothalamus.
Orexins, also known as hypocretins, were identified concurrently by two
independent groups and were found to be endogenous ligands for two orphan G-protein
coupled receptors55-57. Receptors for orexin A and B are found throughout the brain and
participate in a multitude of pathways, but are primarily studied for their role in the
regulation of arousal and feeding behaviors. Within the hypothalamus receptors for
orexin A are enriched in the ventromedial hypothalamic nucleus and orexin B in the
paraventricular nucleus58. Outside of the hypothalamus orexin A receptors are present in
tenia tecta, the hippocampal formation, dorsal raphe, and locus coeruleus, and orexin B
receptors in the cortex, nucleus accumbens, subthalamic and paraventricular thalamic
nuclei, and anterior pretectal nucleus58. In humans, orexin neurons project to locus
coeruleus, dorsal raphe nuclei, amygdala, suprachiasmatic nucleus, basal forebrain,
brainstem, and spinal cord59. Functionally, orexin neurons have been shown to be
glutamatergic and therefore excitatory to their target neurons in multiple brain regions6066

. Orexin neurons receive predominantly excitatory Vglut2 synaptic input and

electrophysiology studies show that orexin neuron resting membrane voltages are
intrinsically depolarized67, making them particularly sensitive to changes in excitatory
synaptic input68-70. Recent data indicate that the orexin system is plastic, where synaptic

186
changes occur in response to both daily and long term fluctuations in neuronal activity.
Orexin levels in the CSF are low during resting phases and high during periods of
activity, which correlates with electrical activity patterns recorded in orexin neurons
during these states71-74. However, environmental changes can impact this process.
C57BL/6 mice fasted for 12 hours show significant potentiation of orexin neurons,
evident by increased frequency of mini excitatory post-synaptic currents and increased
excitatory synapses on the orexin containing cell bodies75. Tuning of synaptic strength
can also occur in response to changes in nutritional status through leptin signaling in an
activity dependent manner76-78. Additionally, maternal obesity, early malnutrition, and
gestational caloric restriction have all been shown to alter the development of
hypothalamic projections and increase the risk for long-term deficits in energy balance7982

. Despite a clear impact for environmental factors in regulating synaptic plasticity and

function, clear mechanisms underlying these changes are poorly understood.
Within multiple regions of the brain immune proteins have been shown to play
important roles in synaptic development, pruning, plasticity, and maintenance but their
roles within the hypothalamus have yet to be elucidated. Our previous research has
implicated immune proteins and pattern recognition receptors with regulation of aging
phenotypes including changes in energy balance. However, the impacts of specific
immune molecules in regulating energy balance phenotypes are currently unknown.
Expression of Immune Proteins in the Aging Hypothalamus
In an aging-mouse model that shows progressive weight loss and characteristics of
frailty, immune proteins are increased in the aging hypothalamus (General Introduction:
Figure 1 and 2). The hypothalamus is a critical brain region for the regulation of energy
balance including regulation of activity, feeding, drinking, and sleep. Despite clear roles
for immune proteins in the regulation of synapses during development and in
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neurodegenerative disease, there is little known on the role of immune proteins in
regulating hypothalamic function and downstream behaviors. Therefore, we set out to
assess the role of a particular class of immune proteins, class I major histocompatibility
complex proteins (MHC I). MHC I proteins were selected as several members of family
were increased in the aged hypothalamus and they have been shown to function in
synaptic regulation in other regions of the brain.
Major Histocompatibility Complex Proteins
Class I major histocompatibility complex proteins (MHC I), also known as human
leukocyte antigens (HLA) are highly polymorphic transmembrane proteins with over 50
known gene sequences corresponding to the protein class. MHC I proteins are
expressed on nearly all nucleated cells and function to present peptide fragments 8-10
amino acids in size generated from endogenous and exogenous protein83. Classical
MHC I proteins (MHC Ia) are highly polymorphic and function in adaptive immunity, while
non-classical proteins (MHC Ib) are less polymorphic, more tissue specific, and function
in both innate and acquired immunity83. MHC I proteins are encoded by a ~3.6-Mb
cluster of genes within the mammalian genome84. Classical MHC Ia molecules in mice
are encoded by the K and D regions and homologous to human HLA-A, HLA-B, and
HLA-C. Non-classical MHC Ib molecules are encoded by the M, Q, and T regions and
homologous to human HLA-E, HLA-F, HLA-G, and HLA-H. MHC I proteins are
composed of a membrane spanning alpha-chain forming the α1, α2, and α3 domains.
The heavy (α) chain non-covalently interacts with soluble β2-microglobulin to form a
heterodimer and a peptide binding groove in the α1α2 or α1β1 domains83. MHC I
peptides are loaded by the peptide-loading complex (PLC) composed primarily of
heterodimeric transporter associated with antigen processing and supporting proteins85.
Following loading, MHC I proteins are trafficked via selective recruitment into cargo
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vesicles to the plasma membrane to present peptides to recipient cells86. MHC I genes
are both constitutively expressed and modulated by several pathways targeting cisacting regulatory promoter elements containing binding sites for nuclear transcription
factor kappa B (NF-κB) and interferon-regulatory factor (IRF) family members87-89. Both
NF-κB and interferon pathways have well documented roles in inflammatory signaling,
and NF-κB signaling is critical for proper nervous system function90. Additionally, in the
CNS MHC I expression can be regulated by neuronal activity through a calcium
dependent mechanism involving CREB signaling91-93.
Major Histocompatibility Complex Proteins in the CNS
A growing body of work has shown a significant role for MHC I proteins in select
areas of the CNS. Within the normal developing nervous system MHC I proteins are
expressed on cortical, hippocampal, and cerebellar neurons with higher expression
earlier in development94-96. MHC I proteins are expressed at the synapse where they
colocalize with both pre and post synaptic proteins97. Expression of MHC I in the
nervous system is regulated by neuronal activity through a calcium dependent
mechanism involving CREB signaling91-93.
Functionally, MHC I proteins have been shown to be important for neuronal
development and synaptic function. Loss of MHC I surface expression using TAP1/β2microglobulin double knockout mice (β2M-/-TAP-/-) results in increased hippocampal
synaptic density and increased action potential frequency97. Additionally, β2M-/-TAP-/mice show several changes in excitatory synaptic pathways within hippocampal circuits.
The AMPA/NMDA ratio is significantly lower at β2M-/-TAP-/- synapses compared to WT in
the Schaffer collateral/CA1 synapses, which reflects an increase in NMDAR-mediated
currents98. These changes likely underlie enhanced NMDAR dependent LTP and the
loss of LTD in β2M-/-TAP-/- mice99. MHC I was shown to regulate NMDAR-induced AMPA
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receptor trafficking and tonically inhibit NMDAR function98. Behaviorally, MHC I deficient
β2M-/-TAP-/- mice have deficits in hippocampal dependent memory including object
recognition, social recognition, and contextual fear memory100. β2M-/-TAP-/- mice also
exhibit sex-specific increased stress responses to saline injection, measured by
quantification of activity and exploratory behaviors in open-field and elevated plus maze
paradigms. Despite well documented roles for MHC I proteins in select regions of the
CNS, functions and expression of MHC I proteins in the hypothalamus are poorly
understood. Additionlly, the roles of specific MHC I isoforms are poorly described.
MHC I isoform H2-Kb (also called H2-K1) expression is increased in the aged
hypothalamus in a mouse model of energy balance dysregulation. MHC I proteins have
defined functions in synaptic development, and given the plastic nature of hypothalamic
connections, we deemed MHC I H2-Kb a priority target. As mechanisms underlying the
regulation of energy balance on the neuronal level are poorly understood, we set out to
determine if MHC I proteins are important for this process. As a first step, we chose to
characterize MHC I expression in the hypothalamus from postnatal development to early
adult. Additionally, we designed and carried out a longitudinal trial to assess homecage
behavior, basal and active state metabolism, and body composition at 2-3 months, 5-6
months, and 11-12 months in cohorts of male C57BL/6J (WT) and mice carrying a
mutation in H2-Kb. B6.C-H2-Kbm1/ByJ (H2-Kbm1) carry mutations in 7 nucleotides leading
to three amino acid substitutions including Glu152Ala, Arg155Tyr, and Leu156Tyr101, 102.
These three amino acid substitutions result in large changes in the size and polarity of
amino acid side chains, thereby altering the crystal structure of H2-Kb. Changes in
crystal structure to lead to the impaired antigen presentation, 18-fold reduced
thermostability, and inability to elicit a T cell response from known H2-Kb presented viral
peptides including those from SEV, OVA, or VSV observed in H2-Kbm1 mutants101-103.
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Based on this data, the H2-Kb antigen presentation function in H2-Kbm1 mice is
significantly impaired and therefore can serve as a model to test the potential function of
H2-Kb in the hypothalamus. As we noted marked changes in energy balance regulation
as early as 2-3 months in H2-Kbm1 mice, we performed follow up studies to determine
underlying causes for the observed progressive obesity phenotype.

Methods and Materials
Mice and Animal Husbandry
B6.C-H2-Kbm1/ByJ male mice (H2-Kbm1, Jackson Labs #001060) and wild-type
C57BL/6J mice (Jackson Labs #000664) were used for all studies. The bm1 mutation in
H2-Kbm1 mice consists of 7 nucleotide differences resulting in three amino acid
substitutions (Glu152Ala, Arg155Tyr, and Leu156Tyr) that occur in the crest of the α2α
helix101-103. H2-Kb in these mice has impaired antigen presentation of classic H2-Kb viral
peptides, reduced thermostability, and inability to elicit a CTL response with viral peptide
binding, and therefore serves as a model of impaired H2-Kb function101-103. Upon arrival
at UNMC, mice were singly-housed in micro isolator cages in rooms with a 12:12 lighting
cycle (lights on 0600 CST), provided with chow (Envigo Teklad #7012) and water ad
libitum. Vivarium temperatures ranged between 20-23 °C. Mice were given two weeks to
recover from transportation stress and acclimate to our facility before any additional
testing was performed. Breeder triads (2♀ and 1♂) of H2-Kbm1 and C57BL/6J mice were
bred to produce homozygous mutant and wild type mice for developmental studies. Mice
were separated by sex at weaning. All studies were carried out in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.
Behavioral Analysis
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8 mice of each genotype (2-3 months) were chosen for control and experimental
groups. Mice were singly-housed in the home cage monitoring (HCM) chambers and
allowed to habituate for 5 days; we then collected data for 16 consecutive days to
ensure at least 14 days of data for each animal. Mice within the system have access ad
libitum to water and powdered chow (PicoLab Mouse Diet 20, #5058). Behavioral
analysis was repeated on the same cohorts of mice at 5-6 months of age to assess
longitudinal changes in behavior. For detailed description of home cage monitoring
system see Chapter 2 Methods and Goulding et al., 2008104.
Active and Resting State Temperature Analysis
Temperatures were assessed in WT and H2-Kbm1 mice at 2-3 months, 5-6 months,
and 11-12 months of age during both the circadian light and dark cycles, corresponding
to resting and active states, respectively. Mouse temperatures were taken using a
mouse rectal temperature probe and thermometer (Thermoworks Microtherma 2)
accurate to 0.1 °C between the hours of 2:00 - 3:00 PM for resting state (light cycle) and
11:00 PM – 12:00 AM (dark cycle) for active state. Temperature data was analyzed by
two-tailed Student’s t-test in Microsoft Excel.
DEXA Scanning and indirect calorimetry
Following each round of home cage testing, we performed indirect calorimetry
(Oxymax, Columbus Instruments) and dual-emission x-ray absorptiometry (DEXA;
Piximus I, GE-Lunar) studies to assess mouse resting and activity associated metabolic
status and body composition, respectively. For full details on system parameters see
Chapter 2 Methods for Metabolic Analysis.
Glucose Tolerance Testing
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Glucose tolerance tests (GTT) were performed on cohorts of WT and H2-Kbm1 mice
at 6-8, 14-16, 32-34, and 45-47 weeks of age. Mice were fasted for 10 hours prior to
testing. Mice were restrained using restraining tube and the tails were cut just distal to
the bone (~1-2 mm) to initiate blood flow. Baseline fasting blood glucose levels were
measured at this time. Mice then received an intra-peritoneal injection of D-glucose
(20% solution, 2g/kg body weight) and blood glucose was measured at 15, 30, 45, 60,
90, and 120 minutes post injection. All measurements were made using Bayer Contour
blood glucose meter and test strips. Data was then analyzed by two-way ANOVA using
SPSS controlling for genotype and time. If a significant genotype by time interactions
was present, comparisons at individual time points were made by two-tailed Student’s ttests.
Insulin ELISA
Whole blood samples collected from 10 hour fasted WT and H2-Kbm1 mice were
allowed to clot at room temperature and serum was prepared by centrifugation at 4000G
for 15 minutes at 4° C. Serum samples were then removed and stored at -80° C until
further processing. An Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem #90080)
was used with mouse insulin standards to analyze fasting insulin levels at 4-6 weeks,
14-16 weeks, and 32-34 weeks, and 45-47 weeks of age. The assay was carried out
using the manufacturer’s protocol for the low range assay (0.1 ng/mL – 6.4 ng/mL). The
plate was read using a SynergyMx plate reader (BioTek) loaded with Gen5 software
(v1.10). Insulin levels at 4-6 and 14-16 weeks were either undetectable or at the bottom
of the standard curve and therefore unreliable. Comparisons of fasting serum insulin
levels in 32-34 and 45-47 week old mice was performed using two-tailed Student’s ttests between WT and H2-Kbm1 groups at each age in Microsoft excel. A total of 8
biological replicates were used for WT mice and 6 for H2-Kbm1 mice at each age.
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Tissue Isolation for Protein Studies
To collect tissues for protein isolation, H2-Kbm1 and wildtype mice were euthanized
with CO2, followed by rapid decapitation. Postnatal C57BL6/J mice were rapidly
decapitated without CO2 euthanasia. The cranium was opened and the brain was
removed. Under a dissecting microscope, individual brain regions were isolated, placed
in 1.5 mL conical tubes and immediately frozen in a dry ice ethanol slurry. Tissues were
stored at -80°C until further processing.
Western Blotting
RIPA buffer (1% Triton X-100, 0.1% SDS, 50mM Tris (pH 7.4), 107 mM NaCl, Halt
Phosphatase Inhibitor (ThermoFisher #78420, 1:100), Protease Inhibitor (Sigma
#P8340, 1:100), 5 mM EGTA, and 5 mM EDTA) was added to thawed tissue and
sonicated for 3 cycles of 2 seconds each. Lysate was then centrifuged at 14,000G for 30
min at 4° C. Protein concentration was quantified by BCA assay. Protein samples were
run on 4-15% SDS gels and transferred to PVDF membranes. Membranes were blocked
in 5% non-fat dry milk in tris-buffered saline with 0.1% tween for all non-phospho specific
antibodies for 1 hour at room temperature. For antibodies to detect phosphorylated
proteins, membranes were blocked in 5% bovine serum albumin for 1 hour at room
temperature. Membranes were probed with primary antibodies (Table 1) overnight at 4°
C and incubated with species specific secondary HRP antibodies for 1 hour at room
temperature.
Quantitative RT-PCR and Analysis
Developmental gene expression of postnatal mouse tissue was measured using
quantitative real time PCR (Eppendorf realplex2 Master Cycler).

Total RNA was

extracted from RNAlater-preserved hypothalamic tissue taken from C57BL/6 mice (P1,
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P5, P15, P28; n = 4 per time point) using a Tissuelyser II system (Qiagen) according to
manufacture protocol. RNA was purified using an RNeasy Mini Kit (Qiagen #74104) with
on-column DNase digestion (Qiagen #79254).
RNA quality was assessed by Agilent RNApico 6000 chips (Agilent # G2938-90046)
on a bioanalyzer (Agilent 2100). RNA purity was assessed using a spectrophotometry
(NanoDrop II, Thermo, Waltham MA) to measure 260/230 and 260/280 ratios. RNA
degradation was assessed by micro gel electrophoresis (BioAnalyzer 2100, Agilent
Technologies). Only RNA samples meeting minimum purity and quality were used for
downstream analysis. Specifically, any samples with A260/A280 ratios less than 1.8
were deemed unsuitable for analysis secondary to RNA contamination. Additionally, any
samples with RNA integrity numbers (RINs) < 7.0 were deemed unsuitable for analysis
secondary to RNA degradation. One-Step RT-PCR was performed using Verso SYBR
Green 1-Step kits (Thermo Scientific Catalog #AB4105) with all samples run in triplicate.
All reactions were processed with no enzyme and no template controls. Quantitect
primers (Qiagen) were used for all reactions (Table 2). RT-PCR data was analyzed for
relative expression using the 2(-

ΔΔ

CT)

method in Microsoft Excel.

A geometric mean

housekeeping gene model was constructed using three common reference genes found
to be stable during development (Tfrc, Gapdh, and Gusb). For review of this method
please see Vandesompele et al., 2002105. Gene stability was assessed using
RefFinder106 which aggregates results from

BestKeeper107, Normfinder108, and

Genorm105.
Tissue Processing for Immunohistochemistry and immunofluorescence
Mice were deeply anesthetized with Avertin and transcardial perfused with 4% PFA
in PBS. Briefly, following anesthesia, mice were sprayed with ethanol and the chest
cavity was opened. The diaphragm was dissected away to expose the apex of the heart.
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Table 1. List of antibodies used for works presented in Chapter 4.

Table 2. List of primers used for works presented in Chapter 4.
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A butterfly needle connected to a transcardial perfusion pump was placed into the left
ventricle near the apex of the heart. Immediately the pump was started and the right
atrium was opened with a dissection scissors. Mice were perfused with PBS for 3
minutes to clear blood, followed by 5 minutes with 4% PFA/PBS. Following perfusion,
organs including liver, heart, muscle, kidneys, brain, eyes, and ependymal fat were
collected, weighed, photographed, and post fixed in 4% PFA/PBS for 24 hours at 4° C.
Tissues were then cyroprotected with 30% sucrose at 4 °C until the tissues sank.
Tissues were embedded in Tissue Tec OCT, and flash frozen in a beaker of isopentane
in a dry ice and ethanol slurry. Tissue blocks were stored at -80 °C until further
processing.
Tissue Sectioning
OCT tissue blocks were allowed to equilibrate to the cryostat temperature of (-22°C
to -17°C, depending on tissue type) for 30 minutes. Tissue sections were collected and
directly mounted on glass slides. Liver tissue was sectioned at 8 µm and brain tissue at
16 µm. After collection, slides were stored at -80°C until further processing.
Oil Red O Staining and Quantification
Liver sections were washed 2 times in distilled water, followed by equilibration in
100% ethylene glycol for 2 minutes. Ethylene glycol was removed and 0.25% Oil Red O
(Sigma-Aldrich #O1516) was added to the slide for 10 minutes. Slides were rinsed in 3
washes of 85% ethylene glycol to differentiate, followed by 2 washes of distilled water.
Slides were cover slipped with an aqueous mounting media and imaged via light
microscopy at 10x magnification. 40x magnification images were taken as representative
inset images. Quantification of integrate density was performed using ImageJ and
genotype comparisons were made by Student’s t-test in Microsoft Excel.
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Fluorescent Immunohistochemistry
Tissue sections were allowed to warm to room temperature for 30 minutes prior to
washing. Slides were washed 3 times in PBS to remove excess OTC, followed by
blocking in 5% bovine serum albumin in PBS. For synaptic analysis and cell signaling,
0.2% triton-X 100 was added to blocking, primary, and secondary antibody solutions. To
enrich for surface expression, triton was not added for developmental MHC I staining. To
assess MHC I and PSD95 colocalization, tissue sections were blocked and incubated
with MHC I antibody overnight at 4° C in the absence of permeabilization agents. This
was followed by another round of blocking, permeabilization with triton, and staining with
PSD95 overnight at 4° C. Primary and secondary antibodies (Table 1) were diluted in
0.5% BSA in PBS with or without triton. Slides were incubated in primary antibody
solution overnight at 4° C and in secondary for 2 hours at room temperature. Tissue was
washed, counterstained with DAPI and cover-slipped with prolong diamond anti-fade
reagent.
Confocal Microscopy
All confocal images were collected using a Zeiss LSM 700 laser scanning confocal
microscope with either Plan-Apochromat 40x/1.3 Oil DICIII M27 (0.26 um resolution) or
EC Plan-Neofluar 20x/0.50 M27 (0.67 um resolution) objectives.
MHC I and synaptic protein colocalization
Z stack confocal images (X: 26.59 um, Y: 26.59 um, Z: 11.99 um) were collected
from the arcuate nucleus, paraventricular nucleus, and the lateral hypothalamus using at
40X with 6X digital zoom on tissue sections stained for surface MHC I and synaptic
proteins as described above. Colocalization analysis was performed using both object
based and intensity based methods with IMARIS software (Bitplane). First, object based
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colocalization was assessed using the detect spots function to identify all MHC I, VGlut2,
and PSD95 puncta. We then quantified all colocalized puncta centers within 400nm of
each other. Additionally, intensity based colocalization was performed using the
colocalization software within IMARIS. Briefly, an identical mask setting was applied for
each channel in all samples, followed by automatic threshold calculation. A
colocalization channel was then built and colocalization statistics were generated (see
Costes, et al., 2004109 for more information). The Mander’s coefficient, Pearson’s
coefficient, and the % colocalized volume were calculated.
Quantification of Vglut1, Vglut2, GAD65, PSD95 positive synaptic puncta
To assess excitatory and inhibitory synapse densities in the hypothalamus, z-stack
confocal images were collected from tissue sections isolated from adult 14-15 month WT
and H2-Kbm1 mice. Images were acquired at 40x with 2x zoom (X: 80.0 µm, Y: 80.0 µm,
Z: 8.11 µm) with a 0.353 µm z-stack step distance and 1000 x 1000 pixel resolution.
Excitatory (Vglut1, Vglut2) and inhibitory (GAD65) synapses were imaged in the lateral
hypothalamus, paraventricular nucleus and arcuate nucleus. Images were loaded into
IMARIS software and puncta densities were quantified using the detect spots function
controlling for puncta size and quality. Differences between genotypes were determined
by two-tailed Student’s t-tests using the average puncta counts for each sample.
Quantification of NPY positive axonal puncta
The distribution and density of NPY projections was quantified in the anterior (near
bregma -1.9) and posterior (near bregma -2.4) arcuate nucleus, dorsal and ventral
aspects of the lateral hypothalamus, paraventricular nucleus, and dorsomedial nucleus
of the hypothalamus. Images were acquired by confocal microscopy at 40x with 4x zoom
to generate z-stacks (X: 40 µm, Y: 40 µm, Z: 6.0 µm) at 500 x 500 resolution with a
0.468 µm z-stack step distance. Images were quantified in IMARIS software using the
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detect spots function controlling for puncta size and quality. Differences between
genotypes were determined by two-tailed Student’s t-tests using the average puncta
counts for each sample.
Quantification of synaptic input onto orexin positive neurons
Confocal z-stack images of orexin positive neurons in the lateral hypothalamus were
acquired at 40x with 2x zoom (X: 80 µm, Y: 80 µm, Z: 15.3 µm) at 1000 x 1000
resolution with a 0.450 µm z step distance. Images were loaded into IMARIS to detect
synaptic puncta and generate surfaces for orexin neurons. To generate surfaces for
orexin positive neurons, individual regions of interest were created around orexin
positive cells. Using the create surfaces function 3D surfaces were generated for
individual orexin neurons. An intensity threshold was created for each channel and
maintained for all samples. The threshold for surface generation was optimized for each
individual cell to extend the surface just distal to the border of orexin staining. This
method allowed us to reliably create surfaces that captured the soma and some proximal
dendritic processes of orexin neurons. Using the detect spots function, all Vglut2 and
NPY puncta were identified within the image frame controlling for quality and size.
Finally, using the split into surface objects function all puncta in contact with each of the
individual orexin neurons were identified. The total number of synaptic puncta in contact
with each cell was then divided by the total cell surface area to generate individual cell
synaptic densities. The primary outputs generated from this analysis included total
Vglut2 and NPY puncta counts, average cell surface area, and the number of Vglut2 and
NPY puncta per 100 µm2 of orexin surface area. We analyzed 55 WT and 57 H2-Kbm1
orexin positive neurons across 4 biological replicates per genotype. Data for surface
area and synapses by surface area were first analyzed by two-way ANOVA to assess
the effect of genotype on each of the perimeters above using IBM SPSS Statistics 22.
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Secondly, we performed boot-strap analysis for 1000 permutations of the data using
Matlab software. Data for Vglut2 puncta per field, and NPY puncta per field were
analyzed by two-tailed Student’s t-tests of the average counts per sample.
cFOS induction via fasting
To assess the gross activity level of orexinergic neurons, we employed a fasting
cFOS induction assay. 3-month old C57BL/6 and H2-Kbm1 mice were split into fed (n =3
per genotype) and fasted (n = 4 per genotype) groups. Animals were fasted for 24 hours
followed by perfusion and tissue processing as described above. Brain sections were
then immunostained as described previously for cFOS, Orexin, and DAPI (Table 1). All
samples were masked and blinded prior to image collection and quantification. To
maximize the field of view, confocal z-stack images were collected at 20x with 0.8x zoom
(X: 400 µm, Y: 400 µm, Z: 12.3 µm) at 1924 x 1924 with a 2.46 µm z-step. Maximum
projection images were generated from confocal z-stacks and analyzed using ImageJ. A
minimum of 5 images were collected per sample with each image containing a variable
number of orexin neurons. The number of cFOS positive cells, Orexin positive cells, and
cFOS/Orexin double positive cells were quantified using the cell-counter plugin in
ImageJ. For each image a weighted percentage of double positive cells was generated
using the formula: % double cFOS/orexin positive cells in image x (# of orexin cells in
image / total # orexin neurons imaged for sample). One animal from each the WT fed
and H2-Kbm1 fed group was removed as they were significant outliers using Dixon’s test.
Importantly, the removal of these points does not affect the primary comparison of this
study between WT fasted and H2-Kbm1 fasted mice. The resulting weighted percentages
were analyzed by One-way ANOVA with Bonferroni post-hoc analysis using IBM SPSS
statistical software.
Fasting Activity Assay
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WT and H2-Kbm1 mice were placed into the homecage monitoring system and
allowed to habituate for 4 days to establish baseline behavior. This acclimation period
allows mice to explore the cage environment, find the food and water sources, establish
a niche, and build a nest. Following this acclimation period mice were fasted under two
paradigms to assess activity patterns in response to fasting. In the first paradigm, food
was removed 15 minutes prior to the initiation of the light cycle in efforts to place mice in
a 12-hour fasted state at the onset of the dark cycle. In the second paradigm, food was
removed 15 minutes prior to the onset of the dark cycle to place mice in a 12-hour fasted
state at the onset of the light cycle. In both paradigms movement and feeding behaviors
were analyzed using the homecage system. Data collected from 2 fed days was used to
create a model of activity including movement (cm) and feeding attempts (number and
duration) for the fed state to serve as control data for overall analysis and analysis of
how fasting affects each mouse. Activity data was generated by aligning 6 minute bin
data for each day and aggregating that data to 60 minute bins. For the light cycle fasting
analysis, this amounted to a 20 hour period from 11:30 AM to 7:30 PM. For dark cycle
fasting a 12 hour period from 6:30 PM to 6:30 AM was analyzed. Overall movement
between WT and H2-Kbm1 mice in the fasted versus fed states was compared by twotailed Student’s t-tests Bonferroni corrected for 2 comparisons on the sum of movement
for WT (n= 7-8) and H2-Kbm1 (n = 7) mice for both fasting paradigms. A two-way ANOVA
was used to assess the effect of genotype on activity at individual timepoints with
fasting. If a significant interaction of genotype*time (p<0.05) was noted, individual twotailed Student’s t-tests Bonferroni corrected for 2 comparison were performed between
fed and fasted groups of each genotype. Differences in movement ratios between fed
and fasted states of WT and H2-Kbm1 mice was assessed by two-tailed Student’s t-test.
Two primary measures of feeding behavior were quantified in during fasting paradigms.
First, we used the number of photo beam breaks to signify the number of feeding
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attempts mice made in fed and fasted conditions. Second, we quantified the duration of
time the photo beam was broken in seconds. The aggregate counts and duration were
then analyzed between WT and H2-Kbm1 mice in the fed and fasted states. Differences
between groups were calculated by two-tailed Student’s t-tests with Bonferroni
correction for four comparisons. We compared the effect of fasting within each genotype,
and the effect across genotype for the same condition.

Results
Class I MHC molecules are dynamically expressed during hypothalamic
development
MHC class I proteins have previously been shown to be expressed within the
hippocampus, cortex, and cerebellum, primarily during neurodevelopment97, 99, 110. MHC I
proteins colocalize with both excitatory pre and post-synaptic proteins, but appear to be
enriched at the post-synaptic density (Goddard et al., 2007). The majority of research on
MHC I proteins in the CNS has targeted hippocampal neurons, due the observation that
they play a role in synaptic plasticity and therefore learning and memory. Many of these
studies focus on developmental timelines with little focus on later life time points. Our
data, and data from several other studies have demonstrated increased expression of
MHC I related proteins with aging, suggesting a reactivation of pathways employed
during neuro development111-114. Interestingly, we noted increased expression of MHC I
proteins in the aged hypothalamus of a mouse with deficits in energy balance regulation.
There are exceptionally few studies interrogating the functions of MHC I proteins in the
hypothalamus, and therefore we set out to characterize MHC I expression in the
hypothalamus in efforts to better understand roles that MHC I proteins may play in
hypothalamic processes necessary for regulating metabolic function.
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To determine if MHC Class I proteins are expressed during hypothalamic
development, we employed a multifold approach using western blotting and confocal
microscopy. Western blot analysis demonstrated that hypothalamic MHC class I proteins
are dynamically expressed through postnatal development, corresponding inversely with
the expression of excitatory (Vglut2 and PSD95) and inhibitory (Gephyrin) synaptic
proteins. Western blot analysis of MHC I protein shows a reduction in expression from
postnatal day 1 through adult (3 months) (P1 1.0 ± 0.17, P3 0.89 ± 0.08, P5 0.90 ± 0.16,
P9 0.70 ± 0.08, Adult 0.44 ± 0.08; p < 0.01 for comparisons between P1, P3, P5 and
Adult by one-way ANOVA) (Figure 1). During this period excitatory synaptic proteins
Vglut2 and PSD95, as well as inhibitory protein gephyrin, increase suggesting
maturation of synaptic networks. One pitfall of Western blot analysis is the inability to
localize protein expression to distinct hypothalamic subregions. Therefore, to determine
if the reduction of MHC I protein was localized to distinct hypothalamic nuclei we
preformed immunohistochemistry on non-permeabilized tissue sections to enrich for
MHC I surface expression. We assessed expression by confocal microscopy of the
arcuate nucleus, paraventricular nucleus, and lateral hypothalamus. Our data
demonstrates a significant reduction in immunofluorescent intensity between P5 and
P15 in the arcuate nucleus (Arc: P5 46.78 ± 7.39 a.u., P15 33.42 ± 4.47 a.u., p < 0.05)
and lateral hypothalamus (LH: P5 35.09 ± 7.19 a.u., P15 22.29 ± 3.44 a.u., p < 0.05)
(Figure 2A,B,D,E). Analysis of the paraventricular nucleus demonstrated a trending
reduction in MHC I staining intensity that failed to reach significance (PVN: P5 22.20 ±
4.24 a.u., P15 19.02 ± 0.96) (Figure 2C,F). Also of note, within each region the pattern
of immunofluorescence appears to change from diffuse staining, to a more localized
pattern on individual cells. This may indicate that subsets of neurons retain higher levels
of somatic MHC I expression than others within the hypothalamus, but further analysis of
single cell expression is necessary to confirm this finding.
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Figure 1. MHC I protein expression in the hypothalamus decreases during
postnatal development and coincides with increases in synaptic proteins. To
determine the pattern of MHC I protein expression in the hypothalamus we probed for
hypothalamic lysates with an antibody recognizing multiple MHC I isoforms and with
antibodies for synaptic proteins. (A) Representative Western blot for hypothalamic
lysates from P1 to adult (3 months) probed for MHC I, Vglut2, PSD95, Gephyrin, and
GAPDH. (B) Quantification of MHC I band intensity demonstrates a reduction in MHC I
protein expression during postnatal development. The reduction in MHC I expression
appears to coincide with the increased expression of excitatory (Vglut2 and PSD95)
and inhibitory (Gephyrin) synaptic proteins. Data represents 3 biological replicates per
time point. Significance of fold change was determined by one-way ANOVA with
Bonferroni post-hoc analysis. Significance is indicated by a = p < 0.01 compared to
P1, b = p < 0.01 compared to P3, c = p < 0.01 compared to P5. Error bars represent
standard deviation from the mean.
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Figure 2. MHC I expression decreases with postnatal age in the developing
hypothalamus. Developmental hypothalamic tissue was stained for MHC I in the
absence of detergent to enrich for MHC I proteins expressed on the surface of cells.
(A-C) Representative images of MHC I expression in the arcuate nucleus (Arc), lateral
hypothalamus (LH), and paraventricular nucleus (PVN) at P5 and P15. Visually a
reduction in florescent intensity and change in distribution are noted in all three
regions. (D-F) Quantification of mean fluorescent intensity revealed a significant
reduction in the Arc (Arc: P5 46.78 ± 7.39 a.u., P15 33.42 ± 4.47 a.u., p < 0.05) and LH
(LH: P5 35.09 ± 7.19 a.u., P15 22.29 ± 3.44 a.u., p < 0.05), but only a trending
reduction in the PVN (PVN: P5 22.20 ± 4.24 a.u., P15 19.02 ± 0.96). Data is
representative of 4 independent samples at P5 and 3 at P15. Statistical differences
determined by two-tailed student t-test. * indicates p < 0.05. Error bars represent
standard deviation of the mean. a.u. indicates arbitrary units for florescent intensity.
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Class I MHC molecules colocalize with synaptic proteins during hypothalamic
development
MHC class I protein expression in hippocampal and cortical neuron populations
colocalizes with both pre and postsynaptic proteins of excitatory synpases (Goddard et
al., 2007). To determine if MHC class I proteins in the developing hypothalamus
colocalize with synaptic proteins, we performed confocal microscopy on tissues stained
with an MHC I antibody and markers of excitatory synaptic proteins including vesicular
glutamate transporter 2 (Vglut2) and postsynaptic density protein 95 (PSD95). To enrich
for surface MHC I expression, tissues were blocked and incubated overnight with MHC I
antibody in detergent free conditions followed by a second round of blocking and
incubation with primaries for synaptic proteins. Using confocal microscopy and IMARIS
software we performed both object based and intensity based colocalization of synaptic
and MHC I proteins. MHC I proteins colocalize with both pre and postsynaptic proteins
dynamically during postnatal hypothalamic development. MHC I proteins show a greater
percentage of colocalization with postsynaptic protein PSD95 compared to presynaptic
Vglut2, and the percentage of colocalization with both synaptic markers is reduced with
developmental age in multiple hypothalamic regions (Figure 3). Using intensity based
colocalization, we note a similar significant decrease in both the Mander’s and Pearson’s
Coefficient of colocalization, and the percent of ROI colocalized from P5 to P15 in
multiple hypothalamic nuclei (data not shown). This data clearly demonstrates that
similar to the hippocampus, MHC I proteins colocalize with excitatory synaptic proteins in
early postnatal hypothalamic tissue, but colocalize at higher levels with postsynaptic
proteins. MHC I proteins have been shown to decrease during development in other
regions and in response to neuronal activity in vitro94-97. Our data demonstrates
developmental differences in MHC I expression and colocalization within a less
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Figure 3. MHC I colocalizes with pre- and post-synaptic proteins early during
neurodevelopment. Tissue sections from P5, P10, and P15 WT mice were
immunostained for MHC I under detergent free conditions followed by staining for
synaptic proteins Vglut2 and PSD95. (A) Representative images of P5 and P15
hypothalamic tissue from within the arcuate nucleus. Far right panels in A show
colocalized puncta (within 400 nm) quantified using IMARIS software. Images from
paraventricular nucleus and lateral hypothalamus show similar staining patterns.
Scale bar represents 2 mm. (B) The percent of PSD95 and Vglut2 puncta that
colocalize with MHC I puncta were quantified in the arcuate nucleus, paraventricular
nucleus, and lateral hypothalamus. MHC I colocalizes more with post-synaptic
PSD95 than pre-synaptic Vglut2 in in all three regions early in development. With
increasing age there is a decrease in MHC I colocalization with both excitatory pre
and post-synaptic proteins in the arcuate nucleus and lateral hypothalamus. Within
the paraventricular nucleus, MHC I colocalization with Vglut2 decreases with
development, but there was no significant difference in colocalization with PSD95. For
P5 and P10, data is representative of 4 biological replicates. For P15, data represents
3 biological replicates. Differences in colocalization percentages were determined
using one-way ANOVA for each brain region and synaptic marker. For comparisons,
a indicates a significant difference (p < 0.05) from P5, b indicates a difference from
P10. Error bars represent standard error of the mean.
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characterized region of the CNS. This data makes an argument for synaptic roles for
MHC I proteins in the hypothalamus, potentially analogous to those in other regions of
the CNS.
Specific Class I MHC isoforms and β2-microglobulin are differentially expressed
during hypothalamic development
The commercially available MHC I antibodies, including the antibody used for the
studies above, recognize multiple MHC class I isoforms. Due to this lack of specificity for
individual MHC Class I isoforms, it is challenging to determine how specific isoforms
change during hypothalamic development. To begin to answer this question, we
performed RT-PCR analysis for several isoforms of MHC I including H2-Kb, H2-Db, H2Q1, H2-Q10, and the major histocompatibility complex light chain beta-2 microglobulin
on P1, P5, P15, and P28 C57BL/6 mice. Developmentally, gene expression is very
dynamic and many housekeeping genes (HKGs) used for RT-PCR normalization are not
spared from developmental differences as neuronal ad glial populations migrate,
proliferate, and differentiate. Therefore, we employed a multiple HKG model to best
normalize expression data. We used a geometric averaging method to establish a model
of HKG expression for each sample105. The three genes selected (GusB, GAPDH, and
Tfrc) were chosen as they had the highest stability when assessed using several
methods (geNorm, Best Keeper, Normfinder). Upon RT-PCR analysis we identifed
expression differences between MHC I isoforms. Transcript expression for H2-Kb
increases from P1 to P28 (P1 1.02 ± 0.25, P28 2.13 ± 0.56, p < 0.01), whereas
expression of H2-Db and H2-Q1 slightly decrease or remain stable through postnatal
hypothalamic development (Figure 4). H2-Q10 was not detected in the hypothalamus at
any age, suggesting expression is either too low to detect in whole tissue RNA extract or
completely absent within this brain region. Interestingly, H2-Kb expression was the only
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Figure 4. MHC I isoforms are differentially expressed in the postnatal
hypothalamus. Specific antibodies for MHC I isoforms are poorly developed making
it challenging to characterize expression at the protein level. In efforts to characterize
the expression patterns of specific MHC I isoforms in the developing hypothalamus,
qRT-PCR was performed for H2-Kb, H2-Db, H2-Q1, H2-Q10, and β2-microglobulin
(b2M). Expression data was normalized to a geometric average of three stable
housekeeping genes (Gusb, Gapdh, and Tfrc) and then normalized to P1 levels to
generate a fold change from P1. H2-Q10 expression was not detected in
hypothalamic RNA and is therefore not represented above. Expression levels for H2Db and H2-Q1 either remained stable or decreased during postnatal development.
Expression of H2-Kb increased later in hypothalamic development, suggesting a
potential continued role in adulthood. β2M, levels drastically increased from P1 to
P28 in the hypothalamus. All comparisons were made my one-way ANOVA with
Bonferroni post-hoc testing. For comparisons, a indicates p < 0.05 compared to P1, b
indicates p < 0.05 compared to P5, c indicates p < 0.05 compared to P15. Data
represents 4 biological replicates per time point. Error bars represent standard
deviation of the mean.
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isoform to increase and maintain relatively high levels throughout development. As MHC
I proteins have been implicated in synaptic plasticity, and the hypothalamus maintains
the ability to tune and rewire itself, we hypothesized that H2-Kb may have a continuing
role in regulating hypothalamic synapses. Additionally, H2-Kb transcript is significantly
elevated in the hypothalamus in a mouse model of age-associated energy balance
deficits, suggesting that H2-Kb may play a role in these processes. To assess if H2-Kb
functions in regulating hypothalamic behaviors, we organized a longitudinal study of
mice carrying a mutated from of H2-Kb, and age-matched C57BL/6 controls using our
state-of-the-art home cage behavioral system.
Mutation of Class I MHC H2-Kb leads to an obesity phenotype characterized by
increased body mass and increased adiposity, despite marked hypophagia
As H2-Kb is expressed in the developing hypothalamus, persists into adulthood, and
is over expressed in an aging model of metabolic energy balance deficits, we chose to
evaluate energy balance and hypothalamic mediated behaviors in mice carrying a
mutation in H2-Kb (H2-Kbm1). H2-Kbm1 mice demonstrate no significant differences in
body weight during postnatal development through roughly 1.5 months of age (Figure
5A). However, early observations of H2-Kbm1 mice at 2-3 months of age demonstrated a
small, but significant increase in body weight (WT 23.32 ± 0.51 g, H2-Kbm1 26.92 ± 0.52
g, adjusted p < 0.01) and adiposity (2-3 months: WT 11.45 ± 0.19%, H2-Kbm1 15.34 ±
0.82%, adjusted p < 0.01) as measured by DEXA scan (Figure 5B,D). H2-Kbm1 mice
continue to gain significantly more weight and store more body fat compared to WT
controls as they aged. At 5-6 months of age H2-Kbm1 mice were more than 30% heavier
(WT 27.53 ± 0.63 g, H2-Kbm1 36.26 ± 0.73 g, adjusted p < 0.0001) and had roughly
double the adiposity as WT controls (WT 14.56 ± 0.51%, H2-Kbm1 27.80 ± 1.77%,
adjusted p < 0.0001). This weight gain and fat deposition occurred until animals were
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Figure 5. H2-Kbm1 mice exhibit a progressive obesity phenotype with onset in
early adulthood. (A) Assessment of WT and H2-Kbm1 mice from birth to early
adulthood demonstrate no significant differences in body weight. (B) Longitudinal
analysis of cohorts of WT and H2-Kbm1 mice demonstrates progressive weight gain
starting at 2-3 months of age and progressing as they age. H2-Kbm1 and WT mice
gain weight with age, but H2-Kbm1 mice remain significantly heavier at 5-6 and 11-12
months. (C) Representative pictures of WT and H2-Kbm1 mice at 11-12 months of age
demonstrate increase in central body mass. (D) DEXA scan analysis revealed
significant increases in adiposity with age in both WT and H2-Kbm1 mice. However,
H2-Kbm1 mice have a significantly higher percentage of body fat than controls at all
ages assessed. For panel A, P0/1 n = 17 per genotype; P7 WT n = 5, H2-Kbm1 n = 17;
1 month WT n = 5, H2-Kbm1 n = 4; 1.5 month WT n = 8, H2-Kbm1 n = 8. For panel B
and C, n = 8 mice per cohort for 2-3 months and 5-6 months, n = 4 for 11-12 months,
p < 0.05 when denoted by # for WT vs H2-Kbm1 at each age; by $ within genotypes
compared to 2-3 months of age; by F within genotypes compared to 5-6 months. All
comparisons made by two tailed student t-test with Bonferroni correction for 9
comparisons. Error bars represent SEM.
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processed for tissue studies at 11-12 months of age (Weight: WT 30.70 ± 1.55 g, H2Kbm1 43.51 ± 0.78 g, adjusted p < 0.01; Adiposity: WT 16.71 ± 2.01%, H2-Kbm1 33.34 ±
1.22%) (Figure 5B,C,D). Much of the fat deposition was in central white adipose tissue,
similar to fat deposition seen in obese adults with metabolic syndrome. Remarkably,
increased weight and adiposity in H2-Kbm1 mice occurs despite significant hypophagia
(Figure 6), indicating that obesity is in H2-Kbm1 is not a result of increased caloric intake.
H2-Kbm1 mice have progressively impaired glucose clearance and increased
fasting insulin levels
Obesity is accompanied by changes in endocrine function that can increase an
individual’s risk for development of downstream complications like diabetes mellitus type
II. To determine if H2-Kbm1 mice showed signs of endocrine dysfunction we performed
glucose tolerance testing (GTT) and measured fasting insulin levels at 4 time points
during the development of obesity. We noted no differences in GTT results at 4-6 or 1416 weeks of age (Figure 7A,B). Fasting insulin levels in mice of both genotypes at these
ages were either undetected or at the bottom of the standard curve and therefore
unreliable. However, at 32-34 weeks of age H2-Kbm1 mice showed a trending genotype
by time interaction and elevated blood glucose level at the 90 minute time point in GTT
(WT 190.5 ± 11.12 mg/dL, H2-Kbm1 229.8 ± 9.20 mg/dL, p < 0.05) (Figure 7C). 32-34
week old H2-Kbm1 mice also demonstrated a significant increase in fasting insulin levels
compared to controls (WT 0.120 ± 0.011 ng/mL, H2-Kbm1 0.448 ± 0.037 ng/mL, p <
0.00001) (Figure 7E). At later stages of obesity development H2-Kbm1 mice have a
reduced

peak

glucose

level,

but

significantly

(p<0.0001,

two-way

ANOVA

genotype*time) impaired clearance upon GTT assessment at the 90 and 120 minute
time points (90 min: WT 223.4 ± 19.0 mg/dL, H2-Kbm1 275.3 ± 23.1 mg/dL, p < 0.05; 120
minutes: WT 185.9 ± 10.5 mg/dL, H2-Kbm1 248.3 ± 23.1 mg/dL, p < 0.01) (Figure7D).
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Figure 6. H2-Kbm1 mice are hypophagic in the homecage monitoring system
compared to WT controls. The amount of daily food consumption is calculated
while mice are in the homecage monitor system and normalized to body weight. At 23 months there is no genotypic difference in food intake. However, H2-Kbm1 mice at 56 months and 11-12 months are significantly hypophagic compared to WT controls.
Interestingly, increased consumption is not observed with increasing weight gain in
H2-Kbm1 mice, as normalized intake is significantly reduced when comparing 2-3
month and both older ages. This suggests that hyperphagia is not a driving factor of
the obesity phenotype in H2-Kbm1 mice. n = 8 mice per cohort for 2-3 months and 5-6
months, n = 4 for 11-12 months, p < 0.05 when denoted by # for WT vs H2-Kbm1 at
each age; by $ within genotypes compared to 2-3 months of age. WT vs H2-K bm1 at
11-12 months, p =0.077. All comparisons made by two tailed student t-test with
Bonferroni correction for 9 comparisons. Error bars represent SEM.
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Figure 7. H2-Kbm1 mice show age-associated reduced clearance of glucose upon
glucose challenge and increased fasting serum insulin levels. Glucose tolerance
tests were performed on WT and H2-Kbm1 mice at 4-6, 14-16, 32-34, and 45-47 weeks
of age as they progressively gained body weight and increased in adiposity. (A, B, and
C) At early time points there are no discernable differences between WT and H2-Kbm1
mice, aside from subtle trends. However, at 32-34 and 45-47 weeks of age clear
differences are demonstrated. (D) H2-Kbm1 mice at 45-47 weeks of age show a
significant (p < 0.0001) genotype*time interaction when assessed by two-way ANOVA.
This difference is carried by a statistically significant reduction in maximum glucose
levels and demonstration of higher glucose levels at the final time point. (E) H2-Kbm1
mice have increased fasting serum levels of insulin at 32-34 weeks (p < 0.001) and 4547 weeks (p < 0.01) of age compared to WT controls. Measurements of fasting insulin
levels at younger ages were lower than the detectable range, and therefore were not
reported. For A-D, all time points were analyzed by Two-way repeated measures
ANOVA. To determine statistical differences at specific time points two-tailed t-tests
were used. 4-6 weeks WT n = 7, H2-Kbm1 n = 7; 14-16 weeks WT n = 8, H2-Kbm1 n = 7;
32-34 and 45-47 weeks WT n = 8, H2-Kbm1 n = 6. For E, statistical differences were
assessed by two-tailed student t-tests. For both time points WT n = 8, H2-Kbm1 n = 6.
For all panels * indicates p < 0.05, ** p <0.01, *** p < 0.001.Error bars represent
standard error of the mean.
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H2-Kbm1 mice also display a significant increase in fasting insulin levels compared to
controls, suggesting the onset of insulin resistance (WT 0.253 ± 0.024 ng/mL, H2-Kbm1
0.970 ± 0.243 ng/mL, p < 0.01) (Figure 7E). This data demonstrates additional
complications of progressive obesity in H2-Kbm1 mice, which begin to mimic
characteristics of metabolic syndrome.
Adult H2-Kbm1 mice have hepatomegaly, hepatic steatosis and increased
pericardial fat deposition
As we noted a progressive obesity phenotype in H2-Kbm1 mice, we performed
necropsy and tissue processing of 12-13 month old mice to further characterize the
obesity phenotype. Upon necropsy, it was evident that H2-Kbm1 mice had increased liver
size and pallor, as well as increased pericardial adipose deposition (Figure 8A). Animals
were perfused for immunohistochemistry, following perfusion the liver was removed and
weighed. H2-Kbm1 mouse livers were visibly larger and had an increased mass compared
to wild-type controls (WT 1.54 ± 0.18 g; H2-Kbm1 2.41 ± 0.31 g, p< 0.05) (Figure 8B).
Further analysis to quantify fat deposition in the liver revealed marked hepatic steatosis,
evident by a significant increase in Oil Red O staining intensity in H2-Kbm1 mice (WT 1.0
± 0.25 a.u., H2-Kbm1 2.35 ± 0.39 a.u., p = 0.027, normalized to WT) (Figure 8C,D).
These data demonstrate that H2-Kbm1 mice acquire downstream pathological
consequences of obesity including what may be signs of nonalcoholic fatty liver disease
(the hepatic manifestation of metabolic syndrome115).
Metabolic Assessment
We performed indirect calorimetry on 2-3 and 5-6 months old H2-Kbm1 mice and WT
controls to evaluate measures of basal and activity associated metabolism. Significant
differences were noted between genotypes at both ages in several measures of
metabolic status. However, after taking adiposity differences into account through
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Figure 8. H2-Kbm1 mice have significant hepatomegaly and steatosis compared
to WT controls. (A) Representative images of WT and H2-Kbm1 mice during terminal
perfusion showing increased liver size and pallor (asterisk), and deposition of
pericardial adipose tissue (arrow). (B) Representative images of fixed liver samples
and quantification of liver mass revealed significant hepatomegaly in H2-Kbm1 mice at
11-12 months of age (WT 1.54 ± 0.18g, H2-Kbm1 2.41 ± 0.31g, p = 0.048). Further
analysis demonstrated of liver tissue showed increased fat deposition within H2-Kbm1
liver tissue. (C) Representative images at 10X and 40X of Oil Red O stained liver
sections from 11-12 month old WT and H2-Kbm1 mice. (D) Quantification of Oil Red O
staining intensity normalized to WT liver shows a significant increase in fat deposition
in H2-Kbm1 liver tissue (WT 1.0 ± 0.25 a.u., H2-Kbm1 2.35 ± 0.39 a.u., p = 0.027). n = 4
per group, a.u. represents arbitrary units for normalized intensity. All comparisons
made by two-tailed student t-tests.
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analysis of covariance testing these differences were negligible. This demonstrates that
changes in metabolic status in H2-Kbm1 mice are a result of increased adiposity and not
specifically an effect of genotype alone. For completeness of presenting metabolic data,
2-3 month and 5-6 month indirect calorimetry data is presented in Figure 9 and Figure
10, respectively. Overall, this analysis allows us to conclude that obesity in H2-Kbm1 is not
a result on an underlying metabolic difference in basal or activity-associated metabolic
function.
Obesity in H2-Kbm1 mice results from increased sedentary states, despite marked
hypophagia
In effort to determine if underlying behavioral differences trigger the development of
obesity in H2-Kbm1 mice, we assessed homecage behavior in cohorts of WT and H2-Kbm1
mice at 2-3 months and 5-6 months of age. In the overall analysis we noted significant
differences in overall 24-hour time budgets and active states temporal organization.
First, H2-Kbm1 are significantly less active than WT controls. At 2-3 months of age H2Kbm1 mice spend an increased percentage of their day in inactive states (H2-Kbm1 63.00 ±
3.89%, WT 54.48 ± 5.3%, p = 0.0093, critical p = 0.01). A trending reduction in
percentage of time spent feeding (H2-Kbm1 6.47 ± 0.97%, WT 8.72 ± 2.42%, p = 0.029,
critical p = 0.01) and other non-forward locomotor activity (H2-Kbm1 26.07 ± 3.14%, WT
30.66 ± 4.11, p = 0.025, critical p = 0.01) were observed, but failed to reach significance
when adjusted for multiple comparisons (Figure 11A). When mice were reassessed at
5-6 months of age these differences became even more striking. H2-Kbm1 mice spend
roughly 10% more time (2.4 hours/day) inactive compared to controls (H2-Kbm1 70.85 ±
6.61%, WT 61.07 ± 6.01%, p = 0.0079, critical p = 0.01). Additionally, H2-Kbm1 at 5-6
months spend significantly less time feeding (H2-Kbm1 6.40 ± 1.50%, WT 11.27 ± 4.21%,
p = 0.0082, critical p = 0.01). (Figure 11B). Time budget data confirms reduced feeding
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Figure 9. Indirect calorimetry measures of basal and activity associated
metabolic function in 2-3 month old WT and H2-Kbm1. (A) Overall basal metabolic
function in H2-Kbm1 mice is unchanged from WT mice when normalized to adiposity for
all measures. (B) Overall activity associated metabolic function in H2-Kbm1 mice is
unchanged from WT mice when normalized to adiposity for all measures. Data is
representative of 8 mice per genotype. Data analyzed by analysis of covariance
(ANCOVA).
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Figure 10. Indirect calorimetry measures of basal and activity associated
metabolic function in 5-6 month old WT and H2-Kbm1 mice. (A) Overall basal
metabolic function in H2-Kbm1 mice is unchanged from WT mice when normalized to
adiposity for all measures. (B) Overall activity associated metabolic function in H2Kbm1 mice is unchanged from WT mice when normalized to adiposity for all
measures. Data is representative of 8 mice per genotype. Data analyzed by analysis
of covariance (ANCOVA).
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in H2-Kbm1 observed in daily chow intake measurements. It also clearly demonstrates
that H2-Kbm1 mice are significantly less active than WT controls. Further analysis of state
probabilities revealed that H2-Kbm1 mice have lower active state probabilities in the last 4
hours of the dark cycle. At 2-3 months, H2-Kbm1 show a clear trend towards reduced
active state probability in this time window (Figure 11C). At 5-6 months H2-Kbm1 mice
show a significant reduction in active state probability at several time points organized
around the end of the dark cycle (Figure 11D). This data clearly demonstrate that the
generation of obesity in H2-Kbm1 mice is not due to hyperphagia, but a result of increased
sedentary states, despite reduced food intake. To identify potential CNS mechanisms of
reduced feeding and activity in H2-Kbm1 mice, we performed molecular and cellular
analysis to assess hypothalamic circuits underlying the regulation of feeding and activity.
Mutation of Class I MHC H2-Kb leads to reduced NPY expression in the arcuate
nucleus
Our initial assessment began with measuring gross levels of synaptic and
neuropeptide proteins in the hypothalamus. MHC I proteins have been shown to play a
role in regulation of synaptic density in hippocampal and cortical networks. To determine
if mutation of H2-Kb leads to synaptic alterations in the hypothalamus of adult mice, we
applied a multi-fold approach looking at excitatory, inhibitory, and hypothalamic specific
synaptic proteins across the entire hypothalamus and within in distinct hypothalamic
subregions. To assess for changes in total synaptic protein levels in the hypothalamus,
protein lysates from 9-10 month old wild-type and H2-Kbm1 mice were probed with
antibodies for specific synaptic proteins. We noted no significant alteration in gross
protein expression for excitatory synaptic proteins (Vglut1, Vglut2, PSD95) or inhibitory
synaptic proteins (gephyrin) by western blot in total protein lysate (data not shown).
However, mutation of H2-Kb led to a trending reduction in NPY expression in total
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Figure 11. H2-Kbm1 mice spend more time in inactive states and are less likely to
be active compared to WT controls. 2-3 month and 5-6 month old WT and H2-Kbm1
mice were analyzed in the homecage monitoring system. (A) At 2-3 months H2-Kbm1
mice spend a significantly higher percentage of their day in an inactive state (black
segment) compared to WT controls (H2-Kbm1 63 ± 3.89%, WT 54.48 ± 5.3%, p =
0.0093, critical p = 0.01). A trending reduction in percentage of time spent feeding
(H2-Kbm1 6.47 ± 0.97%, WT 8.72 ± 2.42%, p = 0.029, critical p = 0.01) and other nonforward locomotor activity (H2-Kbm1 26.07 ± 3.14%, WT 30.66 ± 4.11, p = 0.025,
critical p = 0.01) were also observed. (B) 5-6 month old H2-K bm1 mice spend roughly
10% more of the 24 hour day in an inactive state (H2-Kbm1 70.85 ± 6.61%, WT 61.07 ±
6.01%, p = 0.0079, critical p = 0.0). Additionally, H2-Kbm1 mice spend less time
feeding compared to WT controls (H2-Kbm1 6.40 ± 1.50%, WT 11.27 ± 4.21%, p =
0.0082, critical p = 0.01). (C) H2-Kbm1 show a trending reduction in active state
probability in the final hours of the dark cycle compared to controls. (D) At 5-6 months
of age H2-Kbm1 mice are significantly less likely to be in an active state during the final
two hours of the dark cycle and first hour of the light cycle compared to WT controls.
All comparisons made by two-tailed t-tests corrected for multiple comparisons. *
indicates p < 0.01. Error bars indicate standard error of the mean.
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hypothalamic protein lysates.

This change was not accompanied by a significant

change in the protein level of POMC (Figure 12A). NPY/AgRP neurons predominately
project to the paraventricular nucleus where they antagonize the anorexigenic action of
alpha-MSH release by POMC neurons25 and promote feeding behavior through the
orexigenic action of NPY onto NPY receptor populations. However, there exists an
asymmetric inhibitory circuit within the arcuate nucleus where NPY/AgRP neurons
provide tonic local inhibition of POMC neurons whenever NPY/AgRP neurons are
active21,

26, 27

. While western blot analysis can be informative, it lacks the spatial

resolution needed to detect where changes in NPY specifically occur. In efforts to
identify the origin of reduced NPY in H2-Kbm1 mice and determine if there are other
synaptic changes, we performed immunohistochemistry and confocal microscopy.
Synaptic changes in specific regions of the hypothalamus were assessed in fixed tissue
sections from 12-13 month old mice stained for excitatory (Vglut1, Vglut2), inhibitory
(GAD65), and NPY positive synapses. Images were collected from the arcuate nucleus,
paraventricular nucleus, and lateral hypothalamus. Using this method, not only did we
confirm a reduction in NPY expression, but we identified a neuroanatomical location for
this change. H2-Kbm1 mice have a ~30% reduction in NPY+ puncta within the arcuate
nucleus (WT 442.1 ± 63.7, H2-Kbm1 328.1 ± 65.24 NPY puncta per field, p < 0.05), and
this reduction is carried by the largest change occurring within the posterior arcuate (~
bregma -2.4) (WT 415.1 ± 73.20, H2-Kbm1 266.6 ± 71.81 NPY puncta per field, p < 0.05)
(Figure 12B,C). No changes were observed in other hypothalamic subregions
assessed. It is possible that lower NPY levels in the arcuate nucleus would lead to
reduced inhibition of anorexigenic POMC neurons, thereby driving hypophagia. This
result can be viewed as an underlying potential mechanism for hypophagia observed in
H2-Kbm1 mice. However, it is also possible that lower levels of NPY occur as a
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Figure 12. H2-Kbm1 mice have reduced NPY axon puncta density in the arcuate
nucleus. Immunohistochemistry and Western Blot were performed with an antibody
targeting neuropeptides to assess for genotypic differences. (A) Western blot
analysis of whole hypothalamic lysate revealed a trending reduction in NPY
expression in H2-Kbm1 mice, but no change in POMC expression. (B)
Representative images of anterior and posterior arcuate nucleus NPY distribution in
WT and H2-Kbm1 mice at 20x and 160x. Anterior images were taken at roughly
bregma -1.9 and posterior images were taken at bregma -2.4. A clear reduction in
NPY staining is observed at bregma -2.4. Scale bar equals 50 mm in 20x image and
10 mm in 160x image. (C) Quantification of NPY positive puncta per field at 160x
revealed a significant reduction in the arcuate nucleus (WT 442.1 ± 63.7, H2-K bm1
328.1 ± 65.24 NPY puncta per field, p < 0.05), driven by change in the posterior
arcuate (WT 415.1 ± 73.20, H2-Kbm1 266.6 ± 71.81 NPY puncta per field, p < 0.05).
Data represents average puncta per field for 4 biological replicates per genotype.
Comparisons were made by two-tailed student t-tests and * indicates significance p
< 0.05. Error bars represent standard error of the mean.
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compensatory mechanism in response to obesity, indicating the arcuate nucleus in H2Kbm1 mice is functioning properly and responding to changes in metabolic status.
Mutation of Class I MHC H2-Kb leads to alterations in synapse density in select
regions of the hypothalamus
Mutation of H2-Kb also leads to changes in excitatory synaptic density within
specific nuclei of the hypothalamus. Vglut1+ puncta are significantly increased within the
arcuate nucleus (WT 1050.0 ± 256.1, H2-Kbm1 1385.6 ± 90.7 puncta per field, p < 0.05),
which is accompanied, by a trending increase in inhibitory GAD65+ puncta (WT 2280.7 ±
242.7, H2-Kbm1 2814.6 ± 460.5 puncta per field, p = 0.086) (Figure 13A,C,D). We did
not note any differences in puncta density in the paraventricular hypothalamus, but did
note

large

variability

between

samples

(Figure

13C,D,E). Within

the

lateral

hypothalamus there is a trending reduction in the number of Vglut2 positive synaptic
puncta (WT 3207 ± 341.6, H2-Kbm1 2696 ± 304.5 Vglut2 puncta per field, p = 0.067)
(Figure 13B,E). One of the synaptic targets of Vglut2 synapse in the lateral
hypothalamus are orexin neurons. Altered active states and arousal can be directly
linked to the function and excitation of orexin neurons in the lateral hypothalamus. So,
next we chose to assess if the trending reduction in Vglut2 puncta affected the input to
orexin positive neurons in the lateral hypothalamus.
Mutation of Class I MHC H2-Kb leads to reduced excitatory input onto orexin A
positive lateral hypothalamic neurons
Initiation of active states is driven by excitation of orexin positive neurons scattered
throughout the lateral hypothalamus. Orexin neurons have a 10-fold increase in somatic
mini-excitatory postsynaptic current frequency compared to mini-inhibitory post synaptic
currents, driven by asymmetric excitatory glutamatergic innervation compared to
inhibitory GABAergic innervation75, 116, 117. Additionally, glutamatergic antagonists have
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Figure 13. H2-Kbm1 mice have altered hypothalamic excitatory synapse
density. Excitatory and inhibitory synapse density was measured in the arcuate
nucleus (ARC), paraventricular nucleus (PVN), and lateral hypothalamus (LH) by
immunohistochemistry with antibodies targeting Vglut1, Vglut2, and GAD65. (A)
Representative images from the arcuate nucleus demonstrating increased Vglut1
immunoreactive puncta in H2-Kbm1 mice compared to WT controls. A trending
increase was also observed in the number of GAD65 puncta per field. (B)
Representative images of Vglut2 immunoreactivity in the WT and H2-Kbm1 lateral
hypothalamus. (C) Quantification of Vglut1 puncta demonstrated a significant
increase in Vglut1 immunoreactive synapse density in the arcuate of H2-K bm1 mice
compared to controls (WT 1050.0 ± 256.1, H2-Kbm1 1385.6 ± 90.7 puncta per field, p
< 0.05). No differences were noted in the PVN or LH. (D) Quantification of GAD65
puncta demonstrated a trending increase in the arcuate nucleus of H2-Kbm1 mice
(WT 2280.7 ± 242.7, H2-Kbm1 2814.6 ± 460.5 puncta per field, p = 0.086). (E)
Analysis of Vglut2 puncta density demonstrated a trending reduction in the lateral
hypothalamus of H2-Kbm1 mice (WT 3207 ± 341.6, H2-Kbm1 2696 ± 304.5 Vglut2
puncta per field, p = 0.067). Synapse counts are representative of 4 biological
replicates per genotype. * indicates p < 0.05 by two-tailed student t-test. Scale bar
in all images equals 20 mm.
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been shown to greatly reduce action potential generation in orexin neurons; however
inhibition of GABAA does not lead to an increase in spontaneous action potential firing.
These results indicate that glutamatergic innervation is critical for proper orexin neuron
function. Our data demonstrates that mutation of H2-Kb leads to a gross reduction in
Vglut2 excitatory puncta in the lateral hypothalamus, without changes in additional
excitatory synaptic (Vglut1) for inhibitory synaptic (GAD65) proteins. Considering H2Kbm1 mice show a remarkable reduction in daily activity and reduced Vglut2 excitatory
synaptic puncta in the lateral hypothalamus, we hypothesized that orexin A positive
neurons were receiving less excitatory input in H2K1bm1 mice compared to controls. To
evaluate this, we preformed confocal microscopy capturing z-stacks of hypothalamic
sections stained with orexin A, Vglut2, and NPY. This was followed by 3D reconstruction
of orexin A positive neurons and quantification of synaptic puncta that colocalized with
the surface reconstruction of orexin positive neurons. Using this method, we found that
H2-Kbm1 mice show a significant reduction in Vglut2+ puncta / 100 µm2 of orexin A cell
surface area (WT 5.81 ± 0.25, H2-Kbm1 4.90 ± 0.20 Vglut2+ puncta per 100 µm2 orexin
SA, p < 0.01), but no differences in NPY+ puncta (WT 0.99 ± 0.074, H2-Kbm1 1.06 ± 0.10
NPY+ puncta per 100 µm2 orexin surface area) (Figure 14A,B,D). To further validate this
finding, we performed bootstrapping analysis for 1000 permutations of the mean puncta
density data for Vglut2+ and NPY+ synapses. Frequency distributions generated from this
analysis clearly demonstrate differences between WT and H2-Kbm1 cells for Vglut2+
synapse density demonstrated by minimal overlap of the histograms (Figure 14C).
Differences are not displayed in NPY+ density between genotypes, denoted by
significant overlap of frequency distributions (Figure 14E). This data clearly
demonstrates reductions in Vglut2 innervation of orexin neurons in the lateral
hypothalamus. Functionally, orexin neurons have heightened sensitivity to excitatory
changes, as they exist in an intrinsically depolarized state68-70. Therefore, the small
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Figure 14. H2-Kbm1 orexin neurons have reduced Vglut2 excitatory input
compared to WT controls. Orexin neurons in the lateral hypothalamus were
identified by orexin A staining in tissue sections stained for Vglut2 and NPY to assess
synaptic input to orexin neurons. (A) Representative imaging and data analysis
sequence…Continued on next page.
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Figure 14. Continued (A1) Original confocal z-stack images as displayed in IMARIS
software are shown in the top row labeled raw. (A2) In the second row, images with
spots and surfaces detected are displayed. (A3) Final output image displaying orexin
neuron surface and soynaptic puncta detected within the surface (Vglut2 in green,
NPY in magenta). (B) Quantification of Vglut2 puncta per 100 µm2 of orexin surface
area (SA) demonstrated a significant genotype interaction and reduction in H2-Kbm1
mice when assessed by two-way ANOVA (WT 5.81 ± 0.25, H2-Kbm1 4.90 ± 0.20
Vglut2 puncta per 100 µm2 orexin SA, p < 0.01). (C) Bootstrap analysis for 1000
permutations of the data demonstrated minimal overlap in the frequency distributions
for the mean Vglut2 puncta per 100 mm of orexin SA. (D) Quantification of NPY
puncta per 100 mm of orexin surface area showed no difference between genotypes
(WT 0.99 ± 0.074, H2-K bm1 1.06 ± 0.10 NPY puncta per 100 µm 2 orexin SA). (E)
Bootstrap analysis of NPY data demonstrates major overlap in frequency distribution
verifying no difference between genotypes. All data is representative of quantification
of 55 cells for WT and 57 cells for H2-Kbm1 mice spread across 4 biological replicates
per condition. Data was analyzed by two-way ANOVA. ** indicates p < 0.01. Error
bars represent standard error of the mean.
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changes observed may have large functional outcomes and investigating these
outcomes may offer insight into the mechanism of obesity in H2-Kbm1 mice.
Mutation of H2-Kb leads to reduced fasting induced cFOS induction in orexin
neurons
Fasting results in increased mini excitatory post synaptic potentials and excitatory
synaptic density on orexin neurons within 12 hours75, 118. cFOS can serve as a marker for
whether there are differences in orexin neuron response to fasting, as it is rapidly
increased in neurons in response to firing119, 120. To determine if reduced excitatory drive
onto orexin positive neurons results in a baseline reduction in orexin activation in
response to an attenuation stimulus, we performed a fasting cFOS induction assay on 44.5 month old WT and H2-Kbm1 mice. At the time of testing, H2-Kbm1 mice were
significantly heavier than WT controls (WT 24.50 ± 1.33 g, H2-Kbm1 27.91 ± 2.40 g, p <
0.01), demonstrating the onset of the previously described progressive obesity
phenotype. Mice were fasted for 24 hours (11:00 AM to 11:00 AM) and the brains were
processed for immunohistochemistry. Confocal imaging for orexin A and cFOS was
performed and the numbers of orexin, DAPI, cFOS positive neurons in addition to the
number of cFOS/orexin double positive neurons were quantified. Remarkably, H2-Kbm1
mice fail to show cFOS induction upon fasting. Fasted H2-Kbm1 mice show a significant
reduction in the percentage of orexin/cFOS double positive cells compared to fasted WT
mice (WT Fasted 35.05 ± 4.77%, H2-Kbm1 Fasted 3.91 ± 2.33%, p < 0.01 by one-way
ANOVA) (Figure 15). WT mice show a modest increase in the percent of orexin cells
that are positive for cFOS staining; however this increase is not evident in H2-Kbm1 mice.
Additionally, H2-Kbm1 mice show extremely low levels of cFOS positive orexin neurons in
basal conditions. This data supports the hypothesis of reduced orexinergic activity in H2Kbm1 mice, corresponding to the observed reduced excitatory synaptic density. In
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Figure 15. Orexin neurons in H2-Kbm1
mice fail to respond to fasting
stimulus with increased activity. WT
and H2-Kbm1 mice were fasted for 24
hours
and
processed
for
immunohistochemistry
to
quantify
orexin neurons activation in response to
fasting. c-fos induction serves as a
marker of neuronal activity. (A)
Representative images of c-fos and
orexin staining in WT and H2-Kbm1 mice
in fed and fasted states. Yellow
arrowheads indicate c-fos /Orexin
double positive cells. White arrows
indicate
orexin
positive
c-fos
negative
(B) Quantification of the percentage of c-fos
positive
orexin
neurons
revealed
a
bm1
significant reduction in H2-K
fasted mice compared to fasted controls. A clear
increase was observed in WT mice with fasting and H2-Kbm1 mice appear to have low
c-fos positive orexin neurons at baseline, but this was not analyzed for statistical
difference due to the small sample size of mice in the fed states. Data is
representative for n =2 for WT and H2-Kbm1 fed and n = 4 for WT and H2-Kbm1 fasted
groups. Comparison made by one-way ANOVA with Bonferroni post-hoc
comparisons. ** indicates p < 0.01. Error bars represent standard deviation of the
mean.
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processing mice for the cFOS induction assay, we visually noted less activity in H2-Kbm1
mice compared to WT controls. WT mice were actively scurrying around the cage,
whereas H2-Kbm1 mice appeared stationary in their bedding material. As orexin activation
is a critical regulator of arousal, we chose to further analyze this finding in a quantitative
manner.
H2-Kbm1 mice fail to increase activity in response to dark cycle fasting
Orexin administration results in elevated metabolic rates121, food intake56,

57

,

locomotor activity122, and wakefulness123. Similar behaviors are observed in fasting
animals, where orexin plays a link between metabolic status and motivated behavior124127

. As H2-Kbm1 mice appear to demonstrate orexin deficits, we wanted to determine if

functional outcomes related to orexin activation are altered. As a first step towards this
analysis, we quantified ambulatory activity measurements taken during indirect
calorimetry evaluation. For indirect calorimetry, mice are fasted for roughly 12 hours
prior to assessment. We noted significant periods of reduced activity counts in H2-Kbm1
mice. Activity differences are evident at early time points of analysis, where WT mice are
the most active. Later in the assay, both genotypes show lower activity and the
differences are less apparent (Figure 16A). At 2-3 months H2-Kbm1 mice showed a
significant reduction in total ambulatory activity while in the indirect calorimetry system
(WT 14099 ± 2413 ambulatory counts, H2-Kbm1 6514 ± 1490 ambulatory counts, p <
0.05) (Figure 16B). At older ages, differences are still observed at specific time intervals
(Figure 16C), but these differences become less dramatic with overall ambulatory
activity just failing to reach significance (Figure 16D). To further determine if the
orexinergic system fails to respond to fasting induced attenuation, we designed a 24
hour fasting paradigm within the homecage monitoring system where we can measure
movement and feeding over the circadian day.
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Figure 16. H2-K bm1 mice do not increase activity in response to fasting and
placement in a novel environment, suggesting deficits in orexin function. WT
and H2-Kbm1 mouse activity data from indirect calorimetry analysis was assessed for
ambulatory activity counts over 18 intervals of 17.5 minutes each at 2-3 months and
5-6 months of age. (A) At 2-3 months of age, H2-Kbm1 mice fail to respond to fasting
by increasing activity counts when placed in a novel environment, especially early
upon introduction to the cage. (B) H2-Kbm1 mice are significantly less active over the
entire analysis period compared to WT controls (WT 14099 ± 2413 ambulatory
counts, H2-Kbm1 6514 ± 1490 ambulatory counts, p = 0.018). (C) At 5-6 months of
age H2-Kbm1 mice still fail to respond to fasting with increased activity. (D) Overall
ambulatory activity counts in 5-6 month H2-Kbm1 mice are lower than WT controls,
but fail to reach statistical significance (WT 14776 ± 1278 ambulatory counts, H2Kbm1 10825 ± 1684 ambulatory counts, p = 0.083). Analysis for number of
ambulatory counts over 18 cycles by two-way repeated measures ANOVA
demonstrated a significant interval*genotype interaction (p < 0.001) for both ages.
Within interval comparisons in A and C, and total ambulatory comparisons in B and
D were made by two tailed student t-tests, * indicates p < 0.05, ** p < 0.01, *** p <
0.001. Error bars represent standard error of the mean. n = 8 mice per genotype at
each age.
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Mice were placed in the HCM system and allowed to acclimate for 4 days prior to
fasting. For the first fasting paradigm, food was removed just prior (~15-30 minutes) to
the onset of the light cycle. For the second paradigm, food was removed just prior (15-30
minutes) to the onset of the dark cycle. By performing both paradigms we were able to
assess light and dark cycle behaviors corresponding to different levels of fasting. This is
important as orexin signaling is temporally regulated with higher levels during the active
(dark cycle). When food is removed at the onset of the dark cycle, fasted WT mice show
a trending increase in overall movement over a 20 hour period following food removal,
while fasted H2-Kbm1 show no change compared to their baseline fed state (Figure 17A).
Differences in movement in fasted WT mice appear to occur throughout most of the dark
cycle, with minimal differences during the light cycle (Figure 17B). Analysis of 1 hour bin
time data by repeated measures MANOVA only revealed a significant genotype effect,
therefore no further analysis was performed this data. Using the fed baseline activity for
the same duration of time for each mouse, the fold change in activity was assessed and
averaged for each genotype. Overall there was a trending increase in movement ratio for
fasted WT mice (Figure 17C). Looking at each mouse individually, 5 of 7 WT mice
showed increased movement (>10% increase), 1 showed no change, and 1 had less
(>10% decrease). Whereas, 3 of 7 H2-Kbm1 mice had less movement, 2 showed no
change, and 2 had increased movement (Figure 17C). When mice were fasted just prior
to the dark cycle, this phenotype became even more prominent. Fasted WT mice again
showed an overall trending increase in movement compared to their fed state over a 12
hour period following fasting (WT Fed 363.8 ± 34.8 m, WT Fast 447.9 ± 21.4 m, adjusted
p = 0.12). Whereas, fasted H2-Kbm1 showed a drastic reduction in activity compared to
the fed state (H2-Kbm1 fed 204.8 ± 19.9 m, H2-Kbm1 fast 107.8 ± 6.1 m, adjusted p <
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Figure 17. H2-Kbm1 fasted at the start of the light cycle do no show any increase
in overall locomotor activity. Mice respond to fasting with increased orexin activity
that drives increased movement and food seeking behaviors. To test if H2-Kbm1
demonstrate function aspects relating to deficits in orexin function, mice were fasted
at the start of the light cycle and total movement was quantified for a 20 hour period of
fasting. (A) WT mice show a trending increase in overall movement (WT Fed 444.75 ±
22.5 m, WT Fast 559.8 ± 59.8 m, adjusted p = 0.09), while H2-K bm1 mice show no
change (H2-Kbm1 Fed 245.0 ± 22.1 m, H2-Kbm1 Fast 234.6 ± 36.1 m, adjusted p =
0.81). Comparisons made by two-tailed Student’s t-test Bonferroni corrected for two
comparisons. (B) Movement data organized by hourly bins during the dark and light
cycle shows comparisons at individual time points. Comparison by repeated
measures MANOVA demonstrated only a significant effect of genotype (p < 0.0001).
(C) Total fasting movement for each mouse normalized to its own fed baseline total
movement. Ratios greater than 1 signify greater movement under the fasting
paradigm. Far left bars for WT and H2-Kbm1 represent aggregate ratios for all samples
within a genotype (WT 1.25 ± 0.11, H2-K bm1 1.01 ± 0.19, p = 0.28). Bars on the right
represent individual mice for WT (n = 7) and H2-Kbm1 (n = 7). Comparison of
aggregate ratios by two-tailed Student’s t-test.
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0.001) (Figure 18A). Analysis of individual time points throughout the dark cycle by
repeated measures multivariate ANOVA revealed significant between subject effects for
genotype and genotype by condition on movement distances. Increased movement in
fasted WT mice occurs throughout the dark cycle, but with the largest changes towards
the onset and offset times (Figure 18B). Comparing the average ratio of movement for
fasted and fed WT and H2-Kbm1 mice, there was a clear increase in WT and decrease in
H2-Kbm1 mice (WT 1.38 ± 0.24, H2-Kbm1 0.56 ± 0.06, p < 0.01) (Figure 18C). On the level
of individual mice 4 WT mice showed increased activity (>10%) and 4 showed relatively
no change (<10% increase or decrease) from fed baseline. Whereas, all 7 H2-Kbm1 mice
had less activity (>30% reduction) compared to fed baseline (Figure 18C).
Fasting induced orexin activity is known to drive feeding behaviors including food
pursuit. Therefore, in addition to movement data we quantified the number of feeder
photobeam breaks and total duration of time the beam was broken in both fasting
paradigms. When mice were fasted at the start of the light cycle and followed for 20
hours, we observed a significant reduction in feeding attempts for H2-Kbm1 mice
compared to their fed baseline (H2-Kbm1 fed 566 ± 73, fast 152 ± 35, p <0.001).
Additionally, H2-Kbm1 fasted mice show a significant reduction compared to WT fasted
mice (WT fast 442 ± 92, p < 0.05) (Figure 19A). Quantification of feeding attempt
duration revealed a significant reduction in both WT fasted and H2-Kbm1 fasted mice
compared to their fed baselines. Both fasted and fed H2-Kbm1 mice also had reduced
feeding attempt durations compared to WT mice under the same conditions (Figure
19B). Analysis of feeding activity when fasted at the start of the dark cycle yielded
roughly identical results with a reduction in feeding attempts in fasted H2-Kbm1 mice
compared to fed baseline and fasted WT mice (Figure 19C) and reduced feeding
attempt durations between conditions and genotypes (Figure 19D). WT mice when
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Figure 18. H2-Kbm1 fasted at the start of the light cycle do not show an
increase in overall locomotor activity. Mice respond to fasting with increased
orexin activity that drives increased movement and food seeking behaviors. To test
if H2-Kbm1 demonstrate function aspects relating to deficits in orexin function, mice
were fasted at the start of the light cycle and total movement was quantified for a
20 hour period of fasting. (A) WT mice show a trending increase in overall
movement (WT Fed 363.8 ± 34.8 m, WT Fast 447.9 ± 21.4 m, adjusted p = 0.12),
while H2-Kbm1 mice show a drastic reduction (H2-Kbm1 Fed 204.8 ± 19.9 m, H2-Kbm1
Fast 107.8 ± 6.1 m, adjusted p < 0.001). Comparisons made by two-tailed
Student’s t-test Bonferroni corrected for two comparisons. (B) Movement data
organized by hourly bins during the dark and light cycle shows comparisons at
individual time points. Comparison by repeated measures MANOVA demonstrates
a significant between subject’s effect of genotype (p < 0.00001) and genotype by
condition (p < 0.01). (C) Total fasting movement for each mouse normalized to its
own fed baseline total movement. Ratios greater than 1 signify greater movement
under the fasting paradigm. Far left bars for WT and H2-Kbm1 represent aggregate
ratios for all samples within a genotype (WT 1.38 ± 0.24, H2-Kbm1 0.56 ± 0.0.06, p
< 0.01). Bars on the right represent individual mice for WT (n = 7) and H2-Kbm1 (n =
7). Comparison of aggregate ratios by two-tailed Student’s t-test.
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Figure 19. H2-Kbm1 and WT mice show altered feeding behaviors upon fasting.
Orexin neuron activity is known to drive feeding activity and food pursuit behaviors in
mice upon fasting. To test if H2-Kbm1 have deficits in feeding behaviors in response to
fasting, we measured feeder photobeam breaks and duration of breaks in mice fasted
at the start of the light cycle or start of the dark cycle. (A) H2-Kbm1 mice have a
reduced number of photobeam breaks when challenged by fasting at the start of the
light cycle compared to fed controls and fasted WT mice. (B) The duration of time the
photobeam was broken drastically decreased in both genotypes with fasting at the
start of the light cycle. H2-K bm1 fed and fasted mice have reduced beam break duration
compared to WT fed and fasted mice.(C) Similar to fasting at the start of the light
cycle, when food is removed at the start of the dark cycle H2-Kbm1 show a reduction in
the number of beam breaks compared to fed baseline and fasted WT mice. (D) When
fasted at the start of the dark cycle both H2-Kbm1 and WT mice show reduced time
spent breaking the feeder photobeam. H2-Kbm1 fed and fasted mice show a significant
decrease compared to WT condition matched controls. Data is representative of 20
hours of activity when fasted at the start of the light cycle (A,B) and for 12 hours of
activity when fasted at the start of the dark cycle (B,C). Data is the mean of 7 mice per
genotype for light cycle food removal (A,B) and 8 WT and 7 H2-Kbm1 mice for dark
cycle food removal (C,D). Error bars represent standard error of the mean.
Comparisons made by two-tailed Student’s t-tests Bonferroni corrected for 4
comparisons. $ denotes p < 0.05 when compared within genotype, # indicated p <
0.05 when compared to matched condition in opposite genotype.
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fasted showed trending, but non-significant reductions in feeding attempts compared to
their fed baseline. Overall, this data confirms reduced feeding in H2-Kbm1 during the
normal fed state and demonstrates that H2-Kbm1 under fasting conditions may not
maintain the same level of drive for feeding as fasted WT mice. This is supported by the
data showing overall reductions in feeding duration for both genotypes, but a higher
number of attempts at feeding in fasted WT compared to fasted H2-Kbm1 mice.
Adult H2-Kbm1 mice are hypothermic during dark cycle activity
In addition to sleep, arousal, feeding, and activity orexin neurons have also been
linked to autonomic regulation including sympathetic activity, blood pressure, and
thermoregulation among others128-131. To determine if H2-Kbm1 mice demonstrate
differences in autonomic functions suggestive of further orexin dysfunction, we first
chose to assess body temperature during resting (light cycle) and active (dark cycle)
states at 2-3 months, 5-6 months, and 8-9 months of age. We observed no differences in
resting body temperatures between genotypes at any age (Figure 20A,B,C). However,
at 5-6 months of age H2-Kbm1 mice are hypothermic compared to controls during the
dark cycle (WT 36.48 ± 0.053 °C, H2-Kbm1 35.83 ± 0.125 °C, p < 0.001) (Figure 20B).
This difference persists in 8-9 month old mice (WT 36.48 ± 0.09 °C, H2-Kbm1 36.175 ±
0.09 °C, p < 0.05) (Figure 20C). The difference between genotypes stems from a failure
to increase body temperature, which may be a result of overall decreased activity in H2Kbm1 mice or due to direct deficits in orexin mediated regulation of autonomic function.

Conclusions and Discussion
Here, we present the first data clearly implicating the classical MHC I proteins in
hypothalamic regulation of energy balance. MHC I proteins are dynamically expressed
during hypothalamic development and colocalize with synaptic proteins. MHC I
expression is reduced in the adult hypothalamus, but one isoform, H2-Kb increased in
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Figure 20. H2-Kbm1 mice are hypothermic during the active cycle at 5-6 and 89 months of age. Orexin neuron activity is known to function in autonomic
regulation, including in thermogenesis. To determine in orexin deficits in H2-Kbm1
mice extend to autonomic function, we measured body temperatures in WT and
H2-Kbm1 mice during the resting state (light cycle) and active state (dark cycle) at
three different time points. (A) At 2-3 months of age there were no observed
differences between WT and H2-Kbm1 mice in resting or active state body
temperatures. (B,C) At both 5-6 and 8-9 months of age H2-K bm1 mice are
significantly hypothermic during the active state (5-6 months: WT 36.48 ± 0.05, H2Kbm1 35.48 ± 0.13, p < 0.001; 8-9 months: WT 36.48 ± 0.09, H2-Kbm1 36.18, p <
0.05). No differences between genotypes were found during the resting cycle. 2-3
month data is representative of 4 WT and 8 H2-Kbm1 mice. Data at 5-6 and 8-9
months is representative of 8 mice per genotype. Error bars signify standard error
of the mean. * indicate p < 0.05, *** p < 0.0001 when compared by two-tailed
Student’s t-test.
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transcript expressing in adult mice suggesting a potential continued functional role. In
efforts to identify potential functions of H2-Kb in the hypothalamus we performed
behavioral phenotyping of mice with a mutation of the H2-Kb isoform. Mutation of H2-Kb
leads to a significant early adult onset obesity phenotype with characteristics of
metabolic syndrome. H2-Kbm1 mice show progressive weight gain, central adipose
deposition, glucose intolerance, insulin resistance, and hepatic steatosis. Interestingly,
increased caloric intake does not underlie obesity in H2-Kbm1 mice, as they are markedly
hypophagic compared to WT controls. Our data reveals that obesity results from an
underlying deficit in orexinergic neuron function, which leads to a drastic reduction in
mouse activity and increased time spent in sedentary states. Functionally, orexin
neurons in H2-Kbm1 fail to respond to fasting stimulus, evident by significantly lower cFOS
induction. H2-Kbm1 mice also fail to increase activity when fasted and are significantly
hypothermic during the active cycle, also indicating reduced orexin activity. Our data
also shows reduced excitatory synaptic innervation of orexin neurons, providing a
potential mechanism for orexin neuron deficits in H2-Kbm1 mice. To our knowledge this is
the first evidence for MHC I protein functions in the adult hypothalamus and orexinergic
signaling.
Our studies focused on orexin A neurons in the lateral hypothalamus. Orexin A
neurons signal through both orexin receptor 1 (OX1R) and orexin receptor 2 (OX2R)
equally, whereas orexin B shows a 10-selectivity for OX2R132. Functionally, OX1R
primarily functions in feeding and reward133-135, and OX2R is linked to the promotion of
arousal136, 137. As we noted functional differences in both behaviors, assessing orexin A
activity was deemed a logical first assessment. However, as orexin B neuronal activity
was not assessed we cannot conclude that mutation of H2-Kb leads affects orexin B
function. Future analysis of this pathway will ultimately yield conceptually interesting
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results, no matter the finding. If orexin B neurons are spared with the mutation of H2-Kb
it would suggest a level of cell selectivity for MHC I protein regulation of synapses
previously unappreciated in the hypothalamus. If orexin B neurons are affected, it
implicates H2-Kb in overall regulation of orexin functions.
Orexin neuron activity is linked to behaviors primarily organized around the
promotion of feeding, active states, and autonomic function. More recently, orexin
signaling has implicated in regulation of motivated behaviors131. H2-Kbm1 mice
demonstrate significant impairments in each of these areas, which is highly indicative of
orexinergic dysfunction. Energy balance deficits in H2-Kbm1 mice can be summarized as
obesity secondary to reduced activity, despite marked hypophagia. These changes
clearly resemble those seen in models of orexin function antagonism through
pharmacologic or genetic techniques. Administration of an orexin receptor antagonist or
an antibody against orexin leads to a significant reduction in food intake, even when
animals are in a fasted state135,

138-140

. Our data demonstrates reduced feeding in H2-

Kbm1 mice when challenged with fasting, mimicking the results of orexin antagonism. We
also observe lower daily activity in H2-Kbm1 mice at 2-3 and 6-7 months of age. Orexin
deficient mice have also been described to have lower locomotor activity compared to
WT mice141. Administration of orexin centrally has been shown to increase locomotor
activity and feeding142,

143

. Another clear behavioral change associated with orexin

function is increased activity when challenged by fasting. Orexin deficient mice fail to
increase activity in response to a fasting challenge127. Similarly, H2-Kbm1 demonstrate
reduced activity in the fasted state in two independent experimental paradigms
presented in this study. Another role for the orexin system is in autonomic function,
including

the

regulation

of

thermogenesis.

Administration

of

orexin

A

by

intracereboventricular injection leads to increased body temperature in both fasted and
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anesthetized rodents, demonstrating orexin regulation of body temperature independent
of activity or feeding144, 145. H2-Kbm1 mice are significantly hypothermic during the active
cycle, when orexin neurons have the highest level of activity and peak orexin levels in
the CSF71-74, 146.
Our data also suggests that H2-Kbm1 mice may have deficits in motivated behavior.
Administration of orexin leads to increased food pursuit behaviors when the food source
is either highly palatable (altered diet) or when mice are placed under fasting147-149. Our
data assessing behavioral activity in the homecage system under fasting conditions
revealed a reduction in the number of feeding attempts in fasted H2-Kbm1 mice compared
to fasted controls, suggesting that H2-Kbm1 mice demonstrate reduced food pursuit.
Fasting paradigms and conditioned feeding paradigms have been shown to lead to
cFOS induction in orexin neurons75,

119, 120, 134, 150, 151

. Our data demonstrates no cFOS

induction upon fasting, suggesting reduced orexin activation, which could impair food
pursuit behaviors when food was removed from the original location of the food source.
Even on a larger scale, in terms of obesity development, H2-Kbm1 mice mimic deficits
observed in mice with orexin deficiencies. Orexin deficient animal models often suffer
from adult onset obesity, much like H2-Kb null mice141,

152-155

. Similarly, in humans,

individuals with narcolepsy, a genetic condition characterized by reduced numbers of
orexin neurons, have a two-fold increased risk for obesity development, despite often
being hypophagic156. However, there is a major difference between our data and others
linking orexin deficiencies to obesity. The majority of the previously mentioned studies
directly inhibited or ablated orexin neurons, whereas orexin deficits in our study appear
secondary to mutation of MHC class I H2-Kb. The potential implications these results
have in the generation of obesity phenotypes are not truly appreciated until mechanisms
underlying MHC I expression and MHC I roles in other brain regions are detailed.
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Further analysis of H2-Kbm1 orexin neuron synapses density by electrophysiology
and electron microscopy will yield a more detailed picture of synaptic density and
dynamics of synapse function. Electron microscopy has demonstrated a higher density
of asymmetric (assumed excitatory) synapses and smaller surface areas for orexin
neurons than we detailed based on our approach, likely due to differences in
resolution75. Differences in cell surface area can be explained by the methods of
calculation and our inclusion of proximal dendrites. Our reported low levels of NPY
synaptic puncta in contact with surface reconstructions of orexin neurons is in
accordance with low levels NPY innervation of orexin neurons75. We did not assess
GABAergic synapse density onto orexin neurons, since we noted no change in overall
GABA immunoreactivity across the lateral hypothalamus. GABAergic synaptic contacts
are a minor input to orexin neurons and occur at a rate of 2 per every 10 Vglut2
synapses75. Performing electrophysiology on H2-Kbm1 mice and matched controls in a
fasting paradigm would offer potential explanation for the lack of cFOS induction
observed in our studies. Fasting results in increased frequency of excitatory mEPSCs
with no changes in mIPSCs, and is correlated with increased excitatory synapses in WT
mice75. Our data demonstrating absent cFOS induction implies this process is not
functioning in H2-Kbm1 mice. At the level of the synapse, MHC I proteins have been
implicated in regulating both synapse density as well as function in hippocampal and
cortical neurons93, 97, 98. However, in contrast to our data, MHC I loss in these systems
leads to increased excitatory synapse density and function97. There is also evidence for
roles of specific MHC I isoforms within distinct cell populations. Loss of H2-Kb and H2Db in a double knockout model leads to deficits in formation of the laminar structure of
the visual cortex and impaired synapse elimination, which can be rescued by restoring
H2-Db, but not H2-Kb73. We believe our data in context of the literature provides
evidence for cell and brain region specific differences in MHC I protein function. Orexin
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neuron synaptic connectivity is distinct from other neuron types, with high excitatory and
low inhibitory tone, compared to a more equal distribution in interneurons, and high
inhibitory tone on other types of long projecting neurons157. This underlying difference
may be a foundation for distinct roles of MHC I proteins. Expression patterns and levels
of MHC I on the cell surface may also be critical in regulating neuronal properties.
MHC I genes are constitutively expressed, but influenced by several pathways
targeting cis-acting regulatory promoter elements containing binding sites for nuclear
transcription factor kappa B (NF-κB) and interferon-regulatory factor (IRF) family
members87-89. Both NF-κB and interferon signaling pathways have well documented
roles in inflammatory signaling, and NF-κB signaling is critical for proper nervous system
function90. Additionally, in the CNS MHC I expression can be regulated by neuronal
activity through a calcium dependent mechanism involving CREB signaling91-93. The link
between MHC I expression and inflammatory pathways may be of particular importance
to understanding how MHC I proteins may impact obesity phenotypes. At the most basic
level, viral infections can lead to either increased expression of MHC I proteins or
reduced expression, often through interactions with the immune system. Select
paramyxoviruses158, retroviruses159, and flaviviruses160 may increase MHC Class I
expression. Conversely, adenoviruses161, 162, herpes viruses163-165, pox viruses166, 167, and
select retroviruses159, 168-171 may reduce MHC Class I expression.

The majority of data

for infectious or inflammatory control of MHC Class I expression is centered within the
immune system and little is known about how these mechanisms change neuronal
expression of MHC I proteins. MHC I levels have been shown to increase in neurons in
response to inflammation172, CNS injury173, seizures174, and aging175. Whether neuronal
MHC I expression changes with specific infections, is less understood. If neuronal MHC I
expression can be influenced in similar manners, it is not difficult to postulate on the

245
potential impact on metabolic functions. These impacts may be acute or possibly lead to
alterations in hypothalamic signaling that may impact an individual’s metabolic status
chronically. In the short term, MHC I may play a role in regulating sickness behaviors
(including increased sleepiness, anorexia, and lethargy), which have been directly tied to
the suppression of orexin signaling176. In the long term, dysregulated MHC I proteins
may lead to variations in the connectivity and plasticity of hypothalamic networks,
predisposing individuals to obesity development. While this theory has yet to be
thoroughly tested, there is evidence that early life infections can result in obesity in
animal models, but the underlying mechanisms are unclear177-181.
The majority of our data detailed deficits in orexin system function as they likely
drive the obesity phenotype observed in H2-Kbm1 mice. However, it is also important to
note additional changes in synapses observed in H2-Kbm1 mice including increased
Vglut1 excitatory and reduced NPY density in the arcuate nucleus. NPY neurons in the
arcuate project to PVN and antagonize anorexigenic melanocortin neurons23,

182

. NPY

neurons also robustly inhibit POMC neurons within the arcuate through NPY and
GABAergic projections, thereby providing tonic inhibition of POMC stimulation of
melanocortin neurons when NPY neurons are active20,

183

. Our data demonstrates a

reduction in NPY density in the arcuate nucleus, which may indicate reduced inhibition
onto POMC neurons. Reduced POMC inhibition would lead to increase anorexigenic
activity and promote satiety. As H2-Kbm1 mice are hypophagic, it is possible that changes
in arcuate function play a role in this finding. This neuronal pathway is also highly plastic
and reduced NPY density may also be a response to obesity in efforts to curb weight
gain157. The predominant excitatory transmitter expressed in the majority of the
hypothalamus, including the in the arcuate nucleus is Vglut254. Vglut1 expression is
more limited within the hypothalamus and less is known about its functional roles and
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synaptic partners making our observation of increased Vglut1 density challenging to
interpret. It is the hope that future work will better characterize this system and place our
results into perspective.
The mechanisms underlying how mutation of H2-Kb results in altered excitatory
synaptic density onto orexinergic neurons in the lateral hypothalamus is unknown,
however we speculate that it is a result of altered binding and presentation of
endogenous peptides or through reduced stability on the surface of neurons. H2-Kbm1
carries 7 nucleotide mutations, which lead to three amino acid substitutions101-103. The
resulting changes in amino acid side chains results in significant modification of the H2Kb protein crystal structure and result in altered functional properties101-103. H2-Kbm1 is
18-fold less thermostable on the surface of cells compared to wildtype H2-Kb.
Interestingly, H2-Kbm1 can still bind known H2-Kb antigens, but binding fails to elicit a
CTL immune response, suggesting a lack of classical MHC I function101-103.

The

mechanisms of involvement for MHC I proteins in synaptic development are still poorly
understood, but our data demonstrating that mutation of H2-Kbm1 leads to changes in
synaptic density of orexin neurons suggests that proper binding and presentation of
protein sequences is critical for the process. The question about what is bound in the
clefts of MHC I proteins and the trans-synaptic partner recognizing MHC I proteins in the
CNS is still poorly understood. We postulate that the MHC I presentation of self-proteins
may serve as cell identifiers to other cell types in the CNS, where orexin neurons
present small fragments of proteins that identify the neuron type potentially guiding
synaptic targeting. Mutation of H2-Kb may then alter the presentation of these proteins
and result in improper synaptic development. Another possibility is that mutated H2-Kb is
presenting a new protein or set of proteins that alter its role in synaptic development.
Future studies to isolate and identify what is presented on MHC I proteins in the CNS
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from wildtype and mutated forms may begin to answer these questions. Additionally,
future single cell sequencing experiments will offer more information on the expression
patterns of MHC I proteins in the CNS including cell-to-cell variability within neurons
types and across neuron types.
Our data demonstrates that classical MHC I isoform H2-Kb is expressed in the
hypothalamus and colocalizes with synaptic proteins. Additionally, we show that
mutation of H2-Kb leads to a profound progressive adult-onset obesity phenotype with
characteristics of human metabolic syndrome. Obesity generation in H2-Kbm1 mice is
likely due to deficits in the orexin system resulting from reduced excitatory drive onto
orexin neurons in the lateral hypothalamus. The implication that immune proteins,
particularly class I MHC proteins, may play a role in regulating acute and chronic
synaptic architecture of the hypothalamus may open an entire new set of therapeutic
targets for treating energy balance deficits including obesity.
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Overall Discussion
The works presented in this dissertation relate to a distinct theme that we believe
underlie functional deficits associated with aging. In the most simplistic of terms, our
data demonstrates that altered PRR activity in the brain leads to structural and functional
changes in neurons resulting in behavioral deficits. The loss of Tlr2 and C3, and the
mutation of MHC I H2-Kb all lead to downstream deficits in behaviors, albeit distinctly
different behaviors. Furthermore, increased expression of these proteins is correlated
with age-related functional deficits likely originating from the same brain regions with
altered expression during aging. It is interesting to highlight the behavioral changes in
context of the change in protein expression.

To start, aging is associated with

fragmentation of active states as described in Chapter 2 and increased hypothalamic
expression of Tlr2. When Tlr2 is genetically deleted from mice, we observed
consolidation of active states (i.e. reduced fragmentation). MHC I protein isoform H2-Kb
is also elevated in the aged hypothalamus in mice with significant weight loss, coupled
with altered energy balance regulation. When H2-Kb is mutated in mice, it results in a
progressive obesity phenotype with multiple similarities to metabolic syndrome in
humans. From these two models it appears that loss or mutation of immune proteins
results in phenotypes opposite of those observed in our aged mouse models. However,
loss of C3 or increased C3 expression in aging are both associated with synaptic
phenotypes and locomotor impairments characterized by signs of gait ataxia. Therefore,
modeling age related functional disorders is not a simplistic as the presence of absence
of immune protein expression.
The effect of protein loss on functional behaviors may be dictated by different
functional properties of immune proteins. MHC I and Tlr2 are transmembrane surface
receptors with intracellular signaling capabilities, whereas C3 is a secreted protein that
functions through activation of surface receptors and as an opsonin. Developmentally,
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C3 functions in targeting synapses for pruning, as well as regulation of neuronal
properties through binding of C3R1, 2. In aging, the function of C3 in the brain is less
clear. It is possible that C3 is increased in the aging brain in response to NF-κB
activation by immune protein stimulation and works as a compensatory mechanism to
remove dysfunctional synapses or cell debris. In support of this idea, data has shown
that C3 expression is regulated by NF-κB activity. Our data demonstrates that C3
transcript expression is increased in response to Tlr2 ligation. Therefore, there may be
different mechanisms underlying locomotor deficits in the aged brain and those in C3
deficient mice. The complex interplay of immune proteins and PRRs in the establishment
of immune phenotypes has yet to be adequately detailed. However, it is intriguing to
postulate that within proteins increased in aging, there are both those that function as
drivers and brakes on CNS regulation.
It must also be appreciated that immune proteins appear to be regionally important
in CNS regulation. Our data demonstrates that loss of Tlr2 and mutation of MHC I H2-Kb
both affects hypothalamic functions, while C3 affects cerebellar function. Loss of Tlr2
and mutation of H2-Kb effect hypothalamic regulated behaviors tied to lateral
hypothalamic function, but differ greatly in the phenotypic outcomes. Tlr2 deficient mice
show consolidations of active and inactive states, suggesting increased stability of
orexinergic signaling. Whereas, mutation of MHC I H2-Kb has the profound effect of
drastically reducing orexinergic signaling, leading to progressive obesity and increased
sedentary activity. Conversely, loss of C3 protein did not appear to alter hypothalamic
function, as C3 mice overall did not demonstrate significant changes in metabolism,
adiposity, or large changes in feeding behaviors in the HCM system. Loss of C3 did lead
to significant impairments in locomotor functions including reduced gait speed and
characteristics of gait ataxia. Our data is focused on hypothalamic and cerebellar
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functions, but altered expression of immune proteins have also been linked to changes
in other brain regions, including those involved in cognition3-7.
The timing for when immune protein expression are altered (ie. prenatal, postnatal,
adult, aged) may also be critical to the development of behavioral deficits. Increases in
immune protein expressing in the brain occurs gradually with aging, as does the
expression of potential endogenous agonists. Interestingly, there is significant variability
in the timeline of synaptic phenotypes present in immune protein knockout models.
Complement 3 deficiency results in altered synapse density in the visual cortex as early
as postnatal day 101; whereas, no changes are noted in the hippocampus until 4 months
of age4. Additionally, we noted no gross synaptic changes in the cerebellum at 1 month
or 3 months of age. Similarly, mutation of MHC I proteins have been associated with
postnatal synaptic changes in hippocampal neurons7, as well as changes in 12 month
old adult mice, but no apparent deficits at 6 months of age8. These data demonstrate
that immune proteins likely function in both the establishment and the maintenance of
synaptic networks; therefore altering their expression at any point in life may have
significant impact on neuronal functions. We propose that the gradual accumulation of
extracellular agonists, endogenous or otherwise, drive dysregulation of cell signaling
necessary for proper neuronal function through stimulation of immune receptors. Our
analysis was centered around NF-κB dysregulation based on previous data. However,
other pathways are likely involved in addition to NF-κB. Our protein array data suggests
other potential target pathways including MAPK signaling, cell response to oxidative
stress, and TGF-β signaling, among others.
Finally, it is important to recognize that ‘no cell is an island’, and environmental
changes play crucial roles in regulating cell signaling. The classic functional perspective
for all of the proteins we assessed is rooted in their role within the immune system and
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response to infectious stimulus. While it was only mentioned briefly throughout the
previous chapters, it must be stated that infectious states can have large effects on the
expression levels of immune proteins. Expression levels of toll-like receptors,
complement proteins, and MHC I can all change in response to infection9-16.
Interestingly, MHC I expression can be downregulated in response to specific viruses1727

. Based on this evidence, and what we know about the function of immune proteins in

synaptic regulation, it is possible that infectious states alter neuronal network functions
both acutely and chronically. An acute effect of infection on neuronal function is
supported by evidence demonstrating that sickness behaviors are linked to suppression
of orexin signaling in the lateral hypothalamus28 and in part regulated by toll-like
receptors29-32. To date, much less known about the chronic effects of infections on
neuronal structure and function. However, in support of chronic changes to hypothalamic
function resulting from immune system insults, exposure to early life infection can lead to
adult onset obesity in animal models33-36. Hopefully, future studies will be able to
determine if there is any correlation within pre- or postnatal infection and adult obesity in
humans.
Overall, the study of immune protein roles in the maintenance of neuronal structure
and function is in its relative infancy compared to what is known about the same proteins
in the periphery. We believe that our data adds another level of appreciation to the
complex functions immune proteins play in CNS regulated behaviors associated with
daily living and a healthy lifestyle. It is our hope that future work in these areas will offer
novel targets to combat functional declines in mobility and energy balance.
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